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Summary 
Background Post-mastectomy radiotherapy (PMRT) in patients with 4+ axillary nodes reduces breast 
cancer mortality, but its role in patients with 1-3 involved nodes is controversial. 
Methods BIG2-04-MRC-EORTC SUPREMO is an international parallel randomised controlled trial. 
Eligible women (over 18 years, with ‘intermediate risk’ breast cancer, pT1-2N1, pT3N0 and pT2N0 if 
grade III and/or lympho-vascular invasion, post-mastectomy and axillary surgery) were randomly 
assigned to receive chest-wall radiotherapy (50 Gy 25 fractions or radiobiolgically equivalent 45 Gy 
20 fractions or 40 Gy 15 fractions) or not (1:1 ratio).  Randomisation was in permuted blocks with 
varying block length, stratified by centre, without masking of patients or investigators.  The primary 
endpoint is 10-year overall survival. Here, we present the 2-year quality of life (QOL) results (pre-
specified secondary endpoint). The QOL substudy, open to all UK patients, consists of questionnaires 
(EORTC QLQ-C30 and BR23, Body Image Scale, Hospital Anxiety and Depression Scale (HADS) and EQ-
5D-3L) completed pre-randomisation, 1, 2, 5 and 10 years.  Data were analysed on an intention-to-
treat basis, using repeated mixed-effects methods. The trial is registered with International Standard 
Randomised Controlled Trials (ISRCTN61145589). 
Findings  
Between August 4,2006-April 29, 2013, 1688 patients enrolled internationally, 989/1258 (79%) of 
the UK patients consented to QOL substudy. Patients receiving PMRT reported worse chest-wall 
symptoms (p=0·016) but the difference was small. Symptoms improved from year 1 to 2. 
Chemotherapy was associated with less improvement.  No group differences were observed for arm 
symptoms, body image, fatigue, pain, overall QOL, physical functioning or HADS scores.  
Interpretation PMRT led to more local symptoms up to 2 years post-randomisation, but the 
difference was small. This data will inform shared decision-making whilst survival results (main trial 
endpoint) become available.   
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Research in Context 
Evidence before this study 
Adjuvant chest-wall irradiation after mastectomy remains a core effective element in the loco-
regional management of early breast cancer reducing loco-regional recurrence and breast cancer 
mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients with 4 or 
more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 involved nodes 
is controversial and practices vary. The Oxford overview in 2014 shows an advantage in overall 
survival from PMRT in patients with 1-3 positive nodes. However, the generalisability to 
contemporary practice of historical trials with different standards of surgery, radiotherapy and 
systemic therapy remains uncertain.  Benefits in survival needs to be balanced against risk of loco-
regional and cardio-pulmonary toxicity, particularly in conjunction with potentially cardiotoxic 
anthracyclines and trastuzumab. The recent American Society of Clinical Oncology guidelines on the 
use of PMRT emphasizes the importance of evaluating the risk-benefit ratio, but the overview data is 
derived from patients treated several decades previously and only a limited number of small studies 
looked at patient-reported outcomes, such as symptoms and quality of life. 
Added value of this study 
Our study uniquely investigated the impact of adjuvant PMRT on quality of life in a randomised trial 
including a large, well characterised population of UK patients with ‘intermediate-risk’ breast cancer 
post-mastectomy. At 2 years PMRT was associated with worse self-reported local symptoms (pain, 
swelling, skin problems in the “area of the affected breast”) in comparison with no radiotherapy, but 
the difference is small, unlikely to be of clinical significance and the symptoms improved over time. 
There were no differences in arm symptoms, body image, fatigue, pain, overall QOL, physical 
functioning anxiety or depression. 
Implications of all the available evidence 
The impact on PMRT on 10-year survival, the primary endpoint of the main SUPREMO trial, will not 
be known before 2023. In the meantime, both options of administering or omitting PMRT are 
legitimate for patients in the intermediate risk category (1-3 positive lymph nodes). Our data will 
inform shared decision-making (as recommended in the recent North American guidelines on PMRT) 
and put patients in a better position to make an informed value judgment on what they consider 
relevant for their situation given the data on the patient-reported symptoms and QOL domains 
presented in this report. Both physicians and patients may be helped when weighing up the 
individual estimates of possible benefits of radiotherapy against the impact of PMRT on toxicity and 
quality of life. 
  
 4 
Introduction 
Current multimodality treatment for breast cancer has improved survival rates. 1 Avoiding 
overtreatment and balancing the treatment burden against benefit has become an important 
research field. Examples of trials investigating selective omission of radiotherapy or chemotherapy 
have recently been reported. 2,3  While the impact of mastectomy and chemotherapy on quality of 
life has been well documented the additional effect of adjuvant radiotherapy following mastectomy 
is unclear. Chest wall pain, fatigue, anxiety about recurrence and depressive symptoms can all hold 
back recovery and return to normal activities of daily living. 4 
Adjuvant chest wall irradiation after mastectomy remains a core and highly effective element in the 
loco-regional management of early breast cancer reducing loco-regional recurrence and breast 
cancer mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients 
with 4 or more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 
involved nodes is controversial and practice and guidelines vary.5 The Oxford overview in 2014 
shows an advantage in overall survival from PMRT which included at least the chest wall in the 
target volume in patients with both 1-3 and 4 or more positive nodes.6 However, the generalisability 
of historical trials with different standards of surgery, radiotherapy and systemic therapy remains 
uncertain, especially as contemporary survival rates are much higher than in the studies included in 
the overview.  Potential benefits in survival needs to be balanced against risk of loco-regional and 
cardio-pulmonary toxicity, particularly in conjunction with potentially cardiotoxic anthracyclines and 
trastuzumab. A recent update by the American Society of Clinical Oncology on the use of post-
mastectomy radiotherapy emphasises the importance of evaluating the risk-benefit ratio, 
particularly in patients with a low risk of local failure.7 The benefit of PMRT relies on estimates of 
recurrence risk, modulated by biological tumour characteristics, weighed against the negative 
impact of PMRT on the risks of late toxicity (e.g. cardiac toxicity from radiotherapy may be increased 
by the combination with systemic therapy).8 The data currently available on these modulating 
effects is derived from patients treated several decades previously. 
Selective use of post-mastectomy radiotherapy is being evaluated in the BIG 2.04 MRC EORTC 
SUPREMO trial, which assesses the effects of adjuvant chest wall radiotherapy without axillary 
irradiation in patients with ‘intermediate risk’ early breast cancer who have undergone mastectomy 
and adequate systemic therapy following contemporary guidelines for all treatment modalities. This 
is the largest randomised trial to date to assess the role of PMRT in this subset of patients. The 
endpoints have been previously described. 9 In brief, the primary endpoint of the trial is overall 
survival at 10 years. Secondary end points include various breast cancer recurrence endpoints, 
toxicity, acute and late morbidity (cardiac morbidity and mortality) and quality of life. Sub-studies 
include the TRANS-SUPREMO seeking molecular markers of radiosensitivity, a cardiac substudy, and 
for UK patients only Quality of Life (QOL) assessment and Health Economics evaluation. These sub-
studies will provide an important high-quality evidence base on the balance of potential benefits and 
treatment burden, to support patients and health care professionals during shared decision-making. 
The long-term impact of breast cancer and its treatment on everyday life has been identified as a 
critical knowledge gap and a key priority for breast cancer research 10. For radiotherapy, there is a 
limited information on treatment impact.  A small number of trials have investigated self-reported 
breast, arm, and shoulder symptoms, functional outcomes and quality of life after radiotherapy, 
predominantly in breast conserving therapy11-13. Patients usually report transient and short-term 
effects of radiotherapy, with relatively limited effect on overall quality of life 14,15 .  
No comprehensive QOL data exists in patients having PMRT and only a few studies have compared 
patient-reported outcomes following breast-conserving surgery versus mastectomy with and 
without reconstruction. Recent introduction of oncoplastic surgical techniques is expected to have 
an impact on post-treatment morbidity and patient satisfaction with body image16,17. There is a 
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dearth of level 1 evidence assessing the impact of adjuvant post-mastectomy radiotherapy on QOL 
of patients who have undergone reconstruction.  
The SUPREMO QOL substudy aimed to examine the effects of PMRT on several primary QOL 
outcomes (global QOL, fatigue, physical function, chest wall, shoulder and arm symptoms, body 
image, anxiety and depression) at 1, 2, 5, and 10 years post treatment. Here we report the 2-year 
results. To our knowledge, this is the first study looking at the impact of adjuvant radiotherapy on 
QOL in a large randomised trial confined to patients treated by mastectomy for early breast cancer 
(including patients undergoing breast reconstruction). 
Methods 
Study design and Participants 
SUPREMO was an open label parallel randomized trial. Patients provided written informed consent 
before enrolment.  The full eligibility, exclusion criteria and trial procedures are described in the trial 
protocol provided in the supplementary web material and online (http://www.supremo-
trial.com/SUPREMO%20protocol%20version29.pdf). Briefly, eligible patients were women aged 18 
years or older if they had undergone mastectomy for unilateral breast cancer, and an axillary staging 
procedure with axillary lymph node dissection, if node positive. Patients with ‘intermediate risk’ 
breast cancer were eligible, defined as pT1-2N1, pT3N0 and pT2N0, if also grade III and/or with 
lympho-vascular invasion on histology. Patients needed to be fit for surgery, radiotherapy or 
adjuvant systemic therapy. Exclusion criteria included previous or concurrent malignancy (except 
non-melanomatous skin cancer and carcinoma in situ of the cervix), ductal carcinoma in situ, 
bilateral breast cancer, pregnancy at the time of radiotherapy treatment and male gender. 
Eligible patients were randomly assigned to receive chest-wall radiotherapy or not (1:1 ratio). All 
patients had to receive adequate systemic therapy following contemporary guidelines depending on 
patient and tumour characteristics. If this included chemotherapy, treatment regimes containing at 
least 4 cycles of anthracyclines were recommended. Adjuvant trastuzumab was given according to 
local practice. In 2011 the eligibility criteria were widened, following a protocol amendment (version 
29 August 30,2010) approved by the Ethics Committee, to include neo-adjuvant chemotherapy.   
For patients randomized to chest wall radiotherapy, radiation was given after the chemotherapy 
(when given). Radiotherapy treatment consisted of chest wall radiation to a total dose of 50 Gy in 25 
daily fractions of 2 Gy over 5 weeks. Other permitted radiobiologically equivalent schedules included 
45 Gy in 20 fractions over 4 weeks, and 40 Gy in 15 fractions over 3 weeks. Guidelines on treatment 
planning and set up were given, and there was a radiotherapy quality assurance programme in the 
trial. The use of bolus was permitted and had to be pre-specified per centre. Axillary irradiation was 
not permitted, but medial peri-clavicular and/or internal mammary chain irradiation was permitted 
according to local policy of the centres. Boost radiation was not permitted.  Surgery, systemic 
therapy and pathology were also subject to pre-specified quality assurance. Additional recorded 
data included cardiovascular risk factors, radiotherapy cardiac and lung exposure parameters, 
systemic therapy (type, doses, and dates) and any reconstructive surgery (type, immediate or 
delayed). Patients with gross protocol violations (e.g. margins involved or less than 1mm for invasive 
cancer or DCIS) will be removed before the final analysis of the main trial.  A mammogram of the 
opposite breast, if appropriate, was recommended at least in alternate years for 10 years from the 
date of mastectomy. The primary endpoint of the trial, overall survival, is not centrally reviewed. 
Serious adverse events were to be reported if they occurred during radiotherapy or within 30 days of 
the last radiotherapy session (fraction) whether or not they were related to the randomised 
treatment. Any toxicity assessed as a grade 4 or 5 acute or late morbidity score had to be reported 
on a SAE/SUSAR form for the entire follow up period of the trial. Adverse events were reviewed by 
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the Data Monitoring and Ethical Committee meeting every 6 months (or as often as they considered 
appropriate). Monitoring (source data verification) is carried out by the Cancer Clinical Trials Team in 
Edinburgh on 10% of the patient data of the main trial with site visits allowed in the UK. Higher 
levels of monitoring will be performed, if requested by the Data Monitoring Committee, or if 
particular safety issues are identified by the investigators, the trial management group of the trial 
steering committee. 
The study was approved by the Multi-Centre Research Ethics Committee, Edinburgh (MREC 
05/50501/106) and local research and development offices. Patients provided written informed 
consent before enrolment and had additional options to consent to the sub-studies, including QOL 
substudy. 
Randomisation and masking 
Consenting patients were randomized post-operatively to either chest-wall radiotherapy or no 
chest-wall radiotherapy (1:1 ratio). Patients were randomised by permuted blocks with the block 
length being varied randomly to minimise the effect of entry bias.  Stratification was by treatment 
centre due to possible between centre differences in the manner in which radiotherapy is given.  
There was no masking by patients or investigators. Randomisation was performed via a telephone 
call to The Information and Statistical Division (ISD) at National Services Scotland. 
Procedures for QOL substudy 
All patients eligible for SUPREMO from UK centres were invited to participate in the QOL study. 
Patients who provided informed consent completed a questionnaire booklet in the clinic before 
randomisation. Completed booklets were sent to the trial’s office and subsequent questionnaires 
were posted to patients at 12 and 24 months by the trial’s office. If the baseline questionnaire was 
not returned to the trial’s office further questionnaires could not be sent, as patients’ names and 
addresses were not available to the trial co-ordinator. Reminders were sent to the hospitals where 
baseline questionnaires were overdue. No reminders were sent to patients at 12 and 24 months. 
QOL was assessed using several well-validated questionnaires. 
EORTC QLQ-C30 (version 3·0) and the breast module QLQ-BR23 (version 1·0). The QLQ-C30  
consists of 30 questions addressing 5 functional scales (cognitive, emotional, physical, social, and 
role), 9 symptom scales (appetite loss, constipation, diarrhoea, dyspnoea, fatigue, financial 
difficulties, insomnia, nausea and vomiting, and pain), and one Global Health Status/QOL scale18. The 
EORTC QLQ-BR23  focuses on breast cancer specific issues and includes 23 questions addressing 4 
functional: body image, future perspective, sexual enjoyment, and sexual functioning and 4 
symptom scales: arm symptoms (swelling in arm or hand, arm or shoulder pain, and difficulty raising 
the arm), breast/chest wall symptoms (pain, swelling, oversensitivity, and skin problems in the area 
of the affected breast), systemic therapy side-effects, and upset by hair loss19. All scores for the 
EORTC QLQ-C30 and EORTC QLQ-BR23 were transformed to a scale from 0 to 100. Higher scores on 
the functional scales and Global QOL represent a superior level of functioning and better QOL, 
whereas higher scores in the symptom scales or items represent worse symptoms. 
The Body Image Scale (BIS) is a 10-item scale designed specifically for use with cancer patients to 
assess aspects of attractiveness, sexual attractiveness and feelings or satisfaction with appearance.  
Scores were graded 0-3 and summed to produce a single score, where a higher score indicated more 
problems (score range from 0 to 30)20. 
Hospital Anxiety and Depression Scale (HADS) is a 14-item instrument with two sub-scales for 
anxiety and depression21. Scores range from 0 to 21 on each scale, with higher scores indicating 
more distress. Scores above 11 suggest probable cases of anxiety or depressive illness, and scores 
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between 8 and 10 indicate borderline cases. A combined score of 19 or above is considered 
indicative of psychological distress. 
EQ-5D-3L questionnaire measures health status across five domains: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Respondents specify whether they have no 
problems, some problems or severe problems within each domain, on the day of response. These 
EQ-5D-3L health states descriptions are converted into a single summary index (range from 0 to 1) 
by attaching a value to each of the levels in each dimension. As is standard practice, these values 
were obtained from a large UK population study using a choice-based method of valuation. 22 The 
resulting summary score, or utility value, can then be used directly in the cost-utility analysis.  
Outcomes 
The primary endpoint of SUPREMO trial is 10-year overall survival. Quality of life is a secondary 
endpoint alongside chest-wall recurrence, regional recurrence, disease free survival, acute and late 
morbidity and cost-effectiveness. In the QOL substudy we pre-specified as primary outcomes global 
QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, 
anxiety and depression. Secondary outcomes are role, social, sexual functioning, pain and 
nausea/vomiting. 
Statistical analysis 
Sample size for the SUPREMO QOL study was considered as a problem of estimation rather than a 
significance testing. With 200 evaluable patients per group the proportion of patients exhibiting a 
particular side-effect or specified degree of morbidity in a QOL domain could be estimated with a 
standard error of 3·5% or less. The corresponding difference between the groups could be estimated 
with a standard error of 5% or less.  However, as there is usually a significant attrition over time, in 
order to have sufficient numbers by 10 years a target of 800 patients was set. The total sample size 
of SUPREMO was reduced during the course of the trial, following a protocol amendment approved 
by the ethics committee, from 3500 to 1600 but this did not affect the QOL substudy sample. 
When calculating QOL questionnaire or sub-scale scores, we followed official questionnaire 
guidelines on handling missing individual items. In general, if more than 50% of the items were 
missing, sub-scale scores ware not calculated (missing); if less than 50% of items were missing, those 
were replaced by the mean of the answered items and a score was calculated. Where no guidance 
existed, that score was recorded as missing. 
In order to maintain the Normality of the residuals, the difference from baseline to each subsequent 
questionnaire was calculated for each scale. Repeated analysis of covariance was conducted using 
PROC MIXED, to allow for observations that are missing at random. Time and treatment allocation 
interactions were tested for each scale but are to be reported only where statistically significant. 
Baseline scores were included in each model as a covariate. As the QOL study was not originally 
powered for hypothesis testing, p-values are only included for illustration. However, the treatment 
with radiotherapy was our primary outcome, and any results that have a p-value of ≤0.05 with this 
variable will be discussed. Due to the large number of models, clinical variables will only be 
discussed if they exceed the more conservative threshold value of 0.01. 
The principal analysis modelled the change in score in the pre-specified QOL outcomes (global QOL, 
fatigue, physical function, chest wall, shoulder and arm symptoms, body image, anxiety and 
depression) by time (visit 1 at 12 months or 2 at 24 months) of follow up, age group (<45, 45-54, 55-
69, ≥70), baseline score and treatment (± radiotherapy).  
As almost all patients received some form of systemic therapy and some underwent breast 
reconstructive surgery, secondary exploratory analyses were performed to evaluate whether these 
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treatments influenced the QOL outcome measures. The secondary analysis included clinical 
covariates also considered to have an impact on QOL (extent of axillary surgery, early breast 
reconstruction, adjuvant chemotherapy, adjuvant hormonal therapy and trastuzumab). This was 
performed by creating a basic model of age group, time and baseline score, then adding the clinical 
variables in turn to create a model of best fit. This process was then repeated until no variables 
added significantly to the model. The radiotherapy variable was then added to the best fit model. 
Only patients with complete data for all clinical variables were included in this modelling. 
All analyses were on an intention to treat basis. No additional sensitivity analyses or interim analyses 
were planned for this stage of the trial. The analysis was generated using version 9·4 of the SAS 
System for Windows (www.sas.com Copyright © 2012 SAS Institute Inc. SAS and all other SAS 
Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., 
Cary, NC, USA.)  
This study is registered as an International Standard Randomised Controlled Trial, number 
ISRCTN61145589. 
Role of Funding Source  
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author and the joint senior authors had 
full access to all data in the study and had final responsibility for the decision to submit for 
publication. 
Results 
Between August 4, 2006 and April 29, 2013 the trial recruited 1688 patients internationally. All 
patients eligible for SUPREMO from 111 UK centres were invited to participate in the QOL substudy 
(n=1258). This approach was adopted in order to avoid any bias in selecting centres or patients. The 
consent rate between centres varied (see Table consent rates in the web appendix, page 1). The 
majority of the centres (73 centres) had consent rates of 80% or above. Ten centres did not include 
any of their 66 patients in the QOL study. A total of 989 (79%) UK patients consented to participate, 
of them 95·7% (947/989) patients (returned the baseline questionnaires (476/502 94·8% in the 
control and 471/487 96·7% in the radiotherapy arm). The statistical analysis is based on 947 patients 
who returned the baseline QOL questionnaires (Figure 1). Due to the practical arrangements for the 
QOL data collection, questionnaires for years 1 and 2 could be sent only to patients who returned 
the baseline questionnaire. We have not formally recorded reasons for declining participation as 
according to the Ethics Committee approved patient information sheet, patients were not obliged to 
provide such reasons. The patients from UK who declined participation or did not return the baseline 
questionnaires were older (n=311 mean age 57.7 years, SD 11.9) than those who consented and 
returned the baseline questionnaire (n=947 mean age 56.1 years, SD=11.0; p=0.02). Comparing the 
age of QOL study participants with the rest of the main trial (UK patients not participating in QOL 
study and all patients from other countries) did not show an age difference (n=741 mean age 55.6 
years, SD 11.6, p=0.34).  In order to check further for potential bias in patient selection for the QOL 
substudy, we compared the clinical characteristics of the patients completing the QOL substudy with 
those of the patients in the main trial in Table 1. 
Good patient compliance was achieved with the completion of QOL measures: at year 1 388/466 
83·3% in the control group and 388/467 83·1% in the radiotherapy group; at year 2 (350/463 75·6% 
and 367/457 80·3% respectively. A slightly better compliance was observed in the radiotherapy arm 
at baseline and year 2 (Figure 1).  
Median follow-up for the patients who returned the baseline questionnaires was 748 days  
(interquartile range 417-763) for the control group and 749 days (interquartile range 725-762) for 
radiotherapy group.  
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Patient characteristics 
Patients’ demographic, clinico-pathological characteristics and treatment details are shown in Table 
1. There is good balance in clinical characteristics between the radiotherapy and no radiotherapy 
groups in the QOL substudy. Some 70% (669/947) of patients had T2 tumours, 54% (512/947) were 
Grade 3, 78% (746/947) were ductal carcinomas, 19% (180/947) were oestrogen/progesterone 
receptor negative, and 30% 285/947) Her2 positive. Only a small proportion of 11% (11/947) had 
immediate reconstruction, and 11% (106/947) late reconstruction (by 2 years). A further review of 
the type of breast reconstruction suggested more frequent autologous reconstructions in the 
radiotherapy group, whereas there were more reconstructions with an implant/expander in the 
control group (see Web appendix, page 2).  This trend was observed for both the immediate and the 
late reconstructions.  Some 84% (796/947) of participants had adjuvant chemotherapy, 19% 
(183/947) trastuzumab and 75% 712/947) endocrine therapy. No differences are observed between 
the QOL participants and the full trial.  
The majority of patients in the radiotherapy group of the QOL study received 40 Gy in 15 fractions 
(69%, 327/478), with the remaining patients equally divided between 50 Gy in 25 fractions (11%, 
52/478), 45 Gy in 20 fractions (10%, 48/478) and other/unknown (10%, 51/478). In the main trial, a 
smaller proportion of 52% (445/853) received 40 Gy in 15 fractions, a larger proportion of 27% 
(227/853) had 50 Gy in 25 fractions, 7% (57/853) had 45 Gy in 20 fractions and 15% (124/853) - 
other/unknown. The dose for all EORTC centres was 50 Gy in 25 fractions. 
Baseline and follow-up QOL scores are shown in Table 2. Baseline scores were reported following 
surgery and prior to randomisation. Of note, patients reported relative impairment in global QOL 
with a mean score of 60 (100 is excellent), a high level of fatigue (mean of 40, where 100 is greatest 
degree of fatigue), insomnia (mean of 36-37; 100 is worse) and a degree of arm symptoms, chest 
wall symptoms and pain (in the range of 17 to 24; 100 is worst symptom).  
Pre-specified primary QOL outcomes 
Table 3 presents the results from mixed-effects models analysis of pre-specified primary QOL 
outcomes and pain (a pre-specified secondary QOL outcome).  The tested clinical variables are 
included in Table 3 where they were found to have a significant effect (p<0.01) on either the 
radiotherapy treatment or on changes over time. Such effects were found for adjuvant 
chemotherapy and immediate breast reconstruction but not for extent of axillary surgery, adjuvant 
endocrine therapy or trastuzumab. 
Chest wall symptoms were worse in the group receiving radiotherapy (estimate of effect 2·17; 95% 
Confidence Interval (CI) 0·40, 3·94; p=0·016). There was an improvement between years 1 and 2 
(visit effect -1.34; 95% CI -2·36, -0·31; p=0·010), but the improvement was smaller in the 
radiotherapy group (Figure 2a). Of the clinical factors the use of chemotherapy was associated with 
less improvement in chest wall symptoms but there was no interaction with radiotherapy, 
suggesting an additive effect of chemotherapy (Figure 2a).  There was a borderline age effect, with 
patients <45 years having worse chest-wall symptoms than those ≥70 years (estimate of effect 4·49; 
95% CI 0·59, 8·39; p=0·022). 
Arm problems did not differ significantly according to radiotherapy treatment (Figure 2b), they 
improved in both group between years 1 and 2, with a greater improvement in older patients (data 
not shown). When clinical variables were included the effect of age was no longer apparent. 
However, chemotherapy had an effect with patients receiving chemotherapy showing less 
improvement of arm symptoms over time, suggesting that chemotherapy and age were 
confounders. Significantly more patients who received chemotherapy were in the younger age group 
(97% of patients <45 years, 97% in 45-54 years, 85% in 55-69 years, 37% in ≥70 years groups, P < 
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0·0001). Contrary to the clinical expectations, the extent of axillary surgery (comparison of 3 types: 
1) sentinel node biopsy or node sampling; 2) sentinel node biopsy plus axillary node clearance; 3) 
axillary node clearance) did not have an effect on arm/shoulder symptoms scores (see Web 
appendix, page 3). Furthermore, the extent of axillary surgery did not have an impact on any of the 
pre-specified QOL variables, except a trend for higher HADS-Anxiety in patients with sentinel node 
biopsy plus axillary node clearance. 
Despite the observed differences in chest-wall symptoms patients reported relatively few body 
image problems with improvement between years 1 and 2. Some age effect was observed with 
patients <45 years old reporting more concerns about their body image in comparison with patients 
≥70 years old (estimate of effect 1·96; 95% CI 0·53, 3·39; p=0·0074). 
The overall QOL of patients was not affected by radiotherapy treatment. Furthermore, improvement 
in overall quality of life was observed between baseline and year 1 with further but smaller 
improvement by year 2 (Figure 2c).  
Physical function was not affected by treatment and no change was observed over time (Figure 2d). 
As expected there was an age affect with the younger age group reporting better overall physical 
functioning (Table 3). 
Patients reported high baseline level of fatigue, likely due to the preceding surgery. Significant 
improvement between year 1 and 2 was observed. Immediate reconstruction had a borderline 
impact on the change scores at year 1 (estimate of effect 5·32; 95% CI 0·94, 9·69; p=0·017), possibly 
related to slower recovery from the operation (Figure 2e), but without detectable differences in 
overall QOL or body image. 
No group differences were seen in HADS-Anxiety and HADS-Depressions scores. Women younger 
than 70 reported higher levels of Anxiety with improvement from baseline to year 1 and to year 2  in 
both groups. 
Pre-specified secondary QOL outcomes 
An interesting pattern in self-reporting of general pain was observed. The mean score at baseline 
was just over 20 in both groups, but without any improvement from baseline to year 1 or year 2 
independent of randomisation arm, which is at odds with some of the findings for the primary 
outcomes (global QOL, fatigue, chest-wall symptoms, body image and anxiety) where we observed 
an improvement from baseline. We investigated the potential impact of systemic treatments. 
Borderline effects were found for use of trastuzumab (P=0·06) and chemotherapy (P=0·08), possibly 
associated with the use of taxanes. No effect was found for endocrine therapy (none vs tamoxifen vs 
aromatase inhibitors).  
No between-group differences were observed for nausea/vomiting, sexual, role and social functions. 
Gradual improvement over time was observed without any effect of treatments. Role function and 
social function showing the biggest numerical improvement over time, in year 1 with continued 
improvement in year 2. Patients having radiotherapy reported larger improvements in their social 
function in comparison with those who did not. Patients reported very low scores on sexual 
functioning (mean of 11 out of 100).  We had good completion rate for the general sexual function 
questions 97% (914/947) but only 27% (253/914) patients completed the conditional sexual 
enjoyment questions at baseline suggesting that the vast majority of patients are not sexually active 
(Table2). These observations are consistent with other reports.  
The exploratory analysis of the other scales is in the web appendix page 5. All remaining scales and 
items did not show any impact of radiotherapy treatment and all show improvement or stability 
over time.  
Discussion 
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To our knowledge, this is the first study investigating the impact of adjuvant radiotherapy on quality 
of life after mastectomy in a large randomised trial including a substantial, well characterised 
population of UK patients with ‘intermediate-risk’ breast cancer. The key finding is that PMRT was 
associated with worse local self-reported symptoms (pain, swelling, oversensitivity and skin 
problems in the “area of the affected breast”) in comparison with no radiotherapy, although these 
symptoms improved over time. The estimated effect is small, with a difference in ‘change scores’ 
between the radiotherapy and control group of 2·17 points; 95% CI 0·40, 3·94. There is published 
data on EORTC QLQ-C30 on ‘change scores’ within groups or ‘scores difference’ between groups that 
is clinically significant, but to the best of our knowledge, there is no such available data on EORTC-
BR23 scores 23. We opted to present the mean scores and standard deviations in order to allow 
comparisons with other studies. In an attempt to explore the clinical significance of the observed 
statistically significant difference, we looked at using a generic approach of 0.5 of the standard 
deviation to indicate minimally important difference.  Therefore, we calculated the standard 
deviation of the ‘change score’ for chest wall symptoms from baseline to year 1 in the control group. 
24  The standard deviation was 17.3 and a score 8.65 is likely to indicate a clinically meaningful 
difference. The observed difference of 2.17 is relatively small and unlikely to be of clinical 
significance, which is of course reassuring for patients and clinicians. Recent guidelines from Federal 
Drugs Administration (FDA) recommend establishing a meaningful change in patient reported 
outcome measures at the individual level (i.e., defining a responder) versus at the treatment group 
level 25. The definition of a responder being “a score change in a measure, experienced by an 
individual patient over a predetermined time period that has been demonstrated in the target 
population to have a significant treatment benefit”. Using this approach and a ‘change score’ of 8.65 
as a cut-off score for clinical significance we applied ‘responder analysis’ (web appendix page 7).  We 
calculated proportions of patients whose scores ‘improved’ by < - 8.65 points between baseline and 
year 1, those who remained ‘stable’/no change’ (change score=+/-8.65) and those whose scores 
‘worsened’ by >+8.65 points. This ‘responder analyses’ showed that 16.3% (63/386) of patients 
receiving radiotherapy reported clinically meaningful worse ‘change score’ vs 11.9% (46/385) of 
those without radiotherapy. In other words, 4.4% more patients on radiotherapy experience worse 
chest wall symptoms than those not receiving PMRT. This way of interpretation of results may be 
more informative to clinicians and patients, but a note of caution is appropriate due to the 
assumptions described above.  
There was no impact of radiotherapy to the chest wall on arm symptoms (axillary radiotherapy was 
prohibited in the trial), body image, overall QOL, physical function, fatigue or symptoms of anxiety or 
depression. Exploratory analyses showed that systemic chemotherapy treatment had an additive 
borderline effect on patients’ chest wall and arms symptoms but without an interaction with the 
radiotherapy treatment. This is consistent with other studies 26.   
Sentinel node biopsy procedure is the current standard surgical staging procedure for the axilla. In 
SUPREMO about a quarter of patients (those with pN0 (sn) tumours) in the main and QoL substudy 
underwent limited axillary surgery (sentinel node biopsy or nodal sampling). The extent of axillary 
surgery had no impact on any of the pre-specified QOL outcomes, including arm symptoms. This is 
perhaps an unexpected finding and could be due to lack of sensitivity of the EORTC BR23 scale 
(which has 3 items on ‘pain in arm or shoulder’, ‘swollen arm or hand’ and ‘difficulty raising your 
arm’). The impact of radiotherapy to the axilla on arm symptoms cannot be evaluated in the 
SUPREMO trial, as this was prohibited. Our findings are not generalisable to women who were 
treated with both an axillary nodal dissection and regional nodal radiotherapy. This treatment is 
generally reserved for patients with higher nodal load (N2 and N3 disease) than included in the 
SUPREMO trial (pN0 or pN1).  
Neo-adjuvant treatment was allowed in a later protocol version (version 29), but the number of 
treated patients is too small (n=8) for valid conclusions and therefore we did not perform any 
between group comparisons.   
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We observed a low rate of immediate breast reconstruction (only 111 patients). This procedure was 
associated with higher fatigue levels and slower recovery in comparison with no immediate 
reconstruction but no impact on body image or the other QOL outcomes. The estimated effect of 
immediate reconstruction on fatigue was 5.32, corresponding to a small clinically meaningful 
difference23. This was an exploratory analysis and we used a generic QOL and body image 
questionnaires rather than breast-reconstruction instruments (such as BREAST-Q), which is likely less 
sensitive to specific outcomes 17.  
The observed low levels (11%) of reconstructive surgery (either immediate or delayed to year 2) 
should be noted. This likely reflects the pattern of care in the period of the SUPREMO trial 
recruitment (2006-2013) or may be due to concerns of entering patients who had reconstruction 
into a trial of radiotherapy. There appears to be a trend in using more autologous procedures in 
patients who had radiotherapy and more implants/expanders in those not receiving radiotherapy. 
Due to the small number of reconstructions, SUPREMO trial cannot provide useful information on 
the impact of radiotherapy on breast reconstruction. We are collecting further information on 
delayed (beyond 2 years) reconstructions, which will be analysed at 5 and 10 years and provide 
valuable information on rates of breast reconstruction across the UK, as well as its impact on 
patients’ experiences and satisfaction with body image. Furthermore we do not have the power to 
assess between group differences taking into account the dose schedules in the radiotherapy group.  
A direct comparison of conventional versus hypo-fractionation for chest wall radiotherapy after 
breast reconstruction is being carried out in North America by the Alliance for Clinical Trials in 
Oncology (NCT03414970). The primary objective is to evaluate whether the reconstruction 
complication rate at 24 months post radiation is non-inferior with hypofractionation. The trial is 
ongoing and will complete recruitment in 2021, with final results in August 2025. 
Most of the published literature relating to the impact of adjuvant radiotherapy on QOL relates to 
non-randomised studies, often of small size, which may be subject to selection bias and neither 
surgery, radiotherapy nor were systemic treatments subject to pre-specified quality assurance. 
Comparisons are often difficult because of differing types of surgery, stage of disease, QOL measures 
used and time-points of QOL assessment. Studies often included both patients treated by 
mastectomy and breast conserving surgery. The START trial looked at late effects of different 
schedules of radiotherapy at 5 years and found that up to a third of women reported moderate or 
marked pain in the arm and shoulder and more than 10% experienced arm/hand swelling12. The trial 
included a small number of mastectomy patients (about 20%) and although the QOL results are 
consistent with ours, they are not directly comparable since only 10% had chemotherapy and 20% 
had regional nodal irradiation in addition to breast/chest wall radiotherapy. The experience of 
breast/arm symptoms over 5 years represents chronic morbidity that has stronger association than 
cosmesis with long-term quality of life, making these important outcomes in clinical trials27. 
The Moving Beyond Cancer psychosocial intervention trial studied the QOL of 558 women with stage 
1 and 2 breast cancer treated with surgery alone (breast conserving or mastectomy), surgery with 
radiation, or surgery followed by chemotherapy and radiation  over 1 year, using SF-36 
questionnaire. Similar to our study, physical and psychosocial function improved significantly over 
time. However, the measures of QOL differ from our study and details of chemotherapy regimes  
and staging were not available in the absence of case record review26. A similar pattern of 
improvement in a range of symptoms and QOL measures in the first year post diagnosis was 
observed in a cohort study of 285 women with early breast cancer, treated with surgery (just >20% 
had mastectomy), adjuvant radiotherapy (74%) and systemic therapy in (just >30% of the patients)  
28.  
Finally, we observed that younger women reported worse body image (if under 45) and anxiety 
problems (if under 70 years). This finding is supported by other breast cancer QOL studies, is 
concordant with clinical experience and emphasises the need for targeted psychological 
interventions in those women11,29. Younger women also reported higher general pain scores which   
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did not improve with time, and this was not related to the use of aromatase inhibitors (data not 
shown). The reasons for this are not clear. Persistent pain following breast surgery (breast 
conserving or mastectomy) was reported by half of the patients in a population-based prospective 
study of over 3000 patients. The pain was commoner after adjuvant radiotherapy and in younger 
women. 30 The same finding was also reported in a randomised trial of radiotherapy after breast 
conserving therapy 13,30. The wide variation in reports (25% -60%) may relate to varying definitions of 
pain, different methods of pain assessment and mix of surgery and adjuvant therapy. There is 
insufficient evidence to draw conclusions on each of the treatment-related risk factors for pain. 
Several strengths of SUPREMO QOL substudy should be mentioned. It is the largest post-
mastectomy study which is investigating a well-defined large population of patients treated by 
mastectomy, which was    representative of women with early ‘intermediate-risk’ breast cancer in 
the UK. Individuals in the QOL study were recruited from almost all UK sites. Only 10 out of 111 sites 
did not recruit any of their 66 patients, a relatively small number of centres and unlikely to have an 
impact. We do not know the reasons for the low consent rates in some centres, but it may be 
related to availability of local resources (dedicated clinical research nurses).  This was a large 
pragmatic study and resources were not available to monitor closely consent rates by centre or to 
provide extra support.  
The QOL study was multi-centre from across the UK, representing a wide geographical range, thus 
minimising participating centre bias. The pre-specified QOL sample size was achieved and exceeded, 
strengthening our confidence in the findings. The trial was sufficiently large to allow explorative 
evaluation of the effects of age and multi-modality treatments. High levels of adherence to 
questionnaire completion over time were attained (>70%). In addition, guidelines on surgery, 
radiotherapy and systemic therapy were standardised in the protocol, so any variations in these 
treatment modalities between treatment arms are unlikely to influence the results.  
The main limitation of the QOL substudy is not having a true pre-treatment baseline QOL 
assessment, as all patients were randomised following mastectomy. The relatively low QOL scores at 
the time of randomisation may be explained by the recent breast cancer diagnosis and the surgical 
procedure, and the subsequent improvement in almost all scores, is to be expected.  We did not 
record QOL scores during or shortly after the allocated radiotherapy treatment, so any differences in 
acute symptoms between the groups, which may predict later toxicity, have not been captured. In 
addition, since the main trial is ongoing and the loco-regional control and survival status of the 
patients in the QoL substudy are not known to us, it is possible patients who had relapsed or died 
may have had different patterns of QOL.  
A larger proportion of participants in the QOL study received the dose fractionation schedule as 40 
Gy in 15 fractions (69%) compared to 52% in the main trial, where a larger proportion of 27% 
received 50 Gy in 25 fractions. This difference reflects the variations between the standard practice 
in UK and EORTC centres at the time of the trial.  
At this 2-year analysis we have not evaluated any effect of fractionation on the QOL outcomes. 
However, as the clinical significance of the increased chest wall symptoms in the radiotherapy group 
at 2 years may be relatively limited, we do not expect a major clinical impact of fractionation at this 
early time point. We expect that the difference in symptoms reported by patients between no 
radiotherapy and 40-50 Gy will be larger than any difference observed between fractionation 
schedules. The influence of radiation dose fractionation and technique and the radiation dose 
parameters to organs at risk will be the subject of a more detailed analysis to be performed in the 
irradiated group, including evaluation of toxicity (physician scoring). The results will be reported in a 
separate publication, focusing on the specific technical aspects of the radiotherapy. 
This paper presents a pre-planned analysis at 2 years post randomisation, with the main QOL 
analysis being planned at 5 years and QOL data to be collected for 10 years to capture late adverse 
events. Clearly our results are preliminary and we are therefore cautious in our interpretation. 
 14 
However, it is a reassuring that the loco-regional symptoms are minimal and do not impair global 
QOL and diminish over the initial 2 years of follow up.   While it might be argued that analysing QOL 
at 2 years is too premature, this was a pre-planned analysis. We considered it appropriate to identify 
any potential early signals of a significant impact on QOL in the absence of a definite oncological 
outcome. If severe QoL effects were to be identified early, then this would be relevant for clinical 
decision making in the absence of information on long-term survival benefit. The recent North 
American guidelines on post mastectomy radiotherapy 7 emphasise the importance of shared 
decision making between physician and patient in weighing up the benefits and toxicity of treatment 
in patients with 1- 3 positive node undergoing axillary node clearance. Information on the impact of 
PMRT on QOL may help inform this decision-making process, even before the main trial outcomes 
become available.   Further analyses will be reported at 5 and 10 years to determine if the trends at 
2 years are sustained. It is possible that late radiotherapy toxicity not seen within the first two years 
(such as progressive chest wall fibrosis or increased cardiac toxicity due to the combination of 
radiotherapy and anthracycline-based chemotherapy) may be detected on longer term follow-up 
and should be captured in our 5 and 10 year analyses. However, we recognise that late cardiac 
toxicity from radiotherapy may occur beyond 10 years. 
The impact on PMRT on 10-year survival, the primary end-point of the main SUPREMO trial, will not 
be known before 2023. In the meantime, the decision to administer or omit PMRT can be considered 
‘preference sensitive’ for patients in the SUPREMO trial risk category of 1-3 positive lymph nodes, as 
both options are legitimate. The patients will be in a better position to make a value judgment on 
what they consider relevant for them, given the data on various QOL domains presented in this 
report. Both physicians and patients may thus be helped when weighing up the individual estimates 
of possible benefits of radiotherapy against the impact of PMRT on toxicity and QOL endpoints.  
In conclusion, chest wall radiotherapy led to more chest wall symptoms up to 2 years post-
randomisation, but the difference is small and unlikely to be clinically significant. There was no 
impact on the other pre-specified QOL domains.  However, the trend for worse QOL scores for 
anxiety, body image and chest-wall symptoms in younger women irrespective of irradiation warrants 
further investigation. Longer term follow-up at 5 and 10 years will be needed to see if these early 
trends in quality of life are sustained. 
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Tables 
Table 1. Patients’ demographic and clinical characteristics 
Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Demographic 476 471 835 853 
Age (mean and SD) 56·3 (11·3) 55·8 (10·8) 55·9 (11·2) 55·8 (11·3) 
Menopausal status (number, %) 
Pre-menopausal 
Peri-menopausal 
Post-menopausal 
Not known 
 
126 (26·5) 
43 (9·0) 
290 (60·9) 
17 (3·6) 
 
135 (28·7) 
52 (11·0) 
268 (56·9) 
16 (3·4) 
 
246 (29·5) 
68 (8·1) 
483 (57·8) 
38 (4·6) 
 
243 (28·5) 
85 (10·0) 
475 (55·7) 
50 (5·9) 
     
Tumour characteristics     
Side of primary tumour (number, %) 
Left 
Right 
 
238 (51·2) 
227 (48·8) 
 
216 (47·8) 
236 (52·2) 
 
398 (50·1) 
396 (49·9) 
 
407 (51·3) 
387 (48·7) 
Tumour size (number, %) 
≤2cm 
2·1-5 cm 
>5 cm 
Unknown 
 
132 (27·7) 
337 (70·8) 
5 (1·1) 
2 (0·4) 
 
138 (29·3) 
332 (70·5) 
1 (0·2) 
0 
 
249 (29·8) 
566 (67·8) 
4 (0·5) 
16 (1·9) 
 
261 (30·6) 
566 (66·4) 
4 (0·5) 
22 (2·6) 
Tumour grade (number, %) 
I 
II 
III 
Not specified 
 
20 (4·2) 
190 (39·9) 
262 (55·0) 
4 (0·8) 
 
23 (4·9) 
195 (41·4) 
250 (53·1) 
3 (0·6) 
 
46 (5·5) 
335 (40·1) 
432 (51·7) 
22 (2·6) 
 
57 (6·7) 
333 (39·0) 
432 (50·6) 
31 (3·6) 
Histological type (number, %) 
Ductal 
Lobular 
Mucinous 
Tubular 
Adenocarcinoma 
Other  
 
372 (78·5) 
58 (12·2) 
5 (1·1) 
1 (0·2) 
3 (0·6) 
35 (7·4) 
 
374 (79·4) 
49 (10·4) 
1 (0·2) 
3 (0·6) 
5 (1·1) 
39 (8·3) 
 
641 (78·2) 
95 (11·6) 
7 (0·9) 
4 (0·5) 
16 (2·0) 
57 (7·0) 
 
661 (79·5) 
89 (10·7) 
1 (0·1) 
4 (0·5) 
13 (1·6) 
63 (7·6) 
Molecular markers – (number, %) 
ER+/PR+ 
ER+/PR- 
ER-/PR+ 
ER-/PR- 
ER+/PR unknown 
ER-/PR unknown 
 
Her2 positive 
Her2 negative 
Not measured 
 
218 (46·8) 
48 (10·3) 
5 (1·1) 
87 (18·7) 
96 (20·6) 
12 (2·6) 
 
140 (29·7) 
286 (60·7) 
45 (9·6) 
 
 
217 (46·7) 
48 (10·3) 
0 (0) 
93 (20·0) 
100 (21·5) 
7 (1·5) 
 
145(31·1) 
281 (60·2) 
41 (8·8) 
 
 
417 (51·5) 
83 (10·3) 
8 (1·0) 
156 (19·3) 
131 (16·2) 
15 (1·9) 
 
273 (33·5) 
475 (58·2) 
68 (8·3) 
 
 
416 (50·6) 
99 (12·0) 
3 (0·4) 
162 (19·7) 
132 (16·0) 
11 (1·3) 
 
269 (32·5) 
469 (59·9) 
63 (7·6) 
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Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Axillary Nodes (number, %) 
0 (negative) 
1- 
2- 
3- 
Not known 
 
130 (27·3) 
180 (37·8) 
101 (21·2) 
63(13·4) 
2 (0·4) 
 
113 (24·0) 
199 (42·3) 
111 (23·6) 
48 (10·2) 
0 
 
219 (26·2) 
316 (37·8) 
178 (21·3) 
107 (12·8) 
15 (1·8) 
 
212 (24·9) 
338 (39·6) 
194 (22·7) 
88 (10·3) 
21 (2·5) 
     
Treatment     
Breast Surgery (number, %) 
Mastectomy only 
Immediate breast reconstruction 
prior to RT 
Late breast reconstruction  
 
371 (77·9) 
50 (10·5) 
 
55 (11·6) 
 
359 (76·2) 
61 (13·0) 
 
51 (10·8) 
 
653 (78·2) 
85 (10·2) 
 
97 (11·6) 
 
669 (78·4) 
97 (11·4) 
 
87 (10·2) 
     
Axillary surgery (number, %) 
SLN / node sampling 
SLN plus ANC (Axillary node 
clearance) 
ANC (without SLN) 
 
131 (27·9) 
138 (29·4) 
 
201 (42·8) 
 
108 (22·9) 
124 (26·3) 
 
239 (50·7) 
 
207 (25·5) 
229 (28·2) 
 
377 (46·4) 
 
189 (22·8) 
224 (27·0) 
 
417 (50·2) 
Systemic treatment (number Yes, %) 
Neo-adjuvant chemotherapy1  
Adjuvant chemotherapy 
Anthracyclines 
Taxanes 
Trastuzumab 
 
Endocrine therapy (number Yes, %) 
Neo-adjuvant 
Adjuvant 
Aromatase inhibitor 
Tamoxifen 
Other  
 
1/173 (0·58) 
395/476(83·0) 
372/395(94·2) 
197/395(49·9) 
91/454 (20·5) 
 
 
2/200 (1·0) 
349 (73·3) 
173/349(49·6) 
174/349(49·9) 
2/349 (0·6) 
 
7/173 (4·1) 
401/471(85·1) 
379/401(94·5) 
207/401(51·6) 
92/460 (20·0) 
 
 
8/206 (3·9) 
363 (77·1) 
195/363(53·7) 
168/363(46·3) 
0/363 (0) 
 
7/243 (2·9) 
682/835(81·7) 
636/682(93·3) 
392/682(57·5) 
150/782(19·2) 
 
 
10/288 (3·5) 
598 (71·6) 
275/598(46·0) 
319/598(53·3) 
4/598 (0·8) 
 
16/269 (6·0) 
709/853(83·1) 
655/709(92·4) 
418/709(59·0) 
166/806(20·6) 
 
 
17/316 (5·4) 
631 (73·9) 
314/631(49·8) 
314/631(49·8) 
3/631 (0·5) 
1 Only recorded in protocol v29 onwards; the denominator is the total number of recorded 
chemotherapy treatments from protocol v29 onwards 
ER- estrogen receptor; PR – progesteron receptor; SLN- sentinel lymph node(s) procedure; ANC – 
axillary node clearance 
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Table 2. Quality of Life (QOL) scores (Standard Deviations, SD) at baseline, year 1 and year 2 follow-
up 
 
QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Age at 
randomisation 
56·3 (11·3) 55·8 (10·8) 56·5 (10·9) 56·1 (10·4) 56·8 (10·9) 56·1 (10·4) 
       
Primary endpoints      
EORTC QLQ-C30       
Global 
Health/QOL* 
60·9 (21·6) 60·4 (20·8) 70·0 (20·5) 70·0 (19·8) 70·2 (20·5) 71·8 (20·1) 
Fatigue** 41·6 (25·2) 43·0 (26·1) 30·3 (23·2) 31·0 (24·1) 29·2 (24·2) 27·5 (23·8) 
Physical 
Functioning* 
79·6 (20·2) 80·1 (19·6) 81·9 (19·0) 81·1 (19·1) 82·0 (18·6) 82·1 (19·3) 
       
EORTC QLQ-BR23       
Arm symptoms** 20·3 (20·5) 21·2 (21·7) 21·2 (21·7) 22·4 (22·0) 20·7 (21·4) 19·9 (20·3) 
Chest wall/breast 
symptoms** 
17·3 (17·0) 18·1 (18·3) 13·1 (16·3) 16·1 (16·7) 11·6 (14·6) 14·1 (15·8) 
       
Body Image 
Scale** 
10·3 (7·9) 11·1 (8·2) 9·3 (7·6) 9·8 (7·7) 8·1 (6·7) 8·7 (7·4) 
       
Hospital Anxiety and 
Depression Scale (HADS) 
     
Anxiety 6·2 (4·4) 6·1 (4·3) 6·8 (4·7) 6·5 (4·4) 6·3 (4·3) 6·5 (4·4) 
Depression 4·5 (3·7) 4·6 (3·7) 4·2 (3·7) 4·2 (3·8) 4·0 (3·5) 4·2 (3·9) 
       
Secondary endpoints      
EORTC QLQ-C30       
Role Functioning * 65·2 (30·9) 63·0 (30·5) 79·3 (27·1) 78·8 (25·8) 79·7 (27·6) 81·0 (26·9) 
Social Functioning 
* 
65·5 (28·7) 64·0 (29·1) 79·4 (25·6) 80·3 (24·7) 80·5 (26·1) 83·9 (25·2) 
Pain** 22·6 (26·5) 24·8 (27·9) 21·7 (26·8) 23·7 (26·5) 23·4 (27·3) 21·6 (25·9) 
Nausea 
Vomiting** 
11·2 (17·6) 11·5 (20·1) 5·3 (13·1) 5·1 (12·1) 4·6 (12·2) 5·1 (13·6) 
       
EORTC QLQ-BR23       
Sexual 
Functioning* 
11·5 (18·1) 
n=455 
12·5 (19·0) 
n=459 
15·7 (20·5) 
n=372 
17·6 (21·2) 
n=374 
16·3 (21·7) 
n=325 
18·1 (22·3) 
n=353 
       
Exploratory variables      
EORTC QLQ-C30       
Emotional 
Functioning* 
74·7 (22·6) 73·7 (24·4) 75·2 (23·6) 75·2 (22·3) 77·3 (22·5) 75·7 (23·3) 
Cognitive 
Functioning* 
77·1 (23·4) 75·0 (26·1) 78·2 (22·8) 78·2 (22·9) 78·6 (22·8) 78·2 (23·8) 
Dyspnoea** 20·8 (26·4) 20·0 (26·1) 14·6 (23·5) 14·8 (23·0) 14·3 (23·2) 13·4 (22·5) 
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QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Insomnia** 36·3 (31·1) 37·2 (32·8) 36·4 (33·5) 38·5 (32·8) 33·9 (31·9) 35·0 (30·5) 
Appetite loss** 20·7 (28·9) 19·2 (27·9) 9·5 (19·8) 8·7 (18·5) 9·1 (19·9) 9·0 (20·7) 
Constipation** 18·2 (26·3) 17·0 (26·1) 14·9 (24·5) 14·5 (24·1) 17·6 (27·7) 14·5 (24·3) 
Diarrhoea** 11·9 (20·7) 12·1 (23·8) 7·6 (17·5) 8·4 (18·7) 5·4 (15·1) 8·7 (19·1) 
Financial 
difficulties** 
23·9 (33·1) 23·2 (31·7) 15·8 (28·5) 17·1 (27·8) 14·1 (27·0) 13·8 (26·6) 
       
EORTC QLQ-BR23       
Sexual 
enjoyment* 
49·9 (26·9) 
n=121 
53·0 (29·1) 
n=132 
54·4 (28·3) 
n=136 
56·5 (26·5) 
n=144 
52·5 (26·1) 
n=115 
56·6 (28·8) 
n=136 
Future 
perspective** 
45·8 (31·2) 46·4 (32·8) 49·8 (32·3) 50·9 (31·6) 54·4 (30·1) 54·1 (30·9) 
Systemic therapy 
side-effects** 
34·8 (23·1) 35·2 (22·7) 19·3 (15·2) 19·6 (15·6) 18·6 (14·9) 18·3 (15·0) 
Hair loss** 29·6 (37·5) 31·7 (39·3) 6·2 (20·4) 6·4 (21·8) 3·8 (20·7) 4·9 (17·1) 
       
EQ-5D-3L*** 0·74 (0·22) 0·74 (0·22) 0·75 (0·25) 0·75 (0·24) 0·76 (0·24) 0·77 (0·22) 
 
 
*EORTC QLQ-C30 Functional scores- range 0-100 (higher score = good functioning) 
** EORTC QLQ-C30 Symptom scores – range 0-100 (higher score = worse symptoms) 
*** EQ-5D-3L score-range 0-1. 
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Table 3. Mixed effects models (fixed effects) for the primary QOL outcomes 
 
Outcome Model variable Estimate of 
effects 
95% CI p 
Global 
QOL (C30) 
Baseline score 
Age- ref* >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·57 
- 
1·12 
3·25 
3·54 
0·75 
1·39 
-0·63, -0·52 
- 
-3·45, 5·78 
-0·62, 7·12 
-0·28, 7·36 
-0·46, 1·97 
-0·92, 3·71 
<0·0001 
- 
0·64 
0·10 
0·069 
0·23 
0·24 
 Adjusted mean 
of ‘change 
scores’**  
95% CI p-value*** 
   
RT 
No RT 
8·63 
7·23 
6·86, 10·40 
5·46, 9·01 
<0·0001 
<0·0001 
Fatigue 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Immediate 
reconstruction 
Ref no recon 
RT –ref no RT 
-0·59 
- 
-2·41 
-4·14 
-3·13 
-1·83 
5·32 
 
 
-1·93 
-0·65, -0·54 
- 
-8·07, 3·26 
-8·84, 0·56 
-7·73, 1·47 
-3·20, -0·46 
0·94, 9·69 
 
 
-4·70, 0·84 
<0·0001 
- 
0·40 
0·079 
0·18 
0·0094 
0·017 
 
0·17 
RT 
No RT 
-9·54 
-7·61 
-12·19, -6·89 
-10·35, -4·87 
<0·0001 
<0·0001 
Physical 
function 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·41 
- 
7·91 
7·06 
4·29 
0·20 
-0·17 
-0·46, -0·35 
- 
3·94, 11·87 
3·80, 10·32 
1·06, 7·51 
-0·68, 1·08 
-2·13, 1·79 
<0·0001 
- 
<0·0001 
<0·0001 
0·0092 
0·65 
0·87 
RT 
No RT 
-0·02 
0·14 
-1·53, 1·48 
-1·36, 1·65 
0·97 
0·85 
Chest wall 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT –ref no RT 
-0·57 
- 
4·49 
1·88 
2·36 
-1·34 
3·74 
2·17 
-0·62, -0·52 
- 
0·59, 8·39 
-1·46, 5·22 
-0·79, 5·51 
-2·36, -0·31 
0·87, 6·61 
0·40, 3·94 
<0·0001 
- 
0·022 
0·26 
0·14 
0·010 
0·011 
0·016 
RT 
No RT 
-3·13 
-5·30 
-4·74, -1·51 
-6·88, -3·71 
0·0002 
<0·0001 
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Arm and 
shoulder 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT –ref no RT 
-0·51 
- 
0·86 
2·89 
2·76 
-0·93 
6·15 
-0·53 
-0·57, 0·45 
- 
-4·42, 6·14 
-1·64, 7·41 
-1·51, 7·03 
-2·22, 0·37 
2·26, 10·05 
-2·92, 1·86 
<0·0001 
- 
0·74 
0·21 
0·20 
0·16 
0·0021 
0·66 
RT 
No RT 
-1·44 
-0·91 
-3·63, 0·75 
-3·06, 1·24 
0·19 
0·40 
Body 
Image 
Scale  
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·39 
- 
1·96 
1·39 
0·83 
-0·91 
-0·09 
-0·43, 0·34 
- 
0·53, 3·39 
0·20, 2·58 
-0·33, 1·99 
-1·28, -0·55 
-0·79, 0·61 
<0·0001 
- 
0·0074 
0·022 
0·15 
<0·0001 
0·79 
RT 
No RT 
-1·36 
-1·27 
-1·90, -0·83 
-1·81, -0·73 
<0·0001 
<0·0001 
HADS-
Anxiety 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·30 
- 
1·69 
1·36 
1·21 
-0·05 
-0·16 
-0·35, -0·25 
- 
0·86, 2·53 
0·67, 2·06 
0·53, 1·90 
-0·29, 0·18 
-0·57, 0·25 
<0·0001 
- 
<0·0001 
<0·0001 
0·00050 
0·66 
0·44 
RT 
No RT 
0·44 
0·60 
0·13, 0·76 
0·29, 0·92 
0·0061 
0·00022 
HADS- 
Depression 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·35 
- 
0·07 
-0·05 
-0·04 
0·02 
-0·14 
-0·41, 0·30 
- 
-0·73, 0·87 
-0·72, 0·61 
-0·69, 0·62 
-0·16, 0·20 
0·54, 0·25 
<0·0001 
- 
0·87 
0·88 
0·91 
0·94 
0·48 
RT 
No RT 
-0·19 
0·05 
-0·50, 0·11 
-0·35, 0·25 
0·21 
0·75 
Pain (C30) Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·51 
- 
-0·18 
2·76 
2·18 
0·31 
-0·65 
-0·57, -0·46 
- 
-6·16, 5·80 
-2·17, 7·69 
-2·70, 7·06 
-1·29, 1·91 
-3·62, 2·33 
<0·0001 
- 
0·95 
0·27 
0·38 
0·70 
0·67 
RT 
No RT 
0·28 
0·93 
-1·99, 2·56 
-1·35, 3·20 
0·81 
0·42 
* ref =reference category in the mixed-effects models 
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** the adjusted mean for the individual arms is the mean of the ‘change scores’, (defined as change 
from baseline to year 1 and from baseline to year 2) in each of the treatment groups, adjusted for 
baseline score, visit, and age;  
***p values  - whether each of the means of the ‘change scores’ within each individual arm is 
significantly different from zero (i.e., improvement or deterioration in scores from baseline) 
 
Figure 1. CONSORT diagram – Trial profile of SUPREMO patients participating in the Quality 
of Life (QOL) sub-study 
 
 
 
 
 
 
  
Internationally 
N=835 
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Agreed to QOL 
N=502/626 
(80 .2%) 
Completed 
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*Note: 
1 patient stated RT outside protocol timeframe 
4 patients declined RT following randomisation 
2 patients began RT but did not complete the 
course 
Figures revised
Figure 2. Mean change (95% CI) of QOL scores at years 1 and 2 (adjusted for age group and 
baseline QOL scores).  
*Symptom scores – range 0-100 with higher score = worse symptoms, negative change 
score=improvement 
**Functional scores and Global QOL - range 0-100 with higher score = good functioning, 
positive change score=improvement 
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Summary 
Background Post-mastectomy radiotherapy (PMRT) in patients with 4+ axillary nodes reduces breast 
cancer mortality, but its role in patients with 1-3 involved nodes is controversial. 
Methods BIG2-04-MRC-EORTC SUPREMO is an international parallel randomised controlled trial. 
Eligible women (over 18 years, with ‘intermediate risk’ breast cancer, pT1-2N1, pT3N0 and pT2N0 if 
grade III and/or lympho-vascular invasion, post-mastectomy and axillary surgery) were randomly 
assigned to receive chest-wall radiotherapy (50 Gy 25 fractions or radiobiolgically equivalent 45 Gy 
20 fractions or 40 Gy 15 fractions) or not (1:1 ratio).  Randomisation was in permuted blocks with 
varying block length, stratified by centre, without masking of patients or investigators.  The primary 
endpoint is 10-year overall survival. Here, we present the 2-year quality of life (QOL) results (pre-
specified secondary endpoint). The QOL substudy, open to all UK patients, consists of questionnaires 
(EORTC QLQ-C30 and BR23, Body Image Scale, Hospital Anxiety and Depression Scale (HADS) and EQ-
5D-3L) completed pre-randomisation, 1, 2, 5 and 10 years.  Data were analysed on an intention-to-
treat basis, using repeated mixed-effects methods. The trial is registered with International Standard 
Randomised Controlled Trials (ISRCTN61145589). 
Findings  
Between August 4,2006-April 29, 2013, 1688 patients enrolled internationally, 989/1258 (79%) of 
the UK patients consented to QOL substudy. Patients receiving PMRT reported worse chest-wall 
symptoms (p=0·016) but the difference was small. Symptoms improved from year 1 to 2. 
Chemotherapy was associated with less improvement.  No group differences were observed for arm 
symptoms, body image, fatigue, pain, overall QOL, physical functioning or HADS scores.  
Interpretation PMRT led to more local symptoms up to 2 years post-randomisation, but the 
difference was small. This data will inform shared decision-making whilst survival results (main trial 
endpoint) become available.   
 
Funding Medical Research Council, European Organisation for Research and Treatment of Cancer, 
Cancer Australia, Dutch Cancer Society, Trustees of Hong Kong Shanghai Banking Corporation. 
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Research in Context 
Evidence before this study 
Adjuvant chest-wall irradiation after mastectomy remains a core effective element in the loco-
regional management of early breast cancer reducing loco-regional recurrence and breast cancer 
mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients with 4 or 
more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 involved nodes 
is controversial and practices vary. The Oxford overview in 2014 shows an advantage in overall 
survival from PMRT in patients with 1-3 positive nodes. However, the generalisability to 
contemporary practice of historical trials with different standards of surgery, radiotherapy and 
systemic therapy remains uncertain.  Benefits in survival needs to be balanced against risk of loco-
regional and cardio-pulmonary toxicity, particularly in conjunction with potentially cardiotoxic 
anthracyclines and trastuzumab. The recent American Society of Clinical Oncology guidelines on the 
use of PMRT emphasizes the importance of evaluating the risk-benefit ratio, but the overview data is 
derived from patients treated several decades previously and only a limited number of small studies 
looked at patient-reported outcomes, such as symptoms and quality of life. 
Added value of this study 
Our study uniquely investigated the impact of adjuvant PMRT on quality of life in a randomised trial 
including a large, well characterised population of UK patients with ‘intermediate-risk’ breast cancer 
post-mastectomy. At 2 years PMRT was associated with worse self-reported local symptoms (pain, 
swelling, skin problems in the “area of the affected breast”) in comparison with no radiotherapy, but 
the difference is small, unlikely to be of clinical significance and the symptoms improved over time. 
There were no differences in arm symptoms, body image, fatigue, pain, overall QOL, physical 
functioning anxiety or depression. 
Implications of all the available evidence 
The impact on PMRT on 10 year10-year survival, the primary endpoint of the main SUPREMO trial, 
will not be known before 2023. In the meantime, both options of administering or omitting PMRT 
are legitimate for patients in the intermediate risk category (1-3 positive lymph nodes). Our data will 
inform shared decision-making (as recommended in the recent North American guidelines on PMRT) 
and put patients in a better position to make an informed value judgment on what they consider 
relevant for their situation given the data on the patient-reported symptoms and QOL domains 
presented in this report. Both physicians and patients may be helped when weighing up the 
individual estimates of possible benefits of radiotherapy against the impact of PMRT on toxicity and 
quality of life. 
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Introduction 
Current multimodality treatment for breast cancer has improved survival rates. 1 Avoiding 
overtreatment and balancing the treatment burden against benefit has become an important 
research field. Examples of trials investigating selective omission of radiotherapy or chemotherapy 
have recently been reported. 2,3  While the impact of mastectomy and chemotherapy on quality of 
life has been well documented the additional effect of adjuvant radiotherapy following mastectomy 
is unclear. Chest wall pain, fatigue, anxiety about recurrence and depressive symptoms can all hold 
back recovery and return to normal activities of daily living. 4 
Adjuvant chest wall irradiation after mastectomy remains a core and highly effective element in the 
loco-regional management of early breast cancer reducing loco-regional recurrence and breast 
cancer mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients 
with 4 or more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 
involved nodes is controversial and practice and guidelines vary.5 The Oxford overview in 2014 
shows an advantage in overall survival from PMRT which included at least the chest wall in the 
target volume in patients with both 1-3 and 4 or more positive nodes.6 However, the generalisability 
of historical trials with different standards of surgery, radiotherapy and systemic therapy remains 
uncertain, especially as contemporary survival rates are much higher than in the studies included in 
the overview.  Potential benefits in survival needs to be balanced against risk of loco-regional and 
cardio-pulmonary toxicity, particularly in conjunction with potentially cardiotoxic anthracyclines and 
trastuzumab. A recent update by the American Society of Clinical Oncology on the use of post-
mastectomy radiotherapy emphasiszes the importance of evaluating the risk-benefit ratio, 
particularly in patients with a low risk of local failure.7 The benefit of PMRT relies on estimates of 
recurrence risk, modulated by biological tumour characteristics, weighed against the negative 
impact of PMRT on the risks of late toxicity (e.g. cardiac toxicity from radiotherapy may be increased 
by the combination with systemic therapy)Estimates of recurrence risk, and therefore benefit may 
be modulated by biological tumour characteristics, whereas a negative impact on outcome of excess 
late toxicity may be significant (e.g. cardiac toxicity from radiotherapy may be increased by the 
combination with systemic therapy).8 The data currently available on these modulating effects is 
derived from patients treated several decades previously. 
Selective use of post-mastectomy radiotherapy is being evaluated in the BIG 2.04 MRC /EORTC 
SUPREMO trial (ISRCTN61145589), which assesses the effects of adjuvant chest wall radiotherapy 
without axillary irradiation in patients with ‘intermediate risk’ early breast cancer who have 
undergone mastectomy and adequate systemic therapy following contemporary guidelines for all 
treatment modalities. This is the largest randomised trial to date to assess the role of PMRT in this 
subset of patients. The endpoints have been previously described. 9 In brief, the primary endpoint of 
the trial is overall survival at 10 years. Secondary end points include various breast cancer 
recurrence endpoints, toxicity, acute and late morbidity (cardiac morbidity and mortality) and 
quality of life. Sub-studies include the TRANS-SUPREMO seeking molecular markers of 
radiosensitivity, a cardiac sub-studysubstudy, and for UK patients only Quality of Life (QOL) 
assessment and Health Economics evaluation. These sub-studies will provide an important high-
quality evidence base on the balance of potential benefits and treatment burden, to support 
patients and health care professionals during shared decision-making. 
The long-term impact of breast cancer and its treatment on everyday life has been identified as a 
critical knowledge gap and a key priority for breast cancer research 10. For radiotherapy, there is a 
limited information on treatment impact.  A small number of trials have investigated self-reported 
breast, arm, and shoulder symptoms, functional outcomes and quality of life after radiotherapy, 
predominantly in breast conserving therapy11-13. Patients usually report transient and short-term 
effects of radiotherapy, with relatively limited effect on overall quality of life 14,15 .  
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No comprehensive QOL data exists in patients having post-mastectomy radiotherapy (PMRT and 
only a few studies have compared patient-reported outcomes following breast-conserving surgery 
versus mastectomy with and without reconstruction. Recent introduction of oncoplastic surgical 
techniques is expected to have an impact on post-treatment morbidity and patient satisfaction with 
body image16,17. There is a dearth of level 1 evidence assessing the impact of adjuvant post-
mastectomy radiotherapy on quality of lifeQOL of patients who have undergone reconstruction.  
The SUPREMO QOL sub-studysubstudy aimed to examine the effects of PMRT on several primary 
QOL outcomes (global QOL, fatigue, physical function, chest wall, shoulder and arm symptoms, body 
image, anxiety and depression) at 1, 2, 5, and 10 years post treatment. Here we report the 2-year 
results. To our knowledge, this is the first study looking at the impact of adjuvant radiotherapy on 
QOL in a large randomised trial confined to patients treated by mastectomy for early breast cancer 
(including patients undergoing breast reconstruction). 
Methods 
Patients and ProceduresStudy design and Participants 
SUPREMO was an open label parallel randomized trial. Patients provided written informed consent 
before enrolment.  The full eligibility, exclusion criteria and trial procedures are described in the trial 
protocol provided in the supplementary web material and online (http://www.supremo-
trial.com/SUPREMO%20protocol%20version29.pdf). Briefly, patients were Briefly, eeligible patients 
were women aged 18 years or older if they had undergone mastectomy for unilateral breast cancer, 
and an axillary staging procedure with axillary lymph node dissection, if node positive. Patients with 
‘intermediate risk’ breast cancer were eligible, defined as pT1-2N1, pT3N0 and pT2N0, if also grade 
III and/or with lympho-vascular invasion on histology. Patients needed to be fit for surgery, 
radiotherapy or adjuvant systemic therapy. Exclusion criteria included previous or concurrent 
malignancy (except non-melanomatous skin cancer and carcinoma in situ of the cervix), ductal 
carcinoma in situ,  bilateral breast cancer, pregnancy at the time of radiotherapy treatment and 
male gender. 
All patients had to receive adequate systemic therapy following contemporary guidelines depending 
on patient and tumour characteristics. If this included chemotherapy, treatment regimes containing 
at least 4 cycles of anthracyclines were recommended. Adjuvant trastuzumab was given according to 
local practice. In 2011 the eligibility criteria were widened, following a protocol amendment (version 
29 August 30,2010) approved by the Ethics Committee, to include neo-adjuvant chemotherapy.   
Eligible patients were randomly assigned to receive chest-wall radiotherapy or not (1:1 ratio). For 
patients randomized to chest wall radiotherapy, radiation was given after the chemotherapy (when 
given). Radiotherapy treatment consisted of chest wall radiation to a total dose of 50 Gy in 25 daily 
fractions of 2 Gy over 5 weeks. Other permitted radiobiologically equivalent schedules includedwere 
45 Gy in 20 fractions over 4 weeks, and 40 Gy in 15 fractions over 3 weeks. Guidelines on treatment 
planning and set up were given, and there was a radiotherapy quality assurance programme in the 
trial. The use of bolus was permitted and had to be pre-specified per centre. Axillary irradiation was 
not permitted, but medial peri-clavicular and/or internal mammary chain irradiation was permitted 
according to local policy of the centres. Boost radiation was not permitted.  Surgery, systemic 
therapy and pathology were also subject to pre-specified quality assurance. Additional recorded 
data included cardiovascular risk factors, radiotherapy cardiac and lung exposure parameters, 
systemic therapy (type, doses, dates) and any reconstructive surgery (type, immediate or delayed). 
Patients with gross protocol violations (e.g. margins involved or less than 1mm for invasive cancer or 
DCIS) will be removed before the final analysis of the main trial.  A mammogram of the opposite 
breast, if appropriate, was recommended at least in alternate years for 10 years from the date of 
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mastectomy. The primary endpoint of the trial, overall survival, is not centrally reviewed. Serious 
adverse events were to be reported if they occurred during radiotherapy or within 30 days of the 
last radiotherapy session (fraction) whether or not they were related to the randomised treatment. 
Any toxicity assessed as a grade 4 or 5 acute or late morbidity score had to be reported on a 
SAE/SUSAR form for the entire follow up period of the trial. Adverse events were reviewed by the 
Data Monitoring and Ethical Committee meeting every 6 months (or as often as they considered 
appropriate). Monitoring (source data verification) is carried out by the Cancer Clinical Trials Team in 
Edinburgh on 10% of the patient data of the main trial with site visits allowed in the UK. Higher 
levels of monitoring will be performed, if requested by the Data Monitoring Committee, or if 
particular safety issues are identified by the investigators, the trial management group of the trial 
steering committee. 
The study was approved by the Multi-Centre Research Ethics Committee, Edinburgh (MREC 
05/50501/106) and local research and development offices. Patients provided written informed 
consent before enrolment and had additional options to consent to the sub-studies, including QOL 
substudy. 
Randomisation and masking 
SUPREMO was an open label trial. Consenting patients were randomized post-operatively to either 
chest-wall radiotherapy or no chest-wall radiotherapy (1:1 ratio). Patients were randomised by 
permuted blocks with the block length being varied randomly to minimise the effect of entry bias.  
Stratification was by treatment centre due to possible between centre differences in the manner in 
which radiotherapy is given.  There was no masking by patients or investigators. Randomisation was 
performed via a telephone call to The Information and Statistical Division (ISD) at National Services 
Scotland. 
Procedures for QOL sub-studysubstudy 
 
QOL sub-study 
All patients eligible for SUPREMO from UK centres were invited to participate in the QOL study. 
Patients who provided informed consented completed a questionnaire booklet in the clinic before 
randomisation. Completed booklets were sent to the trial’s office and subsequent questionnaires 
were posted to patients at 12 and 24 months by the trial’s office. If the baseline questionnaire was 
not returned to the trial’s office further questionnaires could not be sent, as patients’ names and 
addresses were not available to the trial co-ordinator. Reminders were sent to the hospitals where 
baseline questionnaires were overdue. No reminders were sent to patients at 12 and 24 months. 
QOL was assessed using several well-validated questionnaires. 
EORTC QLQ-C30 (version 3·0) and the breast module QLQ-BR23 (version 1·0). The QLQ-C30  
consists of 30 questions addressing 5 functional scales (cognitive, emotional, physical, social, and 
role), 9 symptom scales (appetite loss, constipation, diarrhoea, dyspnoea, fatigue, financial 
difficulties, insomnia, nausea and vomiting, and pain), and one Global Health Status/QOL scale18. The 
EORTC QLQ-BR23  focuses on breast cancer specific issues and includes 23 questions addressing 4 
functional: body image, future perspective, sexual enjoyment, and sexual functioning and 4 
symptom scales: arm symptoms (swelling in arm or hand, arm or shoulder pain, and difficulty 
raisingmoving the arm), breast/chest wall symptoms (pain, swelling, oversensitivity, and skin 
problems in the area of the affected breast), systemic therapy side-effects, and upset by hair loss19. 
All scores for the EORTC QLQ-C30 and EORTC QLQ-BR23 were transformed to a scale from 0 to 100. 
Higher scores on the functional scales and Global QOL represent a superior level of functioning and 
better QOL, whereas higher scores in the symptom scales or items represent worse symptoms. 
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The Body Image Scale (BIS) is a 10-item scale designed specifically for use with cancer patients to 
assess aspects of attractiveness, sexual attractiveness and feelings or satisfaction with appearance.  
Scores were graded 0-3 and summed to produce a single score, where a higher score indicated more 
problems (score range from 0 to 30)20. 
Hospital Anxiety and Depression Scale (HADS) is a 14-item instrument with two sub-scales for 
anxiety and depression21. Scores range from 0 to 21 on each scale, with higher scores indicating 
more distress. Scores above 11 suggest probable cases of anxiety or depressive illness, and scores 
between 8 and 10 indicate borderline cases. A combined score of 19 or above is considered 
indicative of psychological distress. 
EQ-5D-3L questionnaire measures health status across five domains: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Respondents specify whether they have no 
problems, some problems or severe problems within each domain, on the day of response. These 
EQ-5D-3L health states descriptions are converted into a single summary index (range from 0 to 1) 
by attaching a value to each of the levels in each dimension. As is standard practice, these values 
were obtained from a large UK population study using a choice-based method of valuation. 22 The 
resulting summary score, or utility value, can then be used directly in the cost-utility analysis.  
Outcomes 
The primary endpoint of SUPREMO trial is 10-year overall survival. Quality of life is a secondary 
endpoint alongside chest-wall recurrence, regional recurrence, disease free survival, acute and late 
morbidity and cost-effectiveness. In the QOL substudy we pre-specified as primary outcomes global 
QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, 
anxiety and depression. Secondary outcomes are role, social, sexual functioning, pain and 
nausea/vomiting. 
Sample Size 
Sample size for the SUPREMO QOL study was considered as a problem of estimation rather than a 
significance testing. With 200 evaluable patients per group the proportion of patients exhibiting a 
particular side-effect or specified degree of morbidity in a QOL domain could be estimated with a 
standard error of 3·5% or less. The corresponding difference between the groups could be estimated 
with a standard error of 5% or less.  However, as there is usually a significant attrition over time, in 
order to have sufficient numbers by 10 years a target of 800 patients was set. The total sample size 
of SUPREMO was reduced during the course of the trial, following a protocol amendment approved 
by the ethics committee, from 3500 to 1600 but this did not affect the QOL sub-study sample. 
Statistical analysis 
Sample Size 
Sample size for the SUPREMO QOL study was considered as a problem of estimation rather than a 
significance testing. With 200 evaluable patients per group the proportion of patients exhibiting a 
particular side-effect or specified degree of morbidity in a QOL domain could be estimated with a 
standard error of 3·5% or less. The corresponding difference between the groups could be estimated 
with a standard error of 5% or less.  However, as there is usually a significant attrition over time, in 
order to have sufficient numbers by 10 years a target of 800 patients was set. The total sample size 
of SUPREMO was reduced during the course of the trial, following a protocol amendment approved 
by the ethics committee, from 3500 to 1600 but this did not affect the QOL sub-studysubstudy 
sample. 
When calculating QOL questionnaire or sub-scale scores, we followed official questionnaire 
guidelines on handling missing individual items. In general, if more than 50% of the items were 
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missing, sub-scale scores ware not calculated (missing); if less than 50% of items were missing, those 
were replaced by the mean of the answered items and a score was calculated. Where no guidance 
existed, that score was recorded as missing. 
In order to maintain the Normality of the residuals, the difference from baseline to each subsequent 
questionnaire was calculated for each scale. Repeated analysis of covariance was conducted using 
PROC MIXED, to allow for observations that are missing at random. Time and treatment allocation 
interactions were tested for each scale but are to be reported only where statistically significant. 
Baseline scores were included in each model as a covariate. As the QOL study was not originally 
powered for hypothesis testing, p-values are only included for illustration. However, the treatment 
with radiotherapy was our primary outcome, and any results that have a p-value of ≤0.05 with this 
variable will be discussed. Due to the large number of models, clinical variables will only be 
discussed if they exceed the more conservative threshold value of 0.01. 
The principal analysis modelled the change in score in the pre-specified QOL outcomes (global QOL, 
fatigue, physical function, chest wall, shoulder and arm symptoms, body image, anxiety and 
depression) by time (visit 1 at 12 months or 2 at 24 months) of follow up, age group (<45, 45-54, 55-
69, ≥70), baseline score and treatment (± radiotherapy).  
As almost all patients received some form of systemic therapy and some underwent breast 
reconstructive surgery, secondary exploratory analyses were performed to evaluate whether these 
treatments influenced the QOL outcome measures. The secondary analysis included clinical 
covariates also considered to have an impact on QOL (extent of axillary surgery, early breast 
reconstruction, adjuvant chemotherapy, adjuvant hormonal therapy and trastuzumab). This was 
performed by creating a basic model of age group, time and baseline score, then adding the clinical 
variables in turn to create a model of best fit. This process was then repeated until no variables 
added significantly to the model. The radiotherapy variable was then added to the best fit model. 
Only patients with complete data for all clinical variables were included in this modelling. 
All analyses were on an intention to treat basis. No additional sensitivity analyses or interim analyses 
were planned for this stage of the trial. The analysis was generated using version 9·4 of the SAS 
System for Windows (www.sas.com Copyright © 2012 SAS Institute Inc. SAS and all other SAS 
Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., 
Cary, NC, USA.)  
This study is registered as an International Standard Randomised Controlled Trial, number 
ISRCTN61145589. 
Role of Funding Source  
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author and the joint senior authors had 
full access to all data in the study and had final responsibility for the decision to submit for 
publication. 
 
Results 
Between August 4, 2006 and April 29, 2013 the trial recruited 1688 patients internationally. All 
patients eligible for SUPREMO from 111 UK centres were invited to participate in the QOL substudy 
(n=1258). This approach was adopted in order to avoid any bias in selecting centres or patients. The 
consent rate between centres varied (see Table consent rates in the web appendix, page 1). The 
majority of the centres (73 centres) had consent rates of 80% or above. Ten centres did not include 
any of their 66 patients in the QOL study. , of which 1258 were from  UK centres and eligible for the 
QOL study. A total of 989 (79%) UK patients consented to participate, of them 95·7% (947/989) 
patients (returned the baseline questionnaires (476/502 94·8% in the control and 471/487 96·7% in 
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the radiotherapy arm). The statistical analysis is based on 947 patients who returned the baseline 
QOL questionnaires (Figure 1). Due to the practical arrangements for the QOL data collection, 
questionnaires for years 1 and 2 could be sent only to patients who returned the baseline 
questionnaire. We have not formally recorded reasons for declining participation as according to the 
Ethics Committee approved patient information sheet, patients were not obliged to provide such 
reasons. The patients from UK who declined participation or did not return the baseline 
questionnaires were older (n=311 mean age 57.7 years, SD 11.9) than those who consented and 
returned the baseline questionnaire (n=947 mean age 56.1 years, SD=11.0; p=0.02). Comparing the 
age of QOL study participants with the rest of the main trial (UK patients not participating in QOL 
study and all patients from other countries) did not show an age difference (n=741 mean age 55.6 
years, SD 11.6, p=0.34).  In order to check further for potential bias in patient selection for the QOL 
substudy, we compared the clinical characteristics of the patients completing the QOL substudy with 
those of the patients in the main trial in Table 1. 
Good patient compliance was achieved with the completion of QOL measures: at  947 patients 
(95·7%) returned the baseline questionnaires (476/502 94·8% control and 471/487 96·7% in 
radiotherapy) year 1 388/466 83·3% in the control group and 388/467 83·1% in the radiotherapy 
group; at year 2 (350/463 75·6% and 367/457 80·3% respectively. A slightly better compliance was 
observed in the radiotherapy arm at baseline and year 2 (Figure 1).  
Median follow-up for the patients who returned the baseline questionnaires was 748 days  
(interquartile range 417-763) for the control group and 749 days (interquartile range 725-762) for 
radiotherapy group.  
 
Patient characteristics 
Patients demographic, clinico-pathological characteristics and treatment details are shown in Table 
1. There is good balance in clinical characteristics between the radiotherapy and no radiotherapy 
groups in the QOL substudy. Some 70% (669/947) of patients had T2 tumours, 54% (512/947) were 
Grade 3, 78% (746/947) were ductal carcinomas, 19% (180/947) were oestrogen/progesterone 
receptor negative, and 30% 285/947) Her2 positive. Only a small proportion of 11% (11/947) had 
immediate reconstruction, and 11% (106/947) late reconstruction (by 2 years). A further review of 
the type of breast reconstruction suggested more frequent autologous reconstructions in the 
radiotherapy group, whereas there were more reconstructions with an implant/expander in the 
control group (see Web appendix, page 2).  This trend was observed for both the immediate and the 
late reconstructions.  Some 84% (796/947) of participants had adjuvant chemotherapy, 19% 
(183/947) trastuzumab and 75% 712/947) endocrine therapy. Two-thirds of patients had T2 
tumours, slightly over half were Grade 3, over 78% were ductal carcinomas, approximately 20% 
were oeEstrogen/pProgesterone rReceptor negative, and 30% Her2 positive. Only a small proportion 
of just over 10% had immediate reconstruction, and 10% late reconstruction (by 2 years). A further 
review of the type of breast reconstruction suggested more frequent autologous reconstructions in 
the radiotherapy group, whereas there were more reconstructions with an implant/expander in the 
control group (see Web appendix, page 2).  This trend was observed for both the immediate and the 
late reconstructions.  Over 80% of participants had adjuvant chemotherapy, 20% trastuzumab and 
over 70% endocrine therapy. No differences are observed between the QOL participants and the full 
trial.  
The majority of patients in the radiotherapy group of the QOL study received 40 Gy in 15 fractions 
(69%, 327/478), with the remaining patients equally divided between 50 Gy in 25 fractions (11%, 
52/478), 45 Gy in 20 fractions (10%, 48/478) and other/unknown (10%, 51/478). In the main trial, a 
smaller proportion of 52% (445/853) received 40 Gy in 15 fractions, a larger proportion of 27% 
(227/853) had 50 Gy in 25 fractions, 7% (57/853) had 45 Gy in 20 fractions and 15% (124/853) - 
other/unknown. The dose for all EORTC centres was 50 Gy in 25 fractions. 
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Baseline and follow-up QOL scores are shown in Table 2. Baseline scores were reported following 
surgery and prior to randomisation. Of note, patients reported relative impairment in global QOL 
with a mean score of 60 (100 is excellent), a high level of fatigue (mean of 40, where 100 is greatest 
degree of fatigue), insomnia (mean of 36-37; 100 is worse) and a degree of arm symptoms, chest 
wall symptoms and pain (in the range of 17 to 24; 100 is worst symptom).  
Pre-specified primary QOL outcomes 
Table 3 presents the results from mixed-effects models analysis of pre-specified primary QOL 
outcomes and pain (a pre-specified secondary QOL outcome).  The tested clinical variables are 
included in Table 3 where they were found to have a significant effect (p<0.01) on either the 
radiotherapy treatment or on changes over time. Such effects were found for adjuvant 
chemotherapy and immediate breast reconstruction but not for extent of axillary surgery, adjuvant 
endocrine therapy or trastuzumab. 
Chest wall symptoms were significantly worse in the group receiving radiotherapy (estimate of effect 
2·17; 95% Confidence Interval (CI) 0·40, 3·94; p=0·016). There was an improvement between years 1 
and 2 (visit effect -1.34; 95% CI -2·36, -0·31; p=0·010), but the improvement was smaller in the 
radiotherapy group (Figure 2a). OfAge had a significant effect: symptoms in older patients showed 
greater improvement than in patients aged under 45 years. From the clinical factors the use of 
chemotherapy was associated with less improvement in chest wall symptoms but there was no 
interaction with radiotherapy, suggesting an additive effect of chemotherapy (Figure 2a).  There was 
a borderline age effect, with patients <45 years having worse chest-wall symptoms than those ≥70 
years (estimate of effect 4·49; 95% CI 0·59, 8·39; p=0·022). 
Arm problems did not differ significantly according to radiotherapy treatment (Figure 2b), they 
improved over timein both group between years 1 and 2, with a greater improvement in older 
patients (data not shown). When clinical variables were included the effect of age was no longer 
significantapparent. However, chemotherapy had an  significant effect with patients receiving 
chemotherapy showing less improvement of arm symptoms over time, suggesting that 
chemotherapy and age were confounders. Significantly more patients who received chemotherapy 
were in the younger age group (97% of patients <45 years, 97% in 45-54 years, 85% in 55-69 years, 
37% in ≥70 years groups, P < 0·0001). Contrary to the clinical expectations, the extent of axillary 
surgery (comparison of 3 types: 1) sentinel node biopsy or node sampling; 2) sentinel node biopsy 
plus axillary node clearance; 3) axillary node clearance) did not have an effect on arm/shoulder 
symptoms scores (see Web appendix, page 3). Furthermore, the extent of axillary surgery did not 
have an impact on any of the pre-specified QOL variables, except a trend for higher HADS-Anxiety in 
patients with sentinel node biopsy plus axillary node clearance. 
Despite the observed differences in chest- wall symptoms patients reported relatively few body 
image problems with improvement between years 1 and 2over time. Some age effect was observed 
with patients <45= 54 years old reporting more concerns about their body image in comparison with 
patients ≥70 years old (estimate of effect 1·96; 95% CI 0·53, 3·39; p=0·0074). 
The overall quality of lifeQOL of patients was not affected by radiotherapy treatment. Furthermore, 
improvement in overall quality of life was observed between baseline and year 1 with further but 
smaller improvement by year 2 (Figure 2c).  
Physical function was not affected by treatment and no change was observed over time (Figure 2d). 
As expected there was an age affect with the younger age group reporting better overall physical 
functioning (Table 3). 
Patients reported high baseline level of fatigue, likely due to the preceding surgery, but without 
differences between the treatment groups. Significant improvement between year 1 and 2 was 
observedover time was observed. Immediate reconstruction had a borderline significant impact on 
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the change scores at year 1 (estimate of effect 5·32; 95% CI 0·94, 9·69; p=0·017)rate of improvement 
showing a slower improvement particularly at year 1, possibly related to slower recovery from the 
operation (Figure 2e), but without detectable differences in overall quality of lifeQOL or body image. 
No group differences were seen in HADS-Anxiety and HADS-Depressions scores. Women younger 
than 70 reported higher levels of Anxiety with improvement from baseline to over year 1 and to year 
2  time in both groups. 
Pre-specified secondary QOL outcomes 
An interesting pattern in self-reporting of general pain was observed. The mean score at baseline 
was just over 20 in both groups, but without any significant improvement from baseline to year 1 or 
year 2 over time independent of randomisation arm, which is at odds with some of the findings for 
the primary outcomes (global QOL, fatigue, chest-wall symptoms, body image and anxiety) where 
we observed an improvement from baselinethe other findings. We investigated the potential effects 
impact of systemic treatments. Borderline effects were found for use of trastuzumab (P=0·06) and 
chemotherapy (P=0·08), possibly associated with the use of taxanes. No significant effect was found 
for endocrine therapy (none vs tamoxifen vs aromatase inhibitors).  
No between-group differences were observed for nausea/vomiting, sexual, role and social functions. 
Gradual improvement over time was observed without any effect of treatments. Role function and 
social function showing the biggest numerical improvement over time, in year 1 with continued 
improvement in year 2. Patients having radiotherapy had significantly biggerreported larger 
improvements in their social function in comparison with those who did not.  (details in online 
Appendix). Patients reported very low scores on sexual functioning (mean of 11 out of 100).  We had 
good completion rate for the general sexual function questions 97% (914/947) but only 27% 
(253/914) patients completed the conditional sexual enjoyment questions at baseline suggesting 
that the vast majority of patients are not sexually active . This is supported by the fact that only 
about 25% responded to the optional question on sexual enjoyment (Table2). These observations 
are consistent with other reports.  
The eExploratory analysis of the other scales are is in the web online appendix page 5. All remaining 
scales and items did not show any impact of radiotherapy treatment and all show improvement or 
stability over time.  
Discussion 
To our knowledge, this is the first study investigating the impact of adjuvant radiotherapy on quality 
of life after mastectomy in a large randomised trial including a substantiallarge, well characterised 
population of UK patients with ‘intermediate-risk’ breast cancer. The key finding is that PMRT was 
associated with worse local self-reported symptoms (pain, swelling, oversensitivity and skin 
problems in the “area of the affected breast”) in comparison with no radiotherapy, although these 
symptoms improved over time. The estimated effect is small, with a difference in ‘change scores’ 
between the radiotherapy and control group of 2·17 points; 95% CI 0·40, 3·94. There is published 
data on EORTC QLQ-C30 on ‘change scores’ within groups or ‘scores difference’ between groups that 
is clinically significant, but to the best of our knowledge, there is no such available data on EORTC-
BR23 scores 23. We opted to present the mean scores and standard deviations in order to allow 
comparisons with other studies. In an attempt to explore the clinical significance of the observed 
statistically significant difference, we looked at using a generic approach of 0.5 of the standard 
deviation to indicate minimally important difference.  Therefore, we calculated the standard 
deviation of the ‘change score’ for chest wall symptoms from baseline to year 1 in the control group. 
24  The standard deviation was 17.3 and a score 8.65 is likely to indicate a clinically meaningful 
difference. The observed difference of 2.17 is relatively small and unlikely to be of clinical 
significance, which is of course reassuring for patients and clinicians. Recent guidelines from Federal 
Drugs Administration (FDA) recommend establishing a meaningful change in patient reported 
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outcomes measures at the individual level (i.e., defining a responder) versus at the treatment group 
level 25. The definition of a responder being “a score change in a measure, experienced by an 
individual patient over a predetermined time period that has been demonstrated in the target 
population to have a significant treatment benefit”. Using this approach and a ‘change score’ of 8.65 
as a cut-off score for clinical significance we applied ‘responder analysis’ (web appendix page 7).  We 
calculated proportions of patients whose scores ‘improved’ by < - 8.65 points between baseline and 
year 1, those who remained ‘stable’/no change’ (change score=+/-8.65) and those whose scores 
‘worsened’ by >+8.65 points. This ‘responder analysis’ showed that 16.3% (63/386) of patients 
receiving radiotherapy reported clinically meaningful worse ‘change score’ vs 11.9% (46/385) of 
those without radiotherapy. In other words, 4.4% more patients on radiotherapy experience worse 
chest wall symptoms than those not receiving PMRT. This way of interpretation of results may be 
more informative to clinicians and patients, but a note of caution is appropriate due to the 
assumptions described above.  
26There was no impact of radiotherapy to the chest wall on arm symptoms (axillary radiotherapy was 
prohibited in the trial), body image, overall QOL, physical function, fatigue or symptoms of anxiety or 
depression. Exploratory analyses showed that systemic chemotherapy treatment had an additive 
borderline effect on patients’ chest wall and arms symptoms but without an interaction with the 
radiotherapy treatment. This is consistent with other studies 27.   
Sentinel node biopsy procedure is the current standard surgical staging procedure for the axilla. In 
SUPREMO about a quarter of patients (those with pN0 (sn) tumours) in the main and QoL substudy 
underwent limited axillary surgery (sentinel node biopsy or nodal sampling). The extent of axillary 
surgery had no impact on any of the pre-specified QOL outcomes, including arm symptoms. This is 
perhaps an unexpected finding and could be due to lack of sensitivity of the EORTC BR23 scale 
(which has 3 items on ‘pain in arm or shoulder’, ‘swollen arm or hand’ and ‘difficulty raising your 
arm’). The impact of radiotherapy to the axilla on arm symptoms cannot be evaluated in the 
SUPREMO trial, as this was prohibited. Our findings are not generalisable to women who were 
treated with both an axillary nodal dissection and regional nodal radiotherapy. This treatment is 
generally reserved for patients with higher nodal load (N2 and N3 disease) than included in the 
SUPREMO trial (pN0 or pN1).  
Neo-adjuvant treatment was allowed in a later protocol version (version 29), but the number of 
treated patients is too small (n=8) for valid conclusions and therefore we did not perform any 
between group comparisons.   
We observed a low rate of immediate breast reconstruction (only 111 patients). T, this procedure 
was associated with higher fatigue levels and slower recovery in comparison with no immediate 
reconstruction but no impact on body image or the other QOL outcomes. The estimated effect of 
immediate reconstruction on fatigue was 5.32, corresponding to a small clinically meaningful 
difference23. This was an exploratory analysis and we used a generic QOL and body image 
questionnaires rather than breast-reconstruction instruments (such as BREAST-Q), which is likely less 
sensitive to specific outcomes 17.  
The observed low levels (11%) of reconstructive surgery (either immediate or delayed to year 2) 
should be noted. This likely reflects the pattern of care in the period of the SUPREMO trial 
recruitment (2006-2013) or may be due to concerns of entering patients who had reconstruction 
into a trial of radiotherapy. There appears to be a trend in using more autologous procedures in 
patients who had radiotherapy and more implants/expanders in those not receiving radiotherapy. 
Due to the small number of reconstructions, SUPREMO trial cannot provide useful information on 
the impact of radiotherapy on breast reconstruction. We are collecting further information on 
delayed (beyond 2 years) reconstructions, which will be analysed at 5 and 10 years and provide 
valuable information on rates of breast reconstruction across the UK, as well as its impact on 
patients’ experiences and satisfaction with body image. Furthermore we do not have the power to 
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assess between group differences taking into account the dose schedules in the radiotherapy group.  
A direct comparison of conventional versus hypo-fractionation for chest wall radiotherapy after 
breast reconstruction is being carried out in North America by the Alliance for Clinical Trials in 
Oncology (NCT03414970). The primary objective is to evaluate whether the reconstruction 
complication rate at 24 months post radiation is non-inferior with hypofractionation. The trial is 
ongoing and will complete recruitment in 2021, with final results in August 2025. 
Due to the low rates of reconstruction in SUPREMO, we do not have the power to assess between 
group differences taking into account the dose schedules in the radiotherapy group.  A direct 
comparison of conventional versus hypo-fractionation for chest wall radiotherapy after breast 
reconstruction is being carried out in North America by the Alliance for Clinical Trials in Oncology 
(NCT03414970). The primary objective is to evaluate whether the reconstruction complication rate 
at 24 months post radiation is non-inferior with hypofractionation. The trial is ongoing and will 
complete recruitment in 2021, with final results in August 2025.  
It should be noted that the observed levels of reconstructive surgery (either immediate or delayed 
to year 2) are low in the range of 10-13%. This likely reflects the pattern of care in the period of the 
SUPREMO trial recruitment (2006-2013) or may be due to concerns of entering patients who had 
reconstruction into a trial of radiotherapy. There appears to be a trend in using more autologous 
procedures in patients who had radiotherapy and more implants/expanders in those not receiving 
radiotherapy. Due to the small number of reconstructions, SUPREMO trial cannot provide useful 
information on the impact of radiotherapy on breast reconstruction, and further evidence is needed. 
We are collecting further information on delayed (beyond 2 years) reconstructions, which will be 
analysed at 5 and 10 years and provide valuable information on rates of breast reconstruction across 
the UK, as well as its impact on patients’ experiences and satisfaction with body image. 
Most of the published literature relating to the impact of adjuvant radiotherapy on quality of lifeQOL 
relates to non-randomised studies, often of small size, which may be subject to selection bias and  
neitherand neither surgery, radiotherapy or systemic treatments were subject to pre-specified 
quality assurance. Comparisons are often difficult because of differing types of surgery, stage of 
disease, QOL measures used and time-points of QOL assessment.  The Sstudies often included both 
patients treated by mastectomy and breast conserving surgery. The START trial looked at late effects 
of different schedules of radiotherapy at 5 years and found that up to a third of women reported 
moderate or marked pain in the arm and shoulder and more than 10% experienced arm/hand 
swelling12. The trial included a small number of mastectomy patients (about 20%) and although the 
QOL results are consistent with ours, they are not directly comparable since only 10% had 
chemotherapy and 20% had regional nodal irradiation in addition to breast/chest wall radiotherapy. 
The experience of breast/arm symptoms over 5 years represents chronic morbidity that has stronger 
association than cosmesis with long-term quality of life, making these important outcomes in clinical 
trials28. 
A more recent multicentre study from Korea in 1156 patients (541 breast conserving surgery and 43 
mastectomy) using the EORTC measures showed poorer QOL with pain, discomfort and anxiety 
during radiotherapy, with improvement over a 3 year period. However, the number of mastectomy 
patients was very small. The Moving Beyond Cancer psychosocial intervention trial studied the QOL 
of  558 women with stage 1 and 2 breast cancer treated with surgery alone (breast conserving or 
/mastectomy) alone, surgery with radiation, or surgery followed by chemotherapy and radiation  
over 1 year, using SF-36 questionnaire. Similar to our study, physical and psychosocial function 
improved significantly over time. However, the measures of QOL differ from our study and details of 
chemotherapy regimes  and staging were not available in the absence of case record review27. A 
similar pattern of improvement in a range of symptoms and QOL measures in the first year post 
diagnosis was observed in a cohort study of 285 women with early breast cancer, treated with 
surgery (just >20% had mastectomy), adjuvant radiotherapy (74%) and systemic therapy in (just 
>30% of the patients)  A similar pattern of improvement over the first year post diagnosis was seen 
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in a cohort of women with early breast cancer treated by surgery (just >20% treated by mastectomy) 
and, where appropriate, adjuvant radiotherapy and systemic therapy using the EORTC QLQ C-30, 
Profile of Mood States (POMS), Psychological Adjustment to Illness Scale (PAIS), the Impact of Event 
Scale (IES) and Fatigue Symptom Inventory29.  
Finally, in accordance with other breast cancer QOL studies we observed that younger women 
reported worse body image (if under 455) and anxiety problems (if under 70 years). This finding is 
supported by other breast cancer QOL studies, is concordant with clinical experience and 
emphasises the need for targeted psychological interventions in those women11,30. Younger women 
also reported higher general pain scores which .  The reasons for this are not clear.  did not improve 
with time, and this was not related to the use of aromatase inhibitors (data not shown). The reasons 
for this are not clear. Persistent pain following breast surgery (breast conserving or mastectomy) 
was reported by half of the patients in a population-based prospective study of over 3000 patients. 
The pain was commoner after adjuvant radiotherapy and in younger women  . 26 The same finding 
was also reported in a randomised trial of radiotherapy after breast conserving therapy and in a 
population-based prospective study of more than 3000 patients following breast cancer surgery13,26. 
In the latter study, half the patients experienced moderate to severe pain, consistent with the range 
of reported pain in the literature from 25%-60%. The wide variation in reports (25% -60%), as the 
authors suggest, may relate to varying definitions of pain, different methods of pain assessment and 
mix of surgery and adjuvant therapy. There is insufficient evidence to draw conclusions on each of 
the treatment- related risk factors for pain. 
Reassuringly all symptoms and QOL scores improved over time. General pain is the only exception, 
and this was not related to the use of aromatase inhibitors (data not shown). There is evidence of 
persistent pain in early breast cancer patients post-surgery, and our findings confirm these 
observations and call for better recognition of this problem in order to implement screening and 
patient support.The scores on sexual functioning and sexual enjoyment indicated that the majority 
of the patients were not sexually active, without between group differences. These observations are 
consistent with other reports.  
Several strengths of SUPREMO trial QOL substudy should be mentioned. It is the largest post-
mastectomy study which is investigatinged a well-defined large population of patients treated by 
mastectomy, which was  and was  representative of women with early ‘intermediate-risk’ breast 
cancer in the UK. Individuals in the QOL study were recruited from almost all UK sites. Only 10 out of 
111 sites did not recruit any of their . 66 patients, a relatively small number of centres and unlikely 
to have an impact. We do not know the reasons for the low consent rates in some centres, but it 
may be related to availability of local resources (dedicated clinical research nurses).  This was a large 
pragmatic study and resources were not available to monitor closely consent rates by centre or to 
provide extra support.  
The QOL study was multi-centre from all across the UK sites, representing a wide geographical 
range, thus minimising participating centre bias. The pre-specified QOL sample size was achieved 
and exceeded, strengthening our the confidence in the findings. The trial was sufficiently large to 
allow explorative evaluation of the effects of age and multi-modality treatments. High levels of 
adherence to questionnaire completion over time were attained (>70%). In addition, guidelines on 
surgery, radiotherapy and systemic therapy were standardised in the protocol, so any variations in 
these treatment modalities between treatment arms are unlikely to influence the results.  
As all patients were randomised following mastectomy, Tthe main limitation of the QOL sub-
studysubstudy is not having a true pre-treatment baseline QOL assessment, as all patients were 
randomised following mastectomy. The relatively low QOL scores at the time of randomisation may 
be explained by the recent breast cancer diagnosis and the surgical procedure, and the subsequent 
improvement in almost all scores, is to be expected.  We did not record QOL scores during or shortly 
after the allocated radiotherapy treatment, so any differences in acute symptoms between the 
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groups, which may predict later toxicity, have not been captured. In addition, since the main trial is 
ongoing and the loco-regional control and survival status of the patients in the QoL sub-
studysubstudy are not known to us, it is possible patients who had relapsed or died may have had 
different patterns of QOL.  
A larger proportion of participants in the QOL study received the dose fractionation schedule as 40 
Gy in 15 fractions (69%) compared to 52% in the main trial, where a larger proportion of 27% 
received 50 Gy in 25 fractions. This difference reflects the variations between the standard practice 
in UK and EORTC centres at the time of the trial.  
At this 2-year analysis we have not evaluated any effect of fractionation on the QOL outcomes. 
However, as the clinical significance of the increased chest wall symptoms in the radiotherapy group 
at 2 years may be relatively limited, we do not expect a major clinical impact of fractionation at this 
early time point. We expect that the difference in symptoms reported by patients between no 
radiotherapy and 40-50 Gy will be larger than any difference observed between fractionation 
schedules. The influence of radiation dose fractionation and technique and the radiation dose 
parameters to organs at risk will be the subject of a more detailed analysis to be performed in the 
irradiated group, including evaluation of toxicity (physician scoring). The results will be reported in a 
separate publication, focusing on the specific technical aspects of the radiotherapy. 
This paper presents a pre-planned analysis at 2 years post randomisation, with the main QOL 
analysis being planned at 5 years and QOL data to be collected for 10 years to capture late adverse 
events. Clearly our results are preliminary and we are therefore cautious in our interpretation. 
However, it is a reassuring that the loco-regional symptoms are minimal and do not impair global 
QOL and diminish over the initial 2 years of follow up.   While it might be argued that analysing QOL 
at 2 years is too premature, this was a pre-planned analysis. We considered it appropriate to identify 
any potential early signals of a significant impact on QOL in the absence of a definite oncological 
outcome. If severe QoL effects were to be identified early, then this would be relevant for clinical 
decision making in the absence of information on long-term survival benefit. The recent North 
American guidelines on postmastectomy radiotherapy 7 emphasise the importance of shared 
decision making between physician and patient in weighing up the benefits and toxicity of treatment 
in patients with 1- 3 positive node undergoing axillary node clearance. Information on the impact of 
PMRT on QOL may help inform this decision-making process, even before the main trial outcomes 
become available.   Further analyses will be reported at 5 and 10 years to determine if the trends at 
2 years are sustained. It is possible that late radiotherapy toxicity not seen within the first two years 
(such as progressive chest wall fibrosis or increased cardiac toxicity due to the combination of 
radiotherapy and anthracycline-based chemotherapy) may be detected on longer term follow-up 
and should be captured in our 5 and 10 year analyses. However, we recognise that late cardiac 
toxicity from radiotherapy may occur beyond 10 years. 
 
Further evidence is needed to comment usefully on the impact of radiotherapy on breast 
reconstruction. We already have the data on immediate reconstruction with a small number of 
procedures, but we are collecting further information on delayed (beyond 2 years) reconstruction, 
which will provide valuable general information on rates of breast reconstruction across the UK as 
well as its impact on patients’ experiences and satisfaction with body image. 
The impact on PMRT on 10- year survival, the primary end-point of the main SUPREMO trial, will not 
be known before 2023. In the meantime, the decision to administer or omit PMRT can be considered 
‘preference sensitive’ for patients in the SUPREMO trial risk category of 1-3 positive lymph nodes, as 
both options are legitimate. The patients will be in a better position to make a value judgment on 
what they consider relevant for them, given the data on various QOL domains presented in this 
report. Both physicians and patients may thus be helped when weighing up the individual estimates 
of possible benefits of radiotherapy against the impact of PMRT on toxicity and quality of lifeQOL 
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endpoints. This will support the application of informed shared decision-making, as recommended 
by the recent North American guidelines, even before the main trial outcome becomes available 7. 
In conclusion, chest wall radiotherapy led to more chest wall symptoms up to 2 years post-
randomisation, but the difference is small and unlikely to be clinically significant. There was the 
difference is small and unlikely to be clinically significant. There was no impact on the other pre-
specified QOL domains.  However, the trend for worse QOL scores for anxiety, body image and 
chest-wall symptoms inHowever, the worse QOL in younger women irrespective of irradiation 
warrants further investigation. Longer term follow-up at 5 and 10 years will be needed to see if 
these early trends in quality of life are sustained. 
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Tables 
Table 1. Patients’ demographic and clinical characteristics 
Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Demographic 476 471 835 853 
Age (mean and SD) 56·3 (11·3) 55·8 (10·8) 55·9 (11·2) 55·8 (11·3) 
Menopausal status (number, %) 
Pre-menopausal 
Peri-menopausal 
Post-menopausal 
Not known 
 
126 (26·5) 
43 (9·0) 
290 (60·9) 
17 (3·6) 
 
135 (28·7) 
52 (11·0) 
268 (56·9) 
16 (3·4) 
 
246 (29·5) 
68 (8·1) 
483 (57·8) 
38 (4·6) 
 
243 (28·5) 
85 (10·0) 
475 (55·7) 
50 (5·9) 
     
Tumour characteristics     
Side of primary tumour (number, %) 
Left 
Right 
 
238 (51·2) 
227 (48·8) 
 
216 (47·8) 
236 (52·2) 
 
398 (50·1) 
396 (49·9) 
 
407 (51·3) 
387 (48·7) 
Tumour size (number, %) 
≤2cm 
2·1-5 cm 
>5 cm 
Unknown 
 
132 (27·7) 
337 (70·8) 
5 (1·1) 
2 (0·4) 
 
138 (29·3) 
332 (70·5) 
1 (0·2) 
0 
 
249 (29·8) 
566 (67·8) 
4 (0·5) 
16 (1·9) 
 
261 (30·6) 
566 (66·4) 
4 (0·5) 
22 (2·6) 
Tumour grade (number, %) 
I 
II 
III 
Not specified 
 
20 (4·2) 
190 (39·9) 
262 (55·0) 
4 (0·8) 
 
23 (4·9) 
195 (41·4) 
250 (53·1) 
3 (0·6) 
 
46 (5·5) 
335 (40·1) 
432 (51·7) 
22 (2·6) 
 
57 (6·7) 
333 (39·0) 
432 (50·6) 
31 (3·6) 
Histological type (number, %) 
Ductal 
Lobular 
Mucinous 
Tubular 
Adenocarcinoma 
Other  
 
372 (78·5) 
58 (12·2) 
5 (1·1) 
1 (0·2) 
3 (0·6) 
35 (7·4) 
 
374 (79·4) 
49 (10·4) 
1 (0·2) 
3 (0·6) 
5 (1·1) 
39 (8·3) 
 
641 (78·2) 
95 (11·6) 
7 (0·9) 
4 (0·5) 
16 (2·0) 
57 (7·0) 
 
661 (79·5) 
89 (10·7) 
1 (0·1) 
4 (0·5) 
13 (1·6) 
63 (7·6) 
Molecular markers – (number, %) 
ER+/PR+ 
ER+/PR- 
ER-/PR+ 
ER-/PR- 
ER+/PR unknown 
ER-/PR unknown 
 
Her2 positive 
Her2 negative 
Not measured 
 
218 (46·8) 
48 (10·3) 
5 (1·1) 
87 (18·7) 
96 (20·6) 
12 (2·6) 
 
140 (29·7) 
286 (60·7) 
45 (9·6) 
 
 
217 (46·7) 
48 (10·3) 
0 (0) 
93 (20·0) 
100 (21·5) 
7 (1·5) 
 
145(31·1) 
281 (60·2) 
41 (8·8) 
 
 
417 (51·5) 
83 (10·3) 
8 (1·0) 
156 (19·3) 
131 (16·2) 
15 (1·9) 
 
273 (33·5) 
475 (58·2) 
68 (8·3) 
 
 
416 (50·6) 
99 (12·0) 
3 (0·4) 
162 (19·7) 
132 (16·0) 
11 (1·3) 
 
269 (32·5) 
469 (59·9) 
63 (7·6) 
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Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Axillary Nodes (number, %) 
0 (negative) 
1- 
2- 
3- 
Not known 
 
130 (27·3) 
180 (37·8) 
101 (21·2) 
63(13·4) 
2 (0·4) 
 
113 (24·0) 
199 (42·3) 
111 (23·6) 
48 (10·2) 
0 
 
219 (26·2) 
316 (37·8) 
178 (21·3) 
107 (12·8) 
15 (1·8) 
 
212 (24·9) 
338 (39·6) 
194 (22·7) 
88 (10·3) 
21 (2·5) 
     
Treatment     
Breast Surgery (number, %) 
Mastectomy only 
Immediate breast reconstruction 
prior to RT 
Late breast reconstruction  
 
371 (77·9) 
50 (10·5) 
 
55 (11·6) 
 
359 (76·2) 
61 (13·0) 
 
51 (10·8) 
 
653 (78·2) 
85 (10·2) 
 
97 (11·6) 
 
669 (78·4) 
97 (11·4) 
 
87 (10·2) 
     
Axillary surgery (number, %) 
SLN / node sampling 
SLN plus ANC (Axillary node 
clearance) 
ANC (without SLN) 
 
131 (27·9) 
138 (29·4) 
 
201 (42·8) 
 
108 (22·9) 
124 (26·3) 
 
239 (50·7) 
 
207 (25·5) 
229 (28·2) 
 
377 (46·4) 
 
189 (22·8) 
224 (27·0) 
 
417 (50·2) 
Systemic treatment (number Yes, %) 
Neo-adjuvant chemotherapy1  
Adjuvant chemotherapy 
Anthracyclines 
Taxanes 
Trastuzumab 
 
Endocrine therapy (number Yes, %) 
Neo-adjuvant 
Adjuvant 
Aromatase inhibitor 
Tamoxifen 
Other  
 
1/173 (0·58) 
395/476 
(83·0) 
372/395(94·2) 
197/395(49·9) 
91/454 (20·5) 
 
 
2/200 (1·0) 
349 (73·3) 
173/349(49·6) 
174/349(49·9) 
2/349 (0·6) 
 
7/173 (4·1) 
401/471 
(85·1) 
379/401(94·5) 
207/401(51·6) 
92/460 (20·0) 
 
 
8/206 (3·9) 
363 (77·1) 
195/363(53·7) 
168/363(46·3) 
0/363 (0) 
 
7/243 (2·9) 
682/835 
(81·7) 
636/682(93·3) 
392/682(57·5) 
150/782(19·2) 
 
 
10/288 (3·5) 
598 (71·6) 
275/598(46·0) 
319/598(53·3) 
4/598 (0·8) 
 
16/269 (6·0) 
709/853 
(83·1) 
655/709(92·4) 
418/709(59·0) 
166/806(20·6) 
 
 
17/316 (5·4) 
631 (73·9) 
314/631(49·8) 
314/631(49·8) 
3/631 (0·5) 
1 Only recorded in protocol v29 onwards; the denominator is the total number of recorded 
chemotherapy treatments from protocol v29 onwards 
ER- estrogen receptor; PR – progesteron receptor; SLN- sentinel lymph node(s) procedure; ANC – 
axillary node clearance 
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Table 2. Quality of Life (QOL) scores (Standard Deviations, SD) at baseline, year 1 and year 2 follow-
up 
 
QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Age at 
randomisation 
56·3 (11·3) 55·8 (10·8) 56·5 (10·9) 56·1 (10·4) 56·8 (10·9) 56·1 (10·4) 
       
Primary endpoints      
EORTC QLQ-C30       
Global 
Health/QOoL* 
60·9 (21·6) 60·4 (20·8) 70·0 (20·5) 70·0 (19·8) 70·2 (20·5) 71·8 (20·1) 
Fatigue** 41·6 (25·2) 43·0 (26·1) 30·3 (23·2) 31·0 (24·1) 29·2 (24·2) 27·5 (23·8) 
Physical 
Functioning* 
79·6 (20·2) 80·1 (19·6) 81·9 (19·0) 81·1 (19·1) 82·0 (18·6) 82·1 (19·3) 
       
EORTC QLQ-BR23       
Arm symptoms** 20·3 (20·5) 21·2 (21·7) 21·2 (21·7) 22·4 (22·0) 20·7 (21·4) 19·9 (20·3) 
Chest wall/breast 
symptoms** 
17·3 (17·0) 18·1 (18·3) 13·1 (16·3) 16·1 (16·7) 11·6 (14·6) 14·1 (15·8) 
       
Body Image 
Scale** 
10·3 (7·9) 11·1 (8·2) 9·3 (7·6) 9·8 (7·7) 8·1 (6·7) 8·7 (7·4) 
       
Hospital Anxiety and 
Depression Scale (HADS) 
     
Anxiety 6·2 (4·4) 6·1 (4·3) 6·8 (4·7) 6·5 (4·4) 6·3 (4·3) 6·5 (4·4) 
Depression 4·5 (3·7) 4·6 (3·7) 4·2 (3·7) 4·2 (3·8) 4·0 (3·5) 4·2 (3·9) 
       
Secondary endpoints      
EORTC QLQ-C30       
Role Functioning * 65·2 (30·9) 63·0 (30·5) 79·3 (27·1) 78·8 (25·8) 79·7 (27·6) 81·0 (26·9) 
Social Functioning 
* 
65·5 (28·7) 64·0 (29·1) 79·4 (25·6) 80·3 (24·7) 80·5 (26·1) 83·9 (25·2) 
Pain** 22·6 (26·5) 24·8 (27·9) 21·7 (26·8) 23·7 (26·5) 23·4 (27·3) 21·6 (25·9) 
Nausea 
Vomiting** 
11·2 (17·6) 11·5 (20·1) 5·3 (13·1) 5·1 (12·1) 4·6 (12·2) 5·1 (13·6) 
       
EORTC QLQ-BR23       
Sexual 
Functioning* 
11·5 (18·1) 
n=455 
12·5 (19·0) 
n=459 
15·7 (20·5) 
n=372 
17·6 (21·2) 
n=374 
16·3 (21·7) 
n=325 
18·1 (22·3) 
n=353 
       
Exploratory variables      
EORTC QLQ-C30       
Emotional 
Functioning* 
74·7 (22·6) 73·7 (24·4) 75·2 (23·6) 75·2 (22·3) 77·3 (22·5) 75·7 (23·3) 
Cognitive 
Functioning* 
77·1 (23·4) 75·0 (26·1) 78·2 (22·8) 78·2 (22·9) 78·6 (22·8) 78·2 (23·8) 
Dyspnoea** 20·8 (26·4) 20·0 (26·1) 14·6 (23·5) 14·8 (23·0) 14·3 (23·2) 13·4 (22·5) 
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QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Insomnia** 36·3 (31·1) 37·2 (32·8) 36·4 (33·5) 38·5 (32·8) 33·9 (31·9) 35·0 (30·5) 
Appetite loss** 20·7 (28·9) 19·2 (27·9) 9·5 (19·8) 8·7 (18·5) 9·1 (19·9) 9·0 (20·7) 
Constipation** 18·2 (26·3) 17·0 (26·1) 14·9 (24·5) 14·5 (24·1) 17·6 (27·7) 14·5 (24·3) 
Diarrhoea** 11·9 (20·7) 12·1 (23·8) 7·6 (17·5) 8·4 (18·7) 5·4 (15·1) 8·7 (19·1) 
Financial 
difficulties** 
23·9 (33·1) 23·2 (31·7) 15·8 (28·5) 17·1 (27·8) 14·1 (27·0) 13·8 (26·6) 
       
EORTC QLQ-BR23       
Sexual 
enjoyment* 
49·9 (26·9) 
n=121 
53·0 (29·1) 
n=132 
54·4 (28·3) 
n=136 
56·5 (26·5) 
n=144 
52·5 (26·1) 
n=115 
56·6 (28·8) 
n=136 
Future 
perspective** 
45·8 (31·2) 46·4 (32·8) 49·8 (32·3) 50·9 (31·6) 54·4 (30·1) 54·1 (30·9) 
Systemic therapy 
side-effects** 
34·8 (23·1) 35·2 (22·7) 19·3 (15·2) 19·6 (15·6) 18·6 (14·9) 18·3 (15·0) 
Hair loss** 29·6 (37·5) 31·7 (39·3) 6·2 (20·4) 6·4 (21·8) 3·8 (20·7) 4·9 (17·1) 
       
EQ-5D-3L*** 0·74 (0·22) 0·74 (0·22) 0·75 (0·25) 0·75 (0·24) 0·76 (0·24) 0·77 (0·22) 
 
 
*EORTC QLQ-C30 Functional scores- range 0-100 (higher score = good functioning) 
** EORTC QLQ-C30 Symptom scores – range 0-100 (higher score = worse symptoms) 
*** EQ-5D-3L score-range 0-1. 
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Table 3. Mixed effects models (fixed effects) for the primary QOL outcomes 
 
Outcome Model variable Estimate of 
effects 
95% CI p 
Global 
QOL (C30) 
Baseline score 
Age- ref* >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·57 
- 
1·12 
3·25 
3·54 
0·75 
1·39 
-0·63, -0·52 
- 
-3·45, 5·78 
-0·62, 7·12 
-0·28, 7·36 
-0·46, 1·97 
-0·92, 3·71 
<0·0001 
- 
0·64 
0·10 
0·0697 
0·23 
0·24 
 Adjusted mean 
of ‘change 
scores’**  
95% CI p-value*** 
   
RT 
No RT 
8·63 
7·23 
6·86, 10·40 
5·46, 9·01 
<0·0001 
<0·0001 
Fatigue 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Immediate 
reconstruction 
Ref no recon 
RT –ref no RT 
-0·59 
- 
-2·41 
-4·14 
-3·13 
-1·83 
5·32 
 
 
-1·93 
-0·65, -0·54 
- 
-8·07, 3·26 
-8·84, 0·56 
-7·73, 1·47 
-3·20, -0·46 
0·94, 9·69 
 
 
-4·70, 0·84 
<0·0001 
- 
0·40 
0·0798 
0·18 
0·0094 
0·017 
 
0·17 
RT 
No RT 
-9·54 
-7·61 
-12·19, -6·89 
-10·35, -4·87 
<0·0001 
<0·0001 
Physical 
function 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·41 
- 
7·91 
7·06 
4·29 
0·20 
-0·17 
-0·46, -0·35 
- 
3·94, 11·87 
3·80, 10·32 
1·06, 7·51 
-0·68, 1·08 
-2·13, 1·79 
<0·0001 
- 
<0·0001 
<0·0001 
0·0092 
0·65 
0·87 
RT 
No RT 
-0·02 
0·14 
-1·53, 1·48 
-1·36, 1·65 
0·97 
0·85 
Chest wall 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT –ref no RT 
-0·57 
- 
4·49 
1·88 
2·36 
-1·34 
3·74 
2·17 
-0·62, -0·52 
- 
0·59, 8·39 
-1·46, 5·22 
-0·79, 5·51 
-2·36, -0·31 
0·87, 6·61 
0·40, 3·94 
<0·0001 
- 
0·022 
0·26 
0·14 
0·010 
0·011 
0·016 
RT 
No RT 
-3·13 
-5·30 
-4·74, -1·51 
-6·88, -3·71 
0·0002 
<0·0001 
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Arm and 
shoulder 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT –ref no RT 
-0·51 
- 
0·86 
2·89 
2·76 
-0·93 
6·15 
-0·53 
-0·57, 0·45 
- 
-4·42, 6·14 
-1·64, 7·41 
-1·51, 7·03 
-2·22, 0·37 
2·26, 10·05 
-2·92, 1·86 
<0·0001 
- 
0·74 
0·21 
0·20 
0·16 
0·0021 
0·66 
RT 
No RT 
-1·44 
-0·91 
-3·63, 0·75 
-3·06, 1·24 
0·19 
0·40 
Body 
Image 
Scale  
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·39 
- 
1·96 
1·39 
0·83 
-0·91 
-0·09 
-0·43, 0·34 
- 
0·53, 3·39 
0·20, 2·58 
-0·33, 1·99 
-1·28, -0·55 
-0·79, 0·61 
<0·0001 
- 
0·0074 
0·022 
0·15 
<0·0001 
0·79 
RT 
No RT 
-1·36 
-1·27 
-1·90, -0·83 
-1·81, -0·73 
<0·0001 
<0·0001 
HADS-
Anxiety 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·30 
- 
1·69 
1·36 
1·21 
-0·05 
-0·16 
-0·35, -0·25 
- 
0·86, 2·53 
0·67, 2·06 
0·53, 1·90 
-0·29, 0·18 
-0·57, 0·25 
<0·0001 
- 
<0·0001 
<0·0001 
0·00050 
0·66 
0·44 
RT 
No RT 
0·44 
0·60 
0·13, 0·76 
0·29, 0·92 
0·0061 
0·00022 
HADS- 
Depression 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·35 
- 
0·07 
-0·05 
-0·04 
0·02 
-0·14 
-0·41, 0·30 
- 
-0·73, 0·87 
-0·72, 0·61 
-0·69, 0·62 
-0·16, 0·20 
0·54, 0·25 
<0·0001 
- 
0·87 
0·88 
0·91 
0·94 
0·48 
RT 
No RT 
-0·19 
0·05 
-0·50, 0·11 
-0·35, 0·25 
0·21 
0·75 
Pain (C30) Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT –ref no RT 
-0·51 
- 
-0·18 
2·76 
2·18 
0·31 
-0·65 
-0·57, -0·46 
- 
-6·16, 5·80 
-2·17, 7·69 
-2·70, 7·06 
-1·29, 1·91 
-3·62, 2·33 
<0·0001 
- 
0·95 
0·27 
0·38 
0·70 
0·67 
RT 
No RT 
0·28 
0·93 
-1·99, 2·56 
-1·35, 3·20 
0·81 
0·42 
* ref =reference category in the mixed-effects models 
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** the adjusted mean for the individual arms is the mean of the ‘change scores’, (defined as change 
from baseline to year 1 and from baseline to year 2) in each of the treatment groups, adjusted for 
baseline score, visit, and age;  
***p values  - whether each of the means of the ‘change scores’ within each individual arm is 
significantly different from zero (i.e., improvement or deterioration in scores from baseline) 
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Responses are in bold. Page numbers below refer to the TRACKED version of the 
manuscript. Page numbers in the CONSORT checklist refer to the CLEAN version. 
 
Editorial comments: 
 
1. Regarding reviewer 1, comment 2 (re: details about/influence of radiotherapy 
technique): please summarise your response to this point about the influence of the 
radiotherapy technique and add to the Discussion. Please also state that the results of your 
more detailed pre-planned analysis of the irradiated group will be reported in a separate 
publication. 
The following paragraph has been added to the Discussion, Page 13 
At this 2-year analysis we have not evaluated any effect of fractionation on the QOL 
outcomes. However, as the clinical significance of the increased chest wall symptoms in 
the radiotherapy group at 2 years may be relatively limited, we do not expect a major 
clinical impact of fractionation at this early time point. We expect that the difference in 
symptoms reported by patients between no radiotherapy and 40-50 Gy will be larger than 
any difference observed between fractionation schedules. The influence of radiation dose 
fractionation and technique and the radiation dose parameters to organs at risk will be 
the subject of a more detailed analysis to be performed in the irradiated group, including 
evaluation of toxicity (physician scoring). The results will be reported in a separate 
publication, focusing on the specific technical aspects of the radiotherapy. 
 
2. Regarding reviewer 1, comment 4: please add some text to the Discussion section of 
your paper acknowledging that because nodal radiotherapy was not given, the findings of 
your study are not generalizable to women treated with axillary nodal dissection and 
regional nodal radiotherapy. 
The following paragraph has been modified in the Discussion to emphasise the point of 
the reviewer, page 11 
Our findings are not generalisable to women who were treated with both an axillary 
nodal dissection and regional nodal radiotherapy. This treatment is generally reserved for 
patients with higher nodal load (N2 and N3 disease) than included in the SUPREMO trial 
(pN0 or pN1).  
 
3. Regarding reviewer 1, comment 6: please mention in the Discussion that you do not 
have power to evaluate between-group differences taking into account the type of 
reconstruction. Please also briefly mention the Alliance for Clinical Trials in Oncology 
NCT03414970 trial in the Discussion, including details about the trial (its primary endpoint, 
its status, and when it will complete). 
The following paragraph has been added to the Discussion, page 12 
Due to the low rates of reconstruction in SUPREMO, we do not have the power to assess 
between group differences taking into account the dose schedules in the radiotherapy 
group.  A direct comparison of conventional versus hypo-fractionation for chest wall 
radiotherapy after breast reconstruction is being carried out in North America by the 
Alliance for Clinical Trials in Oncology (NCT03414970). The primary objective is to evaluate 
whether the reconstruction complication rate at 24 months post radiation is non-inferior 
with hypofractionation. The trial is ongoing and will complete recruitment in 2021, with 
final results in August 2025. 
*Reply to Reviewers Comments
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4. Regarding reviewer 2, major comment 2: please add some additional text to your 
paper to justify your specific reasons for publishing these results at 2 years. 
The following paragraph has been added to the Discussion, page 14 
While it might be argued that analysing QOL at 2 years is too premature, this was a pre-
planned analysis. We considered it appropriate to identify any potential early signals of a 
significant impact on QOL in the absence of a definite oncological outcome. If severe QoL 
effects were to be identified early, then this would be relevant for clinical decision making 
in the absence of information on long-term survival benefit. The recent North American 
guidelines on postmastectomy radiotherapy 7 emphasise the importance of shared 
decision making between physician and patient in weighing up the benefits and toxicity of 
treatment in patients with 1- 3 positive node undergoing axillary node clearance. 
Information on the impact of PMRT on QOL may help inform this decision-making process, 
even before the main trial outcomes become available.    
 
5. Regarding reviewer 2, major comment 3: please add some text to the Discussion 
explaining that you have decided not to include the details of radiotherapy technique in the 
current analyses, and that the results of your more detailed pre-planned analysis of the 
irradiated group will be reported in a separate publication. 
This issue is the same as point 1 above and has been addressed in the Discussion, Page 13. 
At this 2-year analysis we have not evaluated any effect of fractionation on the QOL 
outcomes. However, as the clinical significance of the increased chest wall symptoms in 
the radiotherapy group at 2 years may be relatively limited, we do not expect a major 
clinical impact of fractionation at this early time point. We expect that the difference in 
symptoms reported by patients between no radiotherapy and 40-50 Gy will be larger than 
any difference observed between fractionation schedules. The influence of radiation dose 
fractionation and technique and the radiation dose parameters to organs at risk will be 
the subject of a more detailed analysis to be performed in the irradiated group, including 
evaluation of toxicity (physician scoring). The results will be reported in a separate 
publication, focusing on the specific technical aspects of the radiotherapy. 
 
 
6. Regarding reviewer 2, major comment 4: please could you add this table of consent 
rates for the QoL sub-study in the different centres to the web appendix and cite it at an 
appropriate place in the main text of the Results. 
The Table with consent rates has been added to the Web appendix and the following text 
added to the Results, first paragraph, page 8. 
All patients eligible for SUPREMO from 111 UK centres were invited to participate in the 
QOL sub-study (n=1258). This approach was adopted in order to avoid any bias in selecting 
centres or patients. The consent rate between centres varied (see Table consent rates in 
the web appendix, page 1). The majority of the centres (73 centres) had consent rates of 
80% or above. Ten centres did not include any of their 66 patients in the QOL study. 
 
7. Also regarding reviewer 2, major comment 4: please add some text to the Discussion 
about the low consent rates in some centres and the possible reasons why. 
The following paragraph has been added to the Discussion, page 12 
Only 10 out of 111 sites did not recruit any of their 66 patients, a relatively small number 
of centres and unlikely to have an impact. We do not know the reasons for the low 
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consent rates in some centres, but it may be related to availability of local resources 
(dedicated clinical research nurses).  This was a large pragmatic study and resources were 
not available to monitor closely consent rates by centre or to provide extra support.  
 
8. Regarding reviewer 2, major comment 9: please add some text to the Discussion 
explaining why you used mean scores for QoL measures (ie, in order to enable comparisons 
with other published studies). 
Added to Discussion, Page 11, first paragraph as part of an extended paragraph on 
interpretation of the results. 
We opted to present the mean scores and standard deviations in order to allow 
comparisons with other studies. 
 
9. Regarding reviewer 2, major comment 11: please note that we do not use shading in 
tables; please therefore amend the table footnotes accordingly to avoid referring to shaded 
cells. 
Shading has been removed from Table 3 and the footnote corrected. 
 
10. Also regarding reviewer 2, major comment 11 (p values): Lancet Oncology reporting 
style is to report p values to 2 significant figures (ie, p=0.XX, p=0.0XX, p<0.0XX or p<0.00XX), 
unless p<0.0001 (if this is the case, then please revise to the latter). It looks like most of the 
p values in table 3 do conform to this but please check carefully (in table 3 and elsewhere in 
the paper). 
This has been corrected. 
 
11. Also regarding reviewer 2, major comment 11: please ensure that you state clearly in 
the Methods (statistical analysis section) whether analyses were done by an intention-to-
treat basis or otherwise. 
Stated on page 8. 
 
12. Regarding reviewer 2, minor comment 1A: please summarise your response to this 
point about missing data and add to the Methods, Statistical Analysis section. 
An explanation has been added on page 7. 
When calculating QOL questionnaire or sub-scale scores, we followed official 
questionnaire guidelines on handling missing individual items. In general, if more than 
50% of the items were missing, sub-scale scores ware not calculated (missing); if less than 
50% of items were missing, those were replaced by the mean of the answered items and a 
score was calculated. Where no guidance existed, that score was recorded as missing. 
 
13. Regarding reviewer 2, minor comment 6: please summarise your response to this 
point and add to the Discussion. Responses to Sexual function items 
More details have been added to the Results section (page 10)  
We had good completion rate for the general sexual function questions 97% (914/947) but 
only 27% (253/914) patients completed the conditional sexual enjoyment questions at 
baseline suggesting that the vast majority of patients are not sexually active (Table2). 
These observations are consistent with other reports.  
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Initially we mentioned this observation in the discussion. But subsequently decided to 
remove it, as it does not belong to any existing section, we don’t have space to add 
references to make the discussion more meaningful.  
 
14. Regarding reviewer 3, comment 2: please add some text to the Discussion explaining 
that there is not currently any available data or guidance on what difference in the sub-scale 
scores of EORTC-BR23 is clinically significant (and that such definitions only exist for the 
EORTC QLQ-C30). 
Added to Discussion, Page 10, first paragraph as part of an extended paragraph on 
interpretation of the results. After the previous re-submission, we did additional 
descriptive analysis of the ‘change score’ for chest wall symptoms in an attempt to 
understand if this statistically significant difference is clinically meaningful. We followed 
FDA guidance on using ‘responder analysis’ at the individual level. This analysis has been 
added to the Web appendix, and an extended paragraph describing an alternative 
interpretation of the observed difference added to the Discussion. 
 
The estimated effect is small, with a difference in ‘change scores’ between the 
radiotherapy and control group of 2·17 points; 95% CI 0·40, 3·94. There is published data 
on EORTC QLQ-C30 on ‘change scores’ within groups or ‘scores difference’ between 
groups that is clinically significant, but to the best of our knowledge, there is no such 
available data on EORTC-BR23 scores 23. We opted to present the mean scores and 
standard deviations in order to allow comparisons with other studies. In an attempt to 
explore the clinical significance of the observed statistically significant difference, we 
looked at using a generic approach of 0.5 of the standard deviation to indicate minimally 
important difference.  Therefore, we calculated the standard deviation of the ‘change 
score’ for chest wall symptoms from baseline to year 1 in the control group. 24  The 
standard deviation was 17.3 and a score 8.65 is likely to indicate a clinically meaningful 
difference. The observed difference of 2.17 is relatively small and unlikely to be of clinical 
significance, which is of course reassuring for patients and clinicians. Recent guidelines 
from Federal Drugs Administration (FDA) recommend establishing a meaningful change in 
patient reported outcomes measures at the individual level (i.e., defining a responder) 
versus at the treatment group level 25. The definition of a responder being “a score change 
in a measure, experienced by an individual patient over a predetermined time period that 
has been demonstrated in the target population to have a significant treatment benefit”. 
Using this approach and a ‘change score’ of 8.65 as a cut-off score for clinical significance 
we applied ‘responder analysis’ (web appendix page 7).  We calculated proportions of 
patients whose scores ‘improved’ by < - 8.65 points between baseline and year 1, those 
who remained ‘stable’/no change’ (change score=+/-8.65) and those whose scores 
‘worsened’ by >+8.65 points. This ‘responder analysis’ showed that 16.3% (63/386) of 
patients receiving radiotherapy reported clinically meaningful worse ‘change score’ vs 
11.9% (46/385) of those without radiotherapy. In other words, 4.4% more patients on 
radiotherapy experience worse chest wall symptoms than those not receiving PMRT. This 
way of interpretation of results may be more informative to clinicians and patients, but a 
note of caution is appropriate due to the assumptions described above.  
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15.  Regarding reviewer 4, comment 3: please add some text to the Discussion explain 
that the number of neo-adjuvantly treated patients is too small to do a subgroup analysis of 
these patients. 
A sentence has been added to the Discussion page 11. 
Neo-adjuvant treatment was allowed in a later protocol version (version 29), but the 
number of treated patients is too small (n=8) for valid conclusions and therefore we did 
not perform any between group comparisons.   
 
16. Regarding reviewer 5, comment 1: please acknowledge this point in the Discussion. 
Done, the added text is the same as point 4 above, Page 12 in Discussion.  
 
17. Regarding reviewer 5, comment 2:  please could you add this analysis of the extent 
of nodal surgery on the scores to the web appendix and cite it in the Results section in the 
main paper. 
The analysis on the extent of axillary surgery has been added in the Web appendix and 
the section in the Results extended to include all observations. 
Contrary to the clinical expectations, the extent of axillary surgery (comparison of 3 types: 
1) sentinel node biopsy or node sampling; 2) sentinel node biopsy plus axillary node 
clearance; 3) axillary node clearance) did not have an effect on arm/shoulder symptoms 
scores (see Web appendix, page 3). Furthermore, the extent of axillary surgery did not 
have an impact on any of the pre-specified QOL variables, except a trend for higher HADS-
Anxiety in patients with sentinel node biopsy plus axillary node clearance. 
 
18. Please check with your co-authors, and confirm, that all names are spelt correctly, 
and affiliations listed correctly. We cannot guarantee that we will be able to correct names 
and affiliations after publication of your article. 
This has been done and one correction made Linda Jane Williams 
 
19. Please indicate in the authorship if any authors are full professors. 
Done 
 
20. Please give full first names for all authors (unless 'J Michael Dixon' prefers to be 
listed as such, in which case please confirm). 
I confirm that Professor J Michael Dixon prefers to be listed as above.  
 
21. Please ensure that your Research in Context panel is structured as follows and 
contains the following important details in each section: 
 
Evidence before this study 
This section should include a description of all the evidence that the authors considered 
before undertaking this study. Authors should briefly state: the sources (databases, journal 
or book reference lists, etc) searched; the criteria used to include or exclude studies 
(including any date restrictions of the search, ie, articles published between 
month/day/year and month/day/year), which should not be limited to English language 
publications; the search terms used; the quality (risk of bias) of that evidence; and the 
pooled estimate derived from meta-analysis of the evidence, if appropriate. 
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Added value of this study 
Authors should describe here how their findings add value to the existing evidence. 
 
Implications of all the available evidence 
Authors should state the implications for practice or policy and future research of their 
study combined with existing evidence. 
 
We confirm that the above structure has been followed.   
 
22. Summary: Your abstract should conform to the CONSORT guidelines for abstracts 
(CONSORT for Abstracts: Lancet 2008; 371: 281-83), and must include: 
a) Methods: A brief summary of the main patient characteristics (ie, main entry 
criteria) 
b) Methods: Details of the regimens used. 
c) Methods: Details of how randomisation was done (eg, allocation concealment; 
nature of blinding, if any; how sequence was generated; stratification factors, etc). 
d) Methods: An explicit description of the actual primary endpoint. 
e) Methods: The nature by which analyses were done (eg, intention to treat, per 
protocol). 
f) Methods: The trial registration number. 
g) Methods: The status of the trial - is it ongoing/still enrolling/is this an interim 
analysis, etc?  
h) Findings: Data for the primary endpoint only. 
i) Findings: The most common (grade 3-4) adverse events for all treatment groups (incl 
actual numbers of patients affected); any serious adverse events. Any treatment-related 
deaths (number and cause).  
j) Interpretation: please do not just restate your findings. What do they mean, 
clinically? What are their implications? 
 
See recent issues of the journal for examples. Accuracy and completeness here are 
essential. 
We confirm that the above information has been provided.   
 
23. Please confirm that your study conforms to the CONSORT guidelines by completing 
and returning the checklist. 
We confirm that our study conforms to CONSOT guidelines, we are submitting the 
completed checklist.  
 
CONSORT - for RCTs - http://download.thelancet.com/flatcontentassets/authors/tlo-
consort-checklist.pdf 
 
24. Please ensure your methods section is structured using the following subheadings in 
this order: Study design and participants; Randomisation and masking; Procedures; 
Outcomes; Statistical analysis. 
We confirm that the above subheadings are used to structure the Methods section. 
 
 7 
25. Methods, Study design and participants. Please ensure that the following items are 
included: 
a) Age limit for eligibility. 
b) Indicate the means of disease evaluation (eg, RECIST, etc) 
c) Permitted performance status(es) defined. 
d) An indication of estimated life expectancy of eligible patients. 
e) Laboratory tests required to assess eligibility. 
f) Previous treatments permitted/not permitted (and washout period(s)). 
g) If the trial is second-line (or above), mention criteria for determining progression at 
inclusion. 
h) Comorbidities permitted/not permitted. 
i) Nature of consent sought and IRB approval. 
We confirm the above information has been included 
 
26. Methods: Randomisation and masking. Please include details of: 
a) Sequence generation. A description of the actual method of randomisation (ie, the 
method used to generate the sequence with which participants are allocated to comparison 
groups, including details of the methods used to restrict the randomisation—eg, block, 
stratification). Words and phrases such as "randomised", and "randomly assigned" without 
qualification are not acceptable.  
b) Allocation concealment. A description of the method used to conceal assignment of 
a participant without knowledge of the next assignment in the sequence. 
c) Implementation. Who generated the allocation sequence, who enrolled participants, 
and who assigned them to the trial groups 
We confirm this information has been included. 
 
27. Methods: procedures. Please ensure that the following items are included: 
a) Planned doses of treatment(s). 
b) Duration of treatment/number of cycles planned. 
c) Criteria for a patient to be removed from the study. 
d) Details of permitted dose reductions/interruptions. 
e) Type and frequency of radiographic assessments. 
f) If applicable, whether or not the primary endpoint was centrally reviewed. 
g) Frequency and type of laboratory monitoring. 
h) Frequency and type of adverse event monitoring. 
i) If you have included such data for a drug(s), please confirm that the dose, route, and 
frequency of administration (and the form: eg, a particular salt) are correct. 
We confirm this information has been included. 
 
28. Methods: Outcomes: Please ensure the following items are included: 
a) Definition of the primary endpoint for the trial overall and for this QoL substudy. 
b) Definition of all secondary endpoints for this QoL substudy. 
These have been added on page 7. 
Outcomes 
The primary endpoint of SUPREMO trial is 10-year overall survival. Quality of life is a 
secondary endpoint alongside chest-wall recurrence, regional recurrence, disease free 
survival, acute and late morbidity and cost-effectiveness. In the QOL sub-study we pre-
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specified as primary outcomes global QOL, fatigue, physical function, chest wall 
symptoms, shoulder and arm symptoms, body image, anxiety and depression. Secondary 
outcomes are role, social, sexual functioning, pain and nausea/vomiting. 
 
29. Methods: Statistical analysis. Please ensure the following items are included: 
a) Hypothesis, power calculation, and derivation of sample size. Done 
b) Definitions of population assessed for primary and secondary outcomes, and for 
safety (eg, ITT, per protocol, etc). 
c) Rules for defining patients as not assessable. 
d) Statistical methods for analysis of the primary and secondary outcomes. 
e) Any sensitivity analyses, etc. 
f) Any planned interim analyses. 
g) The trial registration number - "This study is registered [as an International Standard 
Randomised Controlled Trial/with ClinicalTrials.gov/similar], number 
[ISRCTNxxxxxxxx/NCTxxxxxxx/similar]."  
We confirm all above items are included, except c) rules for defining patients as not 
assessable (which does not apply to the study).  
 
30. As I am sure you are aware, the Lancet group are very supportive of protocol-based 
research and so have recently decided to encourage authors to post the protocol document 
on a publicly accessible website; a margin link to the website will then be put in the paper. 
Would you like to do this for your protocol?  If so, please send us the protocol link with your 
final corrections. Please note that if you do wish to do this then the weblink should not be 
temporary. Alternatively, you can place your protocol in the supplementary web appendix. 
 
We have a link to the protocol on the SUPREMO website- http://www.supremo-
trial.com/SUPREMO%20protocol%20version29.pdf. We  are happy for this link to be 
included in the paper. 
 
31. Please give the exact patient enrolment dates (if known)—ie, day, month, year - day, 
month, year.  
Enrolment dates were from August 4, 2006 till April 29, 2013, we have corrected in the 
paper. 
 
32. Results: It is Lancet style to give actual numbers (numerator and denominator) 
together with percentages—eg, '5 (50%) of 10 patients in the treatment group received 
treatment per protocol'. Please ensure that you have done this throughout the Results 
section. 
This has been checked. 
 
33. Results: Please give median follow-up (and IQR) for the analyses presented. 
This information has been added to Results page 8. 
Median follow-up for the patients who returned the baseline questionnaires was 748 days  
(interquartile range 417-763) for the control group and 749 days (interquartile range 725-
762) for radiotherapy group.  
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34. Results: please explicitly state the number of patients included in analyses, and the 
number of patients deemed ineligible (and reasons why). 
The number of patients included in the analysis (n=947) is explicitly stated on page 8. 
 
35. Results: Please do not translate HRs/RRs/ORs into percentages, since this can be 
misleading. Simply indicate the HRs/ORs/RRs and let the reader interpret the data. 
We have not converted any OR into percentages 
 
36. Results: The adverse events table should be stratified by grades 1-2, 3, 4 and 5. For 
adverse events of grade 1 or 2, any occurring in ≥10% of patients should be reported. All 
grade 3, 4, and 5 events should be reported.  
We do not report any adverse events in this manuscript. 
 
37. Please supply the webappendix as a single PDF file, with the pages paginated - when 
you refer to an item in the appendix, please refer to the page number on which it appears, 
not the table or section.  
Completed 
 
38. Please carefully examine your paper and cut any unnecessary duplication or 
repetition. Please note that we do not allow presentation of data in the results text that is 
already displayed in the figures or tables (with the exception of data pertaining to primary 
outcomes). Such duplicated data will be cut during editing if it remains. Equally, we do not 
allow repetition of results beyond the main findings in the Discussion; such text will also be 
cut.  
I did my best  
 
39. The Discussion should start with a summary of the main findings. 
Done 
 
40. If you have claimed a first, please reword to: "To our knowledge… this is the first 
time...", since you can never be 100% sure. 
Done 
 
41. Please ensure the Author contributions section at the end of your paper exactly 
matches those given on your signed author contribution forms. Authors should be referred 
to by their initials in this section. 
We confirm this has been checked and is correct  
 
42. Please ensure the declaration of interest statement at the end of your paper exactly 
matches those given on your ICMJE forms. If there are none then please state "The authors 
declared no conflicts of interest" or "The other authors declared no conflicts of interest." 
We confirm this has been checked and is correct  
 
 
43. We require written and signed consent from any individuals who are cited in the 
acknowledgments section or as personal communications. The following format can be used 
and a signed statement uploaded on resubmission: 
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* "I permit <corresponding author> et al to list my name in the acknowledgments section of 
their manuscript and I have seen a copy of the paper <full article title>." 
 
* "I permit <corresponding author> et al to cite a personal communication from me in their 
manuscript <full article title>." 
We are uploading the signed statements with the submission for 4 or the 5 named 
individuals in the acknowledgments section. We were unable to contact Penny Hopwood 
who has been retired for a few years. We keep trying. We are keen to acknowledge Dr 
Hopwood as she was the original lead for the QOL substudy, designed the study and 
wrote the protocol section.  
 
44. If a medical writer or editor was involved in the creation of your manuscript, we 
need a signed statement from the corresponding author to include their name and 
information about funding of this person. 
No medical writer or editor was involved in the creation of the manuscript. 
 
45. References should be in Vancouver style. For references with six authors or fewer, all 
authors should be listed. For those with seven or more authors, then just the first three 
authors and 'et al' should be listed. Please ensure that reference numbering throughout 
the manuscript is not inserted with electronic referencing software, such as Endnote. 
 
Vancouver style has been followed. We have used Endnote to insert the reference but at 
the end removed Endnote formatting form the references section. I hope this is OK. 
 
46. There should be no more than 30 references - please cut some references. 
Done 
 
47. All web references should have the date they were last accessed. 
We don’t have any web references 
 
48. All abstracts and references in press should be updated with DOIs or page numbers 
as appropriate. For papers listed in references that are "in press" we need to see a galley 
proof and/or letter from the publisher stating that it is "in press" as well as (where known) 
the full expected citation (ie, publication date/volume/issue etc). References that are 
"submitted" should be removed and citations in the text replaced with "(unpublished data; 
authors)". 
No abstracts or “in press” references cited. 
 
49. Please ensure that you provide your figures in editable formats. For trial profiles 
(clinical trials) and study selection diagrams (systematic reviews and meta-analyses), Word 
files (.doc or .docx) made of boxes with editable text are preferred. For any statistical 
images such as histograms, survival or time-to-event curves, line graphs, scatter graphs, and 
forest plots you should provide editable vector files (ie, the original artwork generated by 
the statistical package used to make the image, typically by using "Export" or "Print to file" 
commands); our preferred formats for these files are .eps, .pdf, or .ai. Photographic images 
must be provided at a minimum of 300 dpi at 107 mm wide. We cannot guarantee accurate 
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reproduction of images without these files. For more information, see 
download.thelancet.com/flatcontentassets/authors/artwork-guidelines.pdf 
We confirm that our figures are editable. 
 
50. As your study reports on a multi-centred trial, please provide a list for the appendix 
including each site from which patients were recruited, the name of the principle 
investigator responsible for this site, and the number of patients which were recruited from 
that particular site. This list should be ordered from the centres which contributed the 
greatest number of patients to the trial being listed first, to that which contributed the least 
listed last. 
This list is now provided for all UK centres participating in the QOL substudy  
 
51. When a paper includes a study group name in the byline (as yours does - the BIG 02-
04 MRC EORTC SUPREMO trial investigators), we're now required to supply a separate list of 
the group members in a specific format if we want these names to be acknowledged as 
collaborators in PubMed, similar to this 
citation: https://www.ncbi.nlm.nih.gov/pubmed/27864015. It should not contain the names 
of authors of the manuscript that are already listed, only those in the study group. 
To ensure that the information we supply to PubMed is accurate and complete, please 
upload with your revision a list of all study group members whose names should appear on 
PubMed, presented as a two-column table in Word. First and middle names or initials 
should be placed in the first column, and surnames in the second column. Names should be 
ordered as you wish them to appear on PubMed.  
 
The table will not be included in the paper itself - it's simply used to make sure that PubMed 
adds the names correctly. Please check through all names carefully, and ensure all 
collaborators are included. Please do not include names of authors already listed on the 
manuscript. This form is used for PubMed indexing and subsequent revision can be difficult, 
as it requires resupply of the entire paper to all platforms. We reserve the right to not make 
further changes to the collaborator list after the paper has passed for publication. 
 
Although this was an international trial supported by EORTC and BIG, the data presented 
in this manuscript has been collected by UK centres only, so we did not consider it 
relevant to include the international investigators with this publication. 
 
52. Please state whether this study was fully or in part NIH funded and whether any 
authors are employed by the NIH.  
The study was not funded by NIH and none of the authors are employed by NIH. 
 
53. It is no longer Lancet policy to edit or style supplementary material for the web; 
however, this material will still be hosted on our website as a pdf of the author supplied file. 
Please style your supplementary material as per the guidelines below. Please note that we 
will be unable to correct any errors in the webappendix following publication; as such, 
please check carefully when submitting.  
The guidelines below have been followed. 
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Text 
* Main heading for the web extra material should be in 12 point Times New Roman 
font BOLD 
* Text should be in 10 point Times New Roman font, single spaced 
* Headings should be in 10 point BOLD 
Tables 
* Main table heading should be in 10 point Times New Roman font BOLD 
* Legends should be in 10 point, single spaced 
* Tables should be in 8 point Times New Roman font, single spaced 
* Headings within tables should be in 8 point BOLD 
Data 
* SI units are required 
* Numbers in text and tables should always be provided if % is shown. 
* Means should be accompanied by SDs, and medians by interquartile range. 
* Exact p values should be provided, unless p<0·0001 
Drug names 
* Recommended international nomenclature (rINN) is required  
References 
* Vancouver style (eg, Smith A, Jones, B, Clements S. Clinical transplantation of tissue-
engineered airway. Lancet 2008; 372: 1201-09. Hourigan P. Ankle injuries. In: Sports 
medicine. Chan D, ed. London: Elsevier, 2008: 230-47.) 
* Numbered in order of mention in Web Appendix and numbered separately from 
references in the full paper 
Figures 
* All images must have a minimum resolution of 300 dpi at a width of 107 mm 
* Main figure heading should be in 10 point Times New Roman font BOLD 
* Legends should be in 10 point, single spaced 
 
  
Web appendix
Click here to download Necessary Additional Data: Velikova SUPREMO QOL Web Appendix 16june18.pdf
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Summary  
 
SUPREMO  
A randomised phase III trial assessing the role of chest wall irradiation in women 
with intermediate risk breast cancer following mastectomy.  
 
Eligibility (see Appendix IX for clarification of clinical staging (c), pathological 
staging (p) and pathological staging following neoadjuvant therapy (yp).  
 
 
1.1 Stage II histologically confirmed unilateral breast cancer following mastectomy 
including the following pTNM stages:  
 pT1N1M0  
 pT2N1M0  
 pT2N0M0 if grade III histology and/or lymphovascular invasion 
 pT3N0M0.  
If the tumour area comprises multiple small adjacent foci of invasive carcinoma 
then overall maximum dimension is taken to determine the size for T staging (see 
section 7.2.2 for a more detailed explanation).  Multifocal or multicentric tumours 
can be included (pT1m; pT2m; pT3m).  The size of the largest tumour focus 
determines the T stage classification.  See section 7.2.1). 
 
1.2 Stage II histologically confirmed unilateral breast cancer following neoadjuvant 
systemic therapy and mastectomy, if the original clinical stage was cT1-2cN0-1M0 
or cT1-2pN1(sn)M0 and with the following (ypTNM) stages after neoadjuvant 
systemic therapy:  
 ypT1pN1M0 
 ypT2pN1M0 
 ypT2pN0M0 if grade III histology and/or lymphovascular invasion. 
 ypT0pN0 or ypT1pN0 or ypT0pN1 (pathological complete remission, or near 
complete remission). 
 ypT2N0 independent of grade or lymphovascular invasion, if the original clinical 
stage was cT3N0. 
Also: 
 ypT3N0M0, if original clinical staging was cT1-3cN0 M0 or cT1-3pN0 (sn) M0. 
 
1.3 Unilateral invasive breast cancer that conforms to the initial clinical staging of 
criterion 1, but has been down-staged by neoadjuvant systemic therapy to ypT0 
pN0 or ypT1pN0 or ypT0pN1 (pathological complete remission, or near complete 
remission). If tumour stage cT3 or ypT3, then nodal status must be N0 both before 
and after neoadjuvant systemic therapy.  
 
2. Undergone total mastectomy (with minimum of 1 mm clear margin of invasive 
cancer and DCIS) and axillary staging procedure. 
 
3.1 If axillary node positive (1-3 positive nodes [including micrometastases 
>0.2mm-≤2mm]) then an axillary node clearance (minimum of 8 nodes removed) 
should have been performed. Isolated tumour cells do not count as 
micrometastases. 
 
3.2 Axillary node negative status can be determined on the basis of either axillary 
clearance or axillary node sampling or sentinel node biopsy. 
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3.3 Sentinel nodes identified in the internal mammary chain are considered pN1b or 
pN1c if histologically proven.  Patients can be included in the trial with microscopic 
metastasis in the internal mammary chain detected by sentinel node biopsy, if not 
more than 3 tumour positive nodes in axillary lymph nodes.  If not biopsied, internal 
mammary chain sentinel nodes are considered tumour negative for staging. 
 
3.4 Before neoadjuvant systemic therapy, axillary ultrasound is advised.  Abnormal 
axillary nodes based on imaging (mammogram or ultrasound) should be sampled by 
guided needle sampling or core biopsy.  Where axillary ultrasound is normal, negative 
axillary node status does not require histological confirmation before starting 
neoadjuvant systemic therapy.  Positive, or negative, nodal status may also be 
determined by sentinel node biopsy before start of neoadjuvant therapy. 
 
4. Fit for adjuvant or neoadjuvant chemotherapy (if indicated), adjuvant or 
neoadjuvant endocrine therapy (if indicated) and postoperative irradiation. 
 
5. Written, informed consent.  
 
Additional explanation for the inclusion criteria: 
 
1. Patients undergoing immediate breast reconstruction are eligible for inclusion. 
2. Patients who are carriers of known pathological mutations in BRCA1 or BRCA2 
genes are eligible for inclusion. 
3. Neoadjuvant systemic therapy: 
3.1 Patients who have undergone mastectomy after neoadjuvant systemic 
therapy are eligible for inclusion.  For determination of tumour stage and nodal 
involvement, please see Section 7.3.  
3.2 Tumour grade, hormone receptor status and Her-2 receptor status (or HER 
gene amplification) should be determined on a core biopsy taken before the 
start of neoadjuvant systemic therapy.  Lymphovascular invasion may be 
assessed on both the core biopsy and post treatment excision. 
3.3 T2 tumours that are cN0 and remain ypN0 after neoadjuvant systemic 
therapy can only be included if grade III histology and / or lymphovascular 
invasion. 
3.4 T3 tumours can only be included if N0 both before and after neoadjuvant 
systemic therapy (cN0, pN0(sn), ypN0). 
 
 
Exclusions 
 
1. Any pT0pN0-1 or pT1pN0 tumours after primary surgery.  
 
2. Any pT3pN1 or pT4 tumours.  Initial stage cT3cN1 or pN1(sn) or cT4 in patients 
receiving neoadjuvant systemic therapy cannot be included, even if downstaging 
has occurred and the pathological ypT and N stage is lower. 
 
3. Patients who have 4 or more pathologically involved axillary nodes.  For the 
purpose of this study protocol, nodal scarring after neoadjuvant systemic therapy 
will be considered as evidence of previous pathological nodal involvement and 
count towards the total number of involved axillary nodes. 
 
4. Past history or concurrent diagnosis of ductal carcinoma in situ (DCIS) of the 
contralateral breast, unless treated by mastectomy.  Previous DCIS of the 
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ipsilateral breast if treated with radiotherapy (i.e. previous DCIS treated by 
conservation surgery not followed by radiotherapy would be considered eligible).  
 
5. Bilateral breast cancer.  However, patients who have undergone a prophylactic 
contralateral mastectomy can be included, if the breast was pathologically free of 
invasive tumour. 
 
6. Previous or concurrent malignancy other than non melanomatous skin cancer 
and carcinoma in situ of the cervix.   For previous DCIS see criterion 4. 
 
7. Male.  
 
8. Pregnancy, at the time of radiotherapy treatment. 
 
9. Not fit for surgery, radiotherapy or adjuvant systemic therapy. 
 
10. Unable or unwilling to give informed consent.  
 
 
Randomisation 
Randomisation to chest wall irradiation or no chest wall irradiation 
 
Primary endpoint:   
Overall survival  
 
Secondary endpoints: 
Chest wall recurrence  
Regional recurrence  
Disease free survival  
Metastasis free survival   
Cause of death (breast cancer, intercurrent disease [cardiovascular and non-
cardiovascular])  
Acute and late morbidity    
Quality of life    
Cost effectiveness  
 
Follow up:  10 years  
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Patient undergoes diagnosis and staging 
 
Patient confirmed as potentially suitable by local research staff 
Neoadjuvant systemic therapy, if given 
Surgery 
Eligibility confirmed 
Patient seen by Oncologist – informed consent obtained 
Quality of Life Assessment Initial assessment 
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Randomisation *  
 
QoL assessment 
 Clinical Assessment 
Clinical &  
Cardiac assessment♥ 
 
CHEMOTHERAPY (if appropriate) 
End of chemotherapy 
Cardiac Assessment 
(chemotherapy patients only) 
 
RADIOTHERAPY (if randomised to receive) 
End of radiotherapy  
(or equivalent) Clinical & 
Cardiac Assessment 
 
Clinical & Cardiac assessment 12 months post-surgery QoL assessment° 
60 months post-surgery 
24 months post-surgery 
36 months post-surgery 
48 months post-surgery 
72, 84, 96, 108 months post-surgery 
120 months post-surgery 
 
Clinical assessment QoL assessment° 
Clinical assessment 
Clinical assessment 
Clinical & Cardiac assessment QoL assessment° 
Clinical assessment 
QoL assessment° Clinical & Cardiac assessment 
* Randomisation may be done after chemotherapy 
 with BNP, plasma, ECG, echocardiogram  
 with BNP, plasma 
°  QoL at 12,24,60 and 120 months post-randomisation 
       UK only 
 
Visits(a) 
Patients  involved Screening 
Post (+/-) 
chemo pre (+/-
) RT 
Post (+/-) RT  1 yr 2 yr 3 yr 4 yr 5 yr 6 yr 7 yr 8 yr 9 yr 10 yr 
 
Recurrence2  
 Investigations     Baseline 1 2 3   4 5 6 7 8 9 10 11 12 13   
 Informed consent   All X                             
 Medical history & examination (b) All X  X   X X X X X X X X X X 
 
X  
 Staging tests    All X                             
 Contralateral mammography    All X       
A mammogram of the opposite breast, if appropriate, is 
recommended at least in alternate years for 10 years from the date 
of mastectomy  
 
 
 Blood sampling    If consented to TRANS-SUPREMO X                           X 
 Tumour paraffin block from primary tumour1   All X                           
 
 
  
 Tumour paraffin block at recurrence if available2    All                       
 
X  
 Acute/ Late  morbidity3   All     X   X X X X X X X X X X   
 Cardiac symptoms and examination  
If consented to 
cardiac sub study X X
4 X  X    X     X X  
 Blood sampling for BNP   If consented to cardiac sub study X X
4 X   X       X         X X  
 Electrocardiogram   If consented to cardiac sub study X 
    X5       X5         X X
5  
 Echocardiogram (c) If consented to cardiac sub study X 
    X5       X5         X  X
5  
 QOL and EQ5D economic assessment (d) 
If consented to QOL 
sub study  X    X X     X         X  
  
 
 
(a) Patients in the control arm MUST follow the same follow up schedule as irradiated patients.  
(i) The only exception are patients in the cardiac substudy who receive chemotherapy. This is the only group of patients who must attend a post chemotherapy visit.  
(ii)  For patients receiving chemotherapy, follow up will be on completion of radiotherapy or at 3 months after chemotherapy in non-irradiated patients. 
     For patients not receiving chemotherapy follow up will be on completion of radiotherapy or at 3 months after surgery in non-irradiated patients. 
(b) Questioning for symptoms of recurrent breast cancer, examination of loco-regional area and other relevant clinical areas for evidence of recurrence depending on clinical features. 
(c) In centres where isotope ventriculography is the standard examination for patients requiring anthracycline containing chemotherapy, an echocardiogram will also be required at baseline.  
Echocardiography will be used for all subsequent time points in the study.   
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(d) Baseline (pre randomisation) quality of life assessment will be conducted in the clinic. All subsequent quality of life assessment questionnaires will be mailed to the patient. 
 
 
1 Tumour blocks required from all patients for purpose of audit.  Tissue microarrays only constructed if patient consented to TRANS-SUPREMO. 
2Recurrence defined as local and/or distant relapse and/or development of a contralateral breast primary.  Blood and tissue samples should be obtained prior to any subsequent treatment 
commencing. 
3Morbidity will be measured using the RTOG/EORTC Radiation morbidity scoring system in all patients regardless of whether they are allocated radiotherapy or not.  Any toxicity assessed as a
Grade 4 or 5 Acute or Late Morbidity Score must be reported on a SAE/SUSAR report form. 
4For patients in the cardiac substudy not receiving chemotherapy, the post chemo/pre RT visit will not be required. 
5Echocardiogram and ECG repeated if B type natriuretic peptide (BNP) exceeds threshold value or clinical features warrant it. 
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1. INTRODUCTION 
 
International consensus supports the routine use of adjuvant chest wall irradiation in 
women after mastectomy and systemic therapy for breast tumours =/> 5cm in 
diameter and with 4 or more histologically involved axillary nodes (Recht et al., 1998) 
or with a 20% 10 year risk of loco-regional recurrence (LRR) (Goldhirsch et al., 
1998a). However the value of chest wall irradiation in women at intermediate risk of 
loco-regional recurrence with 1-3 involved nodes after mastectomy and a 10 year risk 
of loco-regional recurrence of less than 15% is uncertain. For such patients loco-
regional radiotherapy is not standard care in most UK centres or internationally. 
Clinical trials of postmastectomy radiotherapy (PMRT) in this subgroup are an 
international priority (NIH consensus statement, 2000; Recht et al., 2001).  
 
From a survey conducted amongst UK clinical oncologists there are wide variations in 
practice in the use of chest wall irradiation in women with 1-3 involved nodes after an 
axillary clearance (Kunkler et al., 2000). This may reflect the absence of definitive data 
from randomised trials assessing the value of adjuvant irradiation in this group of 
patients. A recent survey among European radiation oncologists of the use of PMRT 
in women with 1-3 positive nodes showed wide variations among those advocating 
PMRT from 19% in Italy to 74% in Spain and Portugal (Ceilley et al., 2005).  
 
Of the 15 prospective randomised trials evaluating PMRT for axillary node positive 
patients receiving adjuvant systemic therapy, all but one show the ability of radiation 
to reduce LRR. The proportional reduction in risk of LRR remains fairly constant, 
between one half and two thirds. However, the absolute benefits range widely, from 
6% to 21% (Fowble, 1999). The absolute reduction in risk ranged from 10% to 28% for 
patients with four or more nodes involved and from 3% to 23% for patients with 1-3 
involved nodes. For T3 tumours, it ranged even more widely, from 10% to 45%. 
Whelan et al., (2000) in an overview have estimated the impact of loco-regional 
radiotherapy in current practice from all peer-reviewed published trials (median follow 
up at least 5 years) among patients receiving adjuvant chemotherapy or tamoxifen (or 
both) randomised to receive or not to receive radiotherapy. Radiotherapy was 
associated with a 75% reduction in odds of loco-regional failure, a 31% reduction in 
odds of tumour recurrence and 17% reduction in the odds of death. The effects of 
radiotherapy in terms of reducing recurrence and improving survival are similar in size 
to those of systemic therapy (EBCTCG, 1998).  
 
Loco-regional failure after mastectomy and systemic therapy alone is commonest on 
the chest wall and considerably less common in the axilla or supraclavicular fossa. 
Very rarely it occurs in the internal mammary nodes. Most of the survival benefit is 
thought (but not proven) to be derived from chest wall irradiation.  
 
The Oxford overview (EBCTCG, 2000) suggests that PMRT reduces breast cancer 
mortality in women with a 20% 10 year risk of loco-regional recurrence by 5%. 
Clinically significant gains in survival might also occur in women with a lower than 
20% risk of local recurrence, for example those with 1-3 positive nodes treated by 
mastectomy, axillary clearance, systemic therapy and chest wall irradiation.  
 
Randomised trials comparing mastectomy and systemic therapy with or without loco-
regional irradiation have shown a 9-10% survival benefit at 10 years from the addition 
of loco-regional irradiation to adjuvant cyclophosphamide, methotrexate and 5 
fluorouracil (CMF) in 'high risk' premenopausal women (Overgaard et al., 1997; Ragaz 
et al., 1997). A similar survival benefit has been shown in postmenopausal women at 
high risk of local recurrence (Overgaard et al., 1999).  The larger trial from Denmark of 
1061 premenopausal high risk patients with 1-3 involved nodes shows an 8% gain in 
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overall survival (62% vs 54%) from the addition of comprehensive loco-regional 
irradiation to systemic therapy.  For the 1885 patients with 1-3 involved nodes from a 
combined analysis of the premenopausal and postmenopausal patients in the Danish 
Trials (Overgaard et al., 2007) overall survival at 14 years was 10% higher with the 
addition of PMRT (50% vs 40%, p = 0.0001).  While survival benefit was shown in all 
subgroups of patients, the major benefit accrued to those with 1-3 positive nodes and 
in patients with tumours 5cm or less. The survival advantage of the addition of 
radiotherapy to CMF was greater (9%) in small (<21mm) and intermediate size (21-
50mm) tumours, compared to 7% in larger tumours (>50mm). There were similar 
findings in the Danish trial of postmenopausal patients (Overgaard et al., 1999).  
 
It is possible therefore that while loco-regional radiotherapy may confer most benefit in 
loco-regional control in larger tumours, a greater survival benefit might be conferred in 
smaller tumours and fewer numbers of involved nodes due to a lower competing risk 
of distant metastases (Harris et al., 1999). This hypothesis is supported by a recent 
retrospective analysis of three European Organisation for Research and Treatment of 
Cancer (EORTC) adjuvant breast cancer trials (van der Hage et al., 2003). It shows 
that patients with 1-3 positive nodes gained most in terms of survival (RR 0.48,99% CI 
0.31-0.75,p=<0.001). These data should be interpreted with caution since the analysis 
is retrospective. Long term (20 year) follow up of the Canadian trial of PMRT (Ragaz 
et al., 2005) shows a 7% gain in overall survival  (57% vs 50%) from the addition of 
locoregional RT to systemic therapy. However in an accompanying editorial Whelan & 
Levine (2005) comment that in the 1-3 node positive group treated by PMRT, we 
remain dependent on subgroup analysis and level I evidence is still needed on the 
benefits of PMRT in this subset of patients. In node negative patients the results of 
PMRT are conflicting. No survival advantage was found in this subgroup in the Danish 
randomised trials (Overgaard M, 2002) or in combined analysis of the EORTC trials 
(van der Hage et al., 2003). A recent retrospective study (Jagsi et al., 2005) of a 
population of 887 node negative patients who had undergone mastectomy without 
adjuvant irradiation, showed that size >2cm, margin <2mm, premenopausal status 
and lymphovascular invasion were independent prognostic factors for loco-regional 
recurrence (LRR). Ten year LRR was 10% with one risk factor, 17.9% with two risk 
factors and 40.6% with three risk factors. However, even for T3N0 (stage IIb) tumours, 
the local recurrence risk can be less than 10% at 15 years in patients treated with 
adjuvant systemic therapy (Taghian, 2006).  Furthermore a retrospective comparison 
of patients treated in a centre in Brussels by postoperative radiotherapy after 
mastectomy showed a 2.5%-6.9% overall survival benefit compared to a similar 
population of patients from the US SEER database treated without postmastectomy 
radiotherapy (Voordeckers et al., 2003). The authors acknowledge the limitations of a 
retrospective comparison and commend a randomised trial of adjuvant radiotherapy in 
node negative postmastectomy patients. 
 
Uncertainty remains on the generalisability of the results from the Danish and 
Canadian trials to clinical practice, however, due to specific features of radiotherapy 
techniques, treatment volumes, regimes of systemic therapy and extent of axillary 
surgery which differ from those adopted in many cancer centres. The Danish trials 
(Overgaard et al., 1997; Overgaard et al., 1999) involved comprehensive irradiation of 
the axillary, internal mammary and supraclavicular nodes and a combination of 
photons and electrons to treat the chest wall. Most UK centres do not irradiate the 
internal mammary nodes and use photons alone to treat the chest wall. The intensity 
of the adjuvant CMF regime in the Danish trial has been considered suboptimal 
(Goldhirsch et al., 1998b) and the extent of axillary dissection inadequate.  
Anthracycline containing regimes of adjuvant chemotherapy have proved more 
effective than adjuvant CMF.  They have largely replaced CMF for intermediate risk 
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breast cancer.  There are few data on the interaction of anthracycline based adjuvant 
chemotherapy and PMRT in this group of patients. 
 
The mean number of nodes removed was only seven, probably accounting for the 
high loco-regional recurrence rate (30%) observed in patients with 1-3 involved nodes, 
due to understaging. In the British Columbia trial too the loco-regional failure rate (10 
year actuarial rate 16% and 15 year actuarial 33%) was higher than in other series 
with at least 5 years follow up with 1-3 positive nodes (6%-13%) reported by other 
authors (Recht et al., 1999; Goldhirsch et al., 1988; Kaufmann et al., 1993). A recent 
subgroup analysis of the Danish data, including only patients with 8 or more axillary 
lymph nodes removed, has however shown a 9% absolute survival benefit at 15 
years, and a local recurrence risk reduction from 27% to 4% at 15 years (Overgaard et 
al., 2007). Furthermore, the patients with the best prognosis and the lowest local 
recurrence risk (11%) without radiotherapy still showed a survival benefit of 11% at 15 
years with radiotherapy, but for the patients with the poorest prognosis, there was no 
effect on survival, despite a reduction in locoregional recurrence with radiotherapy 
(Kyndi et al., 2009). However, the loco-regional recurrence rate at 27% is much higher 
than in many North American series, challenging the generalisability of this data to 
contemporary practice. 
 
The recent guidance from the UK National Institute for Clinical Excellence (2009) 
encourages recruitment of patients with intermediate risk breast cancer after 
mastectomy into the SUPREMO trial. 
 
How exactly loco-regional radiotherapy interacts with systemic therapy in contributing 
to survival is still not clear. Systemic therapy is thought mainly to eradicate systemic 
micrometastases more effectively than loco-regional disease (Fu, 1985). Loco-
regional radiotherapy may be important in preventing secondary dissemination from 
the residual loco-regional disease and might increase the potential for cure (Arriagada 
et al., 1995; Ragaz et al., 1997).  
 
Data on the risk of loco-regional recurrence (LRR) in different patient subgroups are 
limited and conflicting (Recht, 1999). Recht et al. (1999) showed that from the ECOG 
trial data on 2,016 assessable patients that with a median follow up of 12.1 years for 
disease free survivors, the cumulative 10 year incidence of LRR (including 
simultaneous distant recurrence) was 13% for patients with 1-3 positive nodes and 
29% for those with four or more positive nodes. These figures are lower than the 
Danish and British Columbia premenopausal trials which showed respectively 30% 
and 33% LRR for 1-3 nodes and 42% and 46% LRR for four or more positive nodes.   
The Scottish Intercollegiate Guidelines Network (SIGN) advocate that 
postmastectomy radiotherapy should be considered for all premenopausal women at 
high risk of local recurrence (SIGN, 1998). The SIGN guidelines indicate that risk is a 
summation of factors, including tumour size (>5 cm), grade, nodal status, lymphatic 
invasion and involvement of deep margins. It remains unclear, however, what degree 
of benefit is achieved for particular subgroups of patients at intermediate risk (e.g. 
those with less than four nodes involved, tumours <5 cm or negative nodes and grade 
3 histology or lymphovascular invasion). Nor is it clear what weight should be 
assigned to other factors, such as tumour size, grade and lympho-vascular invasion.  
 
Some authors have attempted to use combinations of prognostic factors, such as 
tumour size and number of involved nodes, to define subgroups with more specific 
risks of LRR than single factors alone. As Recht (1999) points out, information on 
such combinations is limited (Fowble et al., 1988; Sykes et al., 1989; Pisansky et al., 
1993). Recht et al., (1999) in a multivariate analysis of the ECOG data showed tumour 
size, number of involved nodes and ER status to be predictive of risk of LRR but not 
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age or menopausal status. Other prognostic factors, such as vascular or lymphatic 
invasion (Recht, 1999; Katz et al., 2000, Voogd et al., 2001), tumour grade (O’Rourke 
et al., 1994) and extracapsular nodal extension (Katz et al., 2000) increase the risk of 
recurrence. There may therefore be patients who are axillary node negative with risk 
factors for local recurrence for whom PMRT might confer a survival advantage in 
addition to a reduction in risk of loco-regional recurrence.  
 
Recently Taghian et al.,  (2004) have reported from 5758 node positive women 
enrolled in the NSABP B-15, B-16, B-22 and B-25 trials that the overall cumulative 
incidence of locoregional failure was 13.0% in women with 1-3 positive axillary nodes 
compared to 24.4% and 31.9% in women with 4-9 and  =/> 10 nodes after 
mastectomy and doxorubicin containing adjuvant therapy.  In multivariate analysis, 
age, tumour size, premenopausal status, number of lymph nodes and number of 
lymph nodes dissected were significant risk factors for LRF as first event. However 
compared to institutional or population based series, there is a much higher 
representation of patients who are premenopausal and under the age of 50 in the 
combined NSABP series (Olivotto, Truong and Chua, 2004). These authors also 
highlight the fact that the NSABP trials were primarily designed to assess different 
chemotherapy regimes rather than assess the role of PMRT.  This may limit the 
generalisabilty of such trial data to clinical practice. The value of PMRT in women with 
1-3 positive nodes or node negative but with other risk factors depend on whether the 
benefits in loco-regional control and survival outweigh treatment related morbidity and 
mortality. Morbidity may have a significant impact on quality of life. Complications of 
chest wall irradiation include pneumonitis, cardiac damage and rib fractures.  
 
While data on cardiac morbidity from the Danish premenopausal and postmenopausal 
trials of PMRT show no excess in morbidity or mortality from ischaemic heart disease 
in irradiated patients (Hojris et al., 1999); the cardiac volumes irradiated in these trials 
were minimised by use of electron field techniques used to treat the medial chest wall 
and internal mammary nodes. This technique is not common outside Denmark. 
Tangential fields are more commonly used in the UK to treat the chest wall and some 
of the cardiac volume may be irradiated in order to encompass the chest wall. 
Techniques for minimising dosage to the heart vary between centres, some using 
positioning techniques (Canney et al., 1999) and others partial cardiac blocking 
(Landau et al., 2001). The Oxford overview of trials of postoperative radiotherapy 
(EBCTCG 1995, EBCTCG 2000) shows that a reduction in breast cancer mortality 
from radiotherapy is partially offset by an increase in non breast cancer mortality 
which is mainly cardiovascular. It is estimated that if radiation induced cardiovascular 
morbidity could be eliminated an extra 2-4% 20 year survival from radiotherapy might 
be achieved (EBCTG 2000). The Oxford overview includes many older radiotherapy 
trials where dosage to the heart was higher using radiotherapy techniques which 
would now be considered outmoded (Harris et al., 1999). Modern techniques expose 
the heart to considerably lower doses compared to previous decades (Taylor et al., 
2007; Taylor et al., 2009). Estimates of treatment morbidity, mortality and quality of life 
need to be based on contemporary and commonly used radiotherapy techniques.  
 
Although the cardiac risks of radiotherapy may be less with current techniques, there 
is increasing use of potentially cardiotoxic anthracycline containing adjuvant 
chemotherapy regimes and thus additional risks of chemotherapy induced cardiac 
morbidity and mortality (Bristow et al., 1978, Shapiro et al., 1998, Guldner et al., 2006, 
Hooning et al., 2007).  Furthermore, the use of targeted agents such as trastuzumab, 
can also cause cardiac morbidity (Tan-Chiu et al., 2005, Romond et al., 2005, Robert 
et al., 2006, Smith et al., 2007). The long-term cardiovascular effects of systemic 
therapy may therefore also influence the balance of benefits and risks of even modern 
PMRT. 
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Neoadjuvant chemotherapy (i.e. chemotherapy given prior to surgery) is being 
increasingly administered for operable (stage II) breast cancers, both within and 
outwith clinical trials. The rationale for this approach is the opportunity for 
chemotherapy response monitoring, and the increased rate of breast conservation. 
Trials have demonstrated an equivalent overall survival for patients treated with 
neoadjuvant chemotherapy and patients treated with the same chemotherapy post-
operatively (Bear et al., 2006, Mauri et al., 2005, Mieog et al., 2007). The indications 
for adjuvant radiotherapy after mastectomy are based on the evidence from trials 
discussed in the previous sections, and rely on the pathological staging.  Due to the 
down-staging that can occur with neoadjuvant chemotherapy, the traditional 
pathological criteria can no longer be reliably applied, with the result that the indication 
for adjuvant radiotherapy can be even more uncertain than after primary surgery. The 
series of retrospective studies from the MD Anderson Cancer Centre of patients 
treated with neoadjuvant chemotherapy indicate that both the initial clinical tumour 
stage and the postoperative pathological stage are independent predictors of the loco-
regional recurrence risk, even if a pathological complete response is achieved. 
(Buchholz et al., 2008, Garg et al., 2004, Huang et al., 2004, McGuire et al., 2007). 
There are however no randomised trials investigating the optimal patient selection for 
post-operative radiotherapy to the chest wall and/ or lymph node regions. The 
inclusion of patients treated with neoadjuvant chemotherapy in a trial of post-
mastectomy radiotherapy will help provide an evidence base on which treatment 
decisions for this patient group can be based on in the future (Buchholz et al., 2008). 
 
In summary, a large randomised trial is needed investigating the impact on loco-
regional control, survival, quality of life, morbidity and cost effectiveness of 
postoperative radiotherapy to the chest wall in women at intermediate risk of 
recurrence following mastectomy, receiving neoadjuvant or postoperative systemic 
therapy (if indicated) and axillary clearance.   
 
 
2. OBJECTIVES  
 
To determine the effect of:  
 
Ipsilateral chest wall irradiation following mastectomy and axillary surgical staging for 
women with operable breast cancer at ‘intermediate risk’ of loco-regional recurrence.  
 
On the primary endpoint of:  
  
Overall survival  
 
Secondary endpoints: 
 Chest wall recurrence 
 Regional recurrence  
 Disease-free survival 
 Metastasis-free survival 
 Cause of death (Breast cancer, Intercurrent disease [cardiovascular and non- 
cardiovascular]) 
 Acute and late morbidity 
 Quality of Life 
 Cost effectiveness  
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3. PATIENT ELIGIBILITY (see Appendix IX for clarification of clinical staging (c), 
pathological staging (p) and pathological staging following neoadjuvant therapy (yp). 
 
1.1 Stage II histologically confirmed unilateral breast cancer following mastectomy 
including the following pTNM stages:  
 pT1N1M0  
 pT2N1M0  
 pT2N0M0 if grade III histology and/or lymphovascular invasion 
 pT3N0M0.  
If the tumour area comprises multiple small adjacent foci of invasive carcinoma then 
overall maximum dimension is taken to determine the size for T staging (see section 
7.2.2 for a more detailed explanation).  Multifocal or multicentric tumours can be 
included (pT1m; pT2m; pT3m).  The size of the largest tumour focus determines the T 
stage classification (see section 7.2.1). 
 
1.2 Stage II histologically confirmed unilateral breast cancer following neoadjuvant 
systemic therapy and mastectomy, if the original clinical stage was cT1-2cN0-
1M0 or cT1-2pN1(sn)M0 and with the following (ypTNM) stages after neoadjuvant 
systemic therapy:  
 ypT1pN1M0 
 ypT2pN1M0 
 ypT2pN0M0 if grade III histology and/or lymphovascular invasion 
 ypT0pN0 or ypT1pN0 or ypT0pN1 (pathological complete remission, or near 
complete remission). 
 ypT2N0, independent of grade or lymphovascular invasion, of the original stage 
was cT3N0. 
Also: 
 ypT3N0M0, if original clinical staging was cT1-3cN0 M0 or cT1-3pN0 (sn) M0. 
 
1.3 Unilateral invasive breast cancer that conforms to the initial clinical staging of 
criterion 1, but has been down-staged by neoadjuvant systemic therapy to ypT0pN0 
or ypT1pN0 or ypT0pN1 (pathological complete remission, or near complete 
remission). If tumour stage cT3 or ypT3, then nodal status must be N0 both before 
and after neoadjuvant systemic therapy. 
 
2. Undergone total mastectomy (with minimum of 1 mm clear margin of invasive 
cancer and DCIS) and axillary staging procedure. 
 
3.1 If axillary node positive (1-3 positive nodes [including micrometastases >0.2mm-
≤2mm]) then an axillary node clearance (minimum of 8 nodes removed) should have 
been performed. Isolated tumour cells do not count as micrometastases. 
 
3.2 Axillary node negative status can be determined on the basis of either axillary 
clearance or axillary node sampling or sentinel node biopsy. 
 
3.3 Sentinel nodes identified in the internal mammary chain are considered pN1b or 
pN1c if histologically proven. Patients can be included in the trial with microscopic 
metastasis in the internal mammary chain detected by sentinel node biopsy, if not 
more than 3 tumour positive nodes in axillary lymph nodes. If not biopsied, internal 
mammary chain sentinel nodes are considered tumour negative for staging. 
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3.4 Before neoadjuvant systemic therapy, axillary ultrasound is advised.  Abnormal 
axillary nodes based on imaging (mammogram or ultrasound) should be sampled by 
guided needle sampling or core biopsy.  Where axillary ultrasound is normal, negative 
axillary node status does not require histological confirmation before starting 
neoadjuvant systemic therapy.  Positive, or negative, nodal status may also be 
determined by sentinel node biopsy before start of neoadjuvant therapy. 
 
4. Fit for adjuvant or neoadjuvant chemotherapy (if indicated), adjuvant or neoadjuvant 
endocrine therapy (if indicated) and postoperative irradiation. 
 
5. Written, informed consent.  
 
 
Additional explanation for the inclusion criteria: 
 
1. Patients undergoing immediate breast reconstruction are eligible for inclusion. 
2. Patients who are carriers of known pathological mutations in BRCA1 or BRCA2          
genes are eligible for inclusion. 
3. Neoadjuvant systemic therapy: 
3.1 Patients who have undergone mastectomy after neoadjuvant systemic therapy 
are eligible for inclusion. For determination of tumour stage and nodal 
involvement, please see Section 7.3.  
3.2 Tumour grade, hormone receptor status and Her-2 receptor status (or HER 
gene amplification) should be determined on a core biopsy taken before the start 
of neoadjuvant systemic therapy. Lymphovascular invasion may be assessed on 
both the core biopsy and post treatment excision. 
3.3 T2 tumours that are cN0 and remain ypN0 after neoadjuvant systemic therapy 
can only be included if grade III histology and / or lymphovascular invasion. 
3.4 T3 tumours can only be included if N0 both before and after neoadjuvant 
systemic therapy (cN0, pN0(sn), ypN0). 
 
 
Exclusion criteria   
 
1. Any pT0pN0-1 or pT1pN0 tumours after primary surgery.  
 
2. Any pT3pN1 or pT4 tumours. Initial stage cT3cN1 or pN1(sn) or cT4 in patients 
receiving neoadjuvant systemic therapy cannot be included, even if downstaging has 
occurred and the pathological ypT and N stage is lower. 
 
3. Patients who have 4 or more pathologically involved axillary nodes.  For the 
purpose of this study protocol, nodal scarring after neoadjuvant systemic therapy will 
be considered as evidence of previous pathological nodal involvement and count 
towards the total number of involved axillary nodes. 
 
4. Past history or concurrent diagnosis of ductal carcinoma in situ (DCIS) of the 
contralateral breast, unless treated by mastectomy.  Previous DCIS of the ipsilateral 
breast if treated with radiotherapy (i.e. previous DCIS treated by conservation surgery 
not followed by radiotherapy would be considered eligible).  
 
5. Bilateral breast cancer.  However, patients who have undergone a prophylactic 
contralateral mastectomy can be included, if the breast was pathologically free of 
invasive tumour. 
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6. Previous or concurrent malignancy other than non melanomatous skin cancer and 
carcinoma in situ of the cervix.   For previous DCIS see criterion 4. 
 
7. Male.  
 
8. Pregnancy, at the time of radiotherapy treatment 
 
9. Not fit for surgery, radiotherapy or adjuvant systemic therapy. 
 
10. Unable or unwilling to give informed consent.  
 
  
4. TRIAL DESIGN AND STATISTICAL CONSIDERATIONS  
 
Randomised to chest wall irradiation versus no chest wall irradiation   
 
4.1 Null hypothesis  
 
There is no significant difference in overall survival in patients at 'intermediate risk' of 
loco-regional recurrence from operable breast cancer treated by mastectomy, axillary 
surgical staging and, if indicated, neoadjuvant and/or adjuvant systemic therapy with 
or without chest wall irradiation.  
  
4.2 Sample size and power  
 
If the 10 year survival difference between the non-irradiated and irradiated arms of 
SUPREMO was 7% (56% vs 63% respectively), the sample size to detect a 7% 
difference in overall survival at 10 years with 80% power at the 0.05 level of 
significance would be 1600 allowing a 5% increase for loss to follow up and rounding 
up.  As recruitment will take place over several years and the anticipated survival 
rates will be subject to error, it is also helpful to express power in relation to the 
number of deaths in the study at the time of the primary analysis.  The hypothesised 
survival rates correspond to a hazard ratio of 1.255, and for 80% power with this 
hazard ratio, the necessary number of events (deaths) is 609.   
 
4.3 Statistical plan  
 
All analyses will be based upon the principle of intention-to-treat, and two-tailed 
significance tests and confidence intervals will be used throughout. Analysis of the 
primary outcome variables will be based principally on the calculation of 95% 
confidence intervals for the hazard ratios, based on a Cox proportional hazards 
model. The timing of the first published report is planned to be based on a minimum of 
2.5 years of follow up. This will be subject to modification by the Steering Committee 
on the advice of the Data Monitoring and Ethics Committee.  
 
While the size of the trial limits the analysis of the relationship between systemic 
therapy and radiotherapy in relation to the endpoints for the trial, it is proposed to 
conduct an exploratory analysis of this relationship. 
 
 
5. STAGING   
 
Staging will be conducted according to local centre protocol. Staging policies for each 
centre should be communicated to the trials office in advance of trial entry and any 
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changes to staging procedures during the conduct of the trial.  Full blood count, liver 
biochemistry and chest radiograph should be considered.  
 
 
6. GUIDELINES ON SURGERY  
 
6.1 Mastectomy and axillary node clearance  
 
6.1.1  A total mastectomy (including skin sparing mastectomy) and a minimum of a 
level II axillary clearance should be carried out (a minimum of 8 nodes, from one or 
more surgical procedures, confirmed pathologically). 
  
or 
 
6.1.2  For axillary node negative patients, a total mastectomy and other axillary 
surgical procedures are permissible: either an axillary node sample with a minimum of 
4 pathologically confirmed nodes  
 
 or   
 
6.1.3 Sentinel node biopsy if conducted in a centre which has audited evidence of 
<10% failure to identify the sentinel node in at least 30 patients.  
 
6.2 Breast reconstruction   
 
Patients undergoing immediate breast reconstruction are eligible for the trial. 
Participating centres must state their policy on radiotherapy and immediate 
reconstruction in advance of the trial and notify any changes in policy during the trial 
to the trials office.  
 
 
7. GUIDELINES ON PATHOLOGY  
 
7.1 General guidelines 
 
UICC staging (6th edition) should be used.   
 
7.1.1  The size of the primary tumour should be measured.  
 
7.1.2   All primary tumours should be graded according to the Nottingham 
modification of the Bloom & Richardson grading system as modified by Elston and 
Ellis (1991).  
 
7.1.3   The adequacy of the excision margin should be measured. An adequate 
margin is any margin that is deep, anterior or radial. The margins are to be clear of 
either invasive or non-invasive disease, that is invasive disease or ductal carcinoma in 
situ (DCIS). It does not include the presence or absence of lymphatic/vascular 
invasion.  
 
7.1.4   A minimum of 8 axillary nodes should be examined in an axillary clearance 
(this can be from one or more surgical procedures).  
 
7.1.5   All submitted axillary nodes in an axillary node sample should be examined   
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7.1.6   A copy of the pathology report on the primary tumour and axillary node(s) 
should be sent to the trials office.  
 
7.1.7  The original reported grade and lymphovascular status will be accepted for the 
purpose of the trial. 
 
7.1.8  A password protected website for the trial will be provided giving examples of 
grading and lymphovascular invasion to facilitate standardisation of reporting between 
pathologists. 
 
7.1.9  A panel of three pathologists will undertake the review of all cases entered by 
examining a representative H&E section taken from a tissue block submitted to the 
trial central laboratory.  Each pathologist will review one third of the cases, randomly 
allocated, and assess grade and lymphatic/vascular invasion.  The pathologists will be 
blinded to the original pathology report.  Those cases where the review grade and 
lymphatic/vascular invasion status is in agreement with those originally reported will 
be reviewed no further.  In those cases where there is disagreement between the 
reviewing pathologist and the original report there will be a formal review by all three 
reviewing pathologists to achieve consensus.  Criteria for review will conform to 
current grading guidelines (Elston and Ellis, 1991). 
            
7.2 Multifocal invasive cancer 
 
7.2.1 If there is more than one discrete invasive cancer, the size of the largest focus of 
invasive cancer determines the T stage classification. This must be greater than 2cm 
for classification as a pT2 tumour and greater than 5cm for classification as a pT3 
tumour. 
 
7.2.2 If the tumour area comprises multiple small adjacent foci of invasive carcinoma 
then the overall maximum dimension should be taken and must be greater than 2 cm 
for classification as a pT2 tumour and greater than 5 cm for classification as a pT3 
tumour (see Diagram F below): 
   
 
 
7.3 Patients undergoing neoadjuvant systemic therapy 
 
7.3.1 For determination of tumour stage and nodal involvement, the most advanced 
stage either clinically or pathologically is considered for the inclusion and exclusion 
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criteria. In the case of a pathological complete remission (inclusion criterion 1.3), then 
the clinical staging will apply, based on clinical and imaging examinations. This should 
comprise at least mammography and ultrasound of the breast and axilla. Results from 
other imaging modalities, if performed, such as MRI or FDG-PET may also be taken 
into consideration. 
 
7.3.2 For this group of patients the core biopsy will be used to assess tumour grade 
and hormone status and Her-2 receptor status (or HER gene amplification).  The 
Elston and Ellis modification of the Bloom & Richardson Grading System will be used 
as referred to in 7.1.2 above. Lymphovascular invasion may be assessed on both the 
core biopsy and the post treatment excision. A copy of the pathology report on the 
core biopsy should be sent to the trials office in addition to the reports detailed in 
7.1.6. 
 
7.3.3 For this group of patients nodal scarring is considered evidence of previous 
involvement to define the number of (originally) involved lymph nodes. For inclusion 
this should be 3 nodes or less. 
 
 
8. GUIDELINES ON RADIOTHERAPY  
 
General  
 
Within each participating centre the radiotherapy technique should be standardised for 
all patients participating in the trial. This technique will be communicated to the 
radiotherapy quality assurance programme. Any change in technique must 
immediately be notified to the quality assurance programme.  
 
8.1 Simulation and field irradiation  
 
8.1.1   All patients should be simulated for the planning of chest wall irradiation.  
 
8.1.2  CT planning to minimise dosage to the heart and lung is recommended. Where 
full CT planning is not available a simulator CT through the centre of the Planning 
Target Volume (PTV) is recommended. If this is not possible, an external contour with 
lung estimate is acceptable.  
 
8.1.3  Treatment should be delivered using a technique that ensures an even dose 
distribution (within ICRU guidelines) using megavoltage photons and wedge filters or 
other appropriate method. Megavoltage electrons are permissible provided an 
adequate dose distribution is achieved. 
 
8.1.4  Where it is not possible to treat the whole of the mastectomy scar within the 
tangential fields to limit dosage to lung and/or heart, the use of electron fields to treat 
the medial and/or lateral parts of the scar outside the tangential photon field should be 
considered. Care must be taken to avoid overlap of electron and photon fields.  
 
8.1.5 Supraclavicular fossa and upper axilla 
 
Where a level II axillary clearance has been performed and the axillary nodes are 
pathologically involved, a single direct anterior field covering the supraclavicular fossa 
and the apex of the axilla is recommended.  
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The anterior supraclavicular field may be angled 5-20 degrees to avoid the spinal 
cord. Shielding of the larynx may be used but should not shield the medial 
supraclavicular nodes. 
 
8.1.6 Internal mammary chain 
 
The CTV and PTV should preferably be indicated on the simulator images. As the 
internal mammary nodes are difficult to identify on CT, the PTV based on the internal 
mammary artery plus a 1.5 cm margin in lateral directions and 5mm in the dorsal 
direction should suffice in most cases.  
 
8.2 Position of the patient  
 
The patient will be treated in the supine position. Some form of immobilisation device 
is recommended such as an arm pole and/or vacuum bag. This position should be 
reproduced during simulation, acquisition of planning CT and during treatment.   
 
8.3 Reproducibility of treatment position  
 
The use of EPID (electronic portal imaging device) or equivalent is mandatory in 
centres where this technology is available .  If electronic verification is not available it 
is strongly recommended that a port film is taken during the first week of treatment.  
Centres who are unable to verify patient position on set should contact the QA team to 
discuss options available to them. 
   
8.4 Clinical target volume  
 
8.4.1  The clinical target volume encompasses the skin flaps from 5mm below the 
skin surface and includes the soft tissues down to the deep fascia, but not including 
the underlying muscle and rib cage.  
 
8.4.2 Reflecting international variations in radiotherapy practice and to maximise 
participation in the trial:  
 
(a) UK centres, after a level II or III clearance, may elect to irradiate the Medial 
Supraclavicular Fossa (MSCF) and/or Internal Mammary Chain (IMC), if such is their 
centre's policy, in patients who have pathologically involved nodes and are 
randomised to chest wall irradiation. If they choose to do so they must notify the trial 
centre of their policy and technique prior to randomising patients in the trial.  
 
(b) Non-UK centres after a level II or III clearance may elect to irradiate the Medial 
Supraclavicular Fossa (MSCF) and/or Internal Mammary Chain (IMC), if such is their 
centre's policy, in any patient in either arm of the trial. If they choose to do so, they 
must notify the trial centre of their policy and technique prior to randomising patients in 
the trial.  
 
8.4.3 The lateral axilla, lateral to the Medial Supraclavicular Fossa (MSCF) and cranial 
to the tangential fields must not be irradiated. This is to avoid toxicity of combined 
surgical and radiotherapeutic treatment of this area, in particular the lymphovascular, 
venous and nervous structures. Since the lower axilla (part of level 1) is laterally 
adjacent to the breast, it is unavoidable to irradiate part of this in the tangential fields. 
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8.5 Planning target volume  
 
8.5.1  The planning target volume encompasses the skin flaps. While the deep 
margin encompasses the deep fascia, the treatment volume inevitably includes the 
pectoralis major and rib cage. Depending on the energy used, build up may be 
necessary. To restrict the volume of lung and/or heart the surgical scar may have to 
be left out of the field medially and/or laterally.  
 
8.5.2  The irradiated volume should extend medially to the midline, laterally to the 
mid axillary line and inferiorly to 1-2 cm below the level of the inframammary fold and 
superiorly to the level of the sternoclavicular joint. Care should be taken in setting the 
upper field margin to avoid irradiation of the axilla. If there is a clinical need to do so, it 
is acceptable to compromise PTV slightly taking into account location of the tumour 
and scar to spare organs at risk. 
 
8.6 Treatment planning and reference point   
 
8.6.1  Participating centres are encouraged to adopt 3-dimensional planning for trial 
patients as soon as it becomes available in their centre on Sim-CT or CT-Sim. 
 
8.6.2   Dose inhomogeneity should not vary by more than 12% in the central slice. 
This should be between a point outside of lung and the maximum should be an 
isodose encompassing a 2cm square area (to allow for irregularities in calculation of 
maximum point dose by planning systems).  
 
8.6.3  The lung density correction must be clearly stated when calculating the dose 
distribution. Centres should be aware of incorporating lung density correction on an 
individual plan.  
 
8.6.4  Chest wall 
 
Doses must be prescribed to the reference point which lies at or near the centre of the 
target volume (ICRU 50). This point is half way between the lung surface and the skin 
surface on the perpendicular bisector of the posterior beam edge.  Maximum and 
minimum doses must also be stated to describe dose homogeneity and must follow 
ICRU 50 recommendations.  
 
8.6.5  Supraclavicular fossa and upper axilla 
 
The dose with photons should be prescribed to Dmax (100% or a depth of 1.5cm 
using 6 MV photons; other energies may also be used). 
 
8.6.6  The dose is prescribed to the ICRU 50 reference point for photons and to the 
100% isodose for electrons.  
 
8.6.7  Irradiation of large volumes of the heart and lung should be avoided by 
keeping the central lung distance to 3cm or less measured by computer tomography 
or simulator.  Alternatively, verification of lung depth may be carried out using machine 
films.  
 
8.6.8  Bolus may be applied to whole or part of the chest wall. Centres must specify 
their policy for the use of bolus in advance of participation in the trial and notify the 
trial administrator of any changes in policy during the trial.  Centres should specify 
whether bolus is applied to part (e.g. the scar area) or all of the chest wall and for all 
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or a specified number of fractions and the thickness of bolus used for a given photon 
energy.  
 
8.6.9  Centres electing to irradiate the internal mammary nodes must use CT planning 
for this purpose. The internal mammary nodes should be treated with a mixture of 
photons and electrons, using the electrons of appropriate energy and limited 
penetration to reduce the dose to the heart. 
 
8.7 Sequencing of systemic therapy and radiotherapy  
  
8.7.1  In patients not receiving chemotherapy, radiotherapy should be started within 
12 weeks after the date of mastectomy. If more than one surgical procedure has been 
performed (e.g. the patient returns for an axillary node clearance), the date of final 
definitive surgery should be used. The date of final definitive surgery should also be 
used when patients have undergone a course of chemotherapy between initial and 
final surgery. 
 
8.7.2  In patients receiving chemotherapy, radiotherapy should be started  within 6 
weeks of the end of chemotherapy.  
 
8.7.3  All chemotherapy should be given before radiotherapy. 
  
8.7.4 Trastuzumab, or other targeted biological agents, should be administered 
according to local policy. 
 
8.7.5 Sequencing of endocrine therapy and chemotherapy may be according to local 
practice. 
 
8.8 Dosage and fractionation   
 
8.8.1  The dose distribution should be shown at least in the plane through the beam 
axes. The target area (planned target volume [PTV]) in this plane should be outlined.  
 
8.8.2 Fractionation regimes  
 
 The recommended dose/fractionation regime is:  
 
 50 Gy TAD in 25 daily fractions over 5 weeks 
  
 Other admissible dose and fractionation schedules are: 
 45 Gy TAD in 20 daily fractions over 4 weeks 
 40 Gy TAD in 15 daily fractions over 3 weeks 
 42.4 or 42.56 Gy TAD in 16 daily fractions over 3 weeks plus 1 day  
 
8.8.3   Breast reconstruction 
 
Breast reconstruction is not a contra-indication to radiotherapy. Centres should state 
their radiotherapy dose and fractionation policy for patients undergoing radiotherapy 
after breast reconstruction in the trial. Cancer control should be the overriding 
concern.  
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8.9 Radiotherapy equipment  
 
8.9.1  Megavoltage photons are recommended.  Electrons of appropriate energy may 
be used. The choice of energy depends on the thickness of tissue between the skin 
surface and the underlying deep fascia.  
 
8.9.2  Beam calibration should be carried out in accordance with a specified written 
protocol, preferably as described in the IPEM absorbed dose protocol (Code of 
Practice, 1990).  
 
 
9. ACUTE AND LATE MORBIDITY 
 
Baseline cardiac risk factors will be collected on all patients. Acute and late morbidity 
will be assessed using the EORTC/RTOG radiation morbidity scale [Cox et al., 
1995](see Appendix VIII) in all patients regardless of whether they are allocated 
radiotherapy or not. Morbidity relating to all treatment modalities should be recorded. 
The acute morbidity will be assessed at the end of the course of radiotherapy or at 3 
months post surgery for non-irradiated patients who have not received chemotherapy 
or at 3 months post chemotherapy for non-irradiated patients who have received 
chemotherapy. Late morbidity assessments will be carried out at 12, 24, 36, 48, 60, 
72, 84, 96, 108, 120 months after surgery.  
 
 
10. GUIDELINES ON ADJUVANT SYSTEMIC THERAPY 
 
1. All patients should be considered for optimal adjuvant systemic therapy, if indicated. 
 
2. For each patient, centres will be required to state whether (a) a taxane or 
anthracycline-containing regimen and (b) hormonal therapy has been used.  
 
3. Choice of adjuvant systemic therapy should take account of tumour grade, lympho-
vascular invasion, menopausal status, nodal status and oestrogen receptor status and 
if appropriate HER2 status. 
 
4. In patients receiving adjuvant systemic therapy an anthracycline-containing regime 
for at least 3 months or 4 cycles should be encouraged. 
 
5. The recommended minimum allowable starting dose per injection of doxorubicin in 
regimes such as adriamycin and cyclophosphamide (AC) should be 60mg/m2 and in 
cyclophosphamide, adriamycin and 5-fluorouracil (CAF) or FAC is 50mg/m2.  
 
6. Where doxorubicin is given as a single agent in regimes such as Bonnadonna (4 
cycles of adriamycin followed by 8 cycles of CMF) the recommended minimum  
starting dose per injection is 75mg/m2.  
 
7. The recommended allowable starting dose per injection of epirubicin in regimes 
such as Epirubicin and Cyclophosphamide (EC) is 90 mg/m2 and in CEF or FEC is 
50mg/m2 when given on days 1 and 8 or 75mg/m2 when given on day 1 every 21 
days.  
 
8. Where epirubicin is given as a single agent in regimes such as EpiCMF, the 
minimum allowable starting dose per injection is 90mg/m2.  
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9. Taxane–containing regimes are permissible but it is recommended that they also 
incorporate anthracyclines. Centres will be asked to specify which regime they use. 
 
10. It is recommended that all chemotherapy is given first and followed by 
radiotherapy in patients randomised to radiotherapy. 
 
11. It is recommended that patients with oestrogen or progesterone receptor positive 
cancers should receive adjuvant endocrine therapy for a minimum of five years. For 
postmenopausal women tamoxifen or an aromatase inhibitor are advised. It is 
recommended that premenopausal women should receive tamoxifen, ovarian ablation 
or a combination or both. Centres will be asked to specify which endocrine therapy will 
be used. 
 
12. It is acknowledged that there may be some patients, particularly the elderly or 
those with inadequate cardiac function or general medical condition, for whom a 
combination of classical or intravenous cyclophosphamide, methotrexate and 5 
fluorouracil (CMF) may be more appropriate than an anthracycline-containing regime. 
 
13. Patients can receive adjuvant trastuzumab or other targeted biological agents as 
appropriate, according to local practice. 
 
 
11. REGISTRATION AND RANDOMISATION PROCEDURES 
  
11.1  Stratification will be by treating centre   
    
Centres should specify their policies of neoadjuvant and adjuvant systemic therapies 
and surgical procedures before entering patients into the trial.   
  
11.2  Randomisation procedure   
  
11.2.1 Consenting patients treated by neoadjuvant systemic therapy (if indicated), 
mastectomy, axillary surgical staging and adjuvant systemic therapy (if indicated) for 
intermediate risk breast cancer will be randomised in SUPREMO to receive or not 
receive postoperative chest wall irradiation.   
  
11.2.2 Patients will be randomised by permuted blocks with the block length being 
varied randomly to minimise the effect of entry bias.   
 
11.2.3 Randomisation should occur when radiotherapy is normally discussed. For 
centres participating in the Cardiac substudy (UK only), ideally patients would be 
randomised before the start of chemotherapy treatment. However it is recognised that 
the patient and/or clinician may wish to defer discussion about the main trial, TRANS-
SUPREMO and the Quality of Life substudy until later during a planned course of 
chemotherapy. If discussion is deferred, the patient will be enrolled into the cardiac 
study with the proviso that they will consider randomisation to the main trial and 
substudies at a later point during their chemotherapy. If the patient declines 
randomisation at this later stage they will remain enrolled in the cardiac substudy, and 
follow the schedule outlined in section 20. 
 
11.2.4 Eligibility and agreement to participate will be recorded on the Screening Log to 
be retained at each centre. Trial Screening Summary Forms should be completed and 
returned to the SUPREMO Trial Coordinator at ISD quarterly.  Reasons for not 
entering patients in the randomised controlled trial will be recorded. After surgery 
eligibility will be confirmed. Patients who are interested will be given a patient 
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information sheet by the centre. Written informed consent to participation will be 
obtained.   
  
11.2.5 For those patients consenting, the randomisation checklist should be 
completed by the centre and patients will be randomised through the Edinburgh trials 
office of the Information Services Division (ISD) Cancer Clinical Trials Team (formerly 
Scottish Cancer Therapy Network) in the UK and by agreement through other 
international trial organisations.   
 
11.2.6 Once the patient has been formally entered into the trial, and the treatment 
allocation has been confirmed to the centre by fax, a letter should be sent to the 
patient’s general practitioner (GP) on hospital-headed paper. Electronic notification to 
the GP is also acceptable where this is the local practice.  
 
 
12. FOLLOW UP ARRANGEMENTS 
 
12.1 Follow Up Clinic Visits  
 
12.1.1 Follow up clinic visits will be made postoperatively for at least 10 years:  
 
(a) - for patients in the cardiac substudy who receive chemotherapy, within 3 weeks of 
completing chemotherapy, before radiotherapy starts. 
 
(b) i.- for all patients who have received chemotherapy, at the end of the course of 
radiotherapy or 3 months after chemotherapy in patients not receiving radiotherapy. 
 
(b) ii. - for patients who have not received chemotherapy, at the end of the course of 
radiotherapy or 3 months after the date of mastectomy (or date of final definitive 
surgery, if applicable) in patients not receiving radiotherapy. 
 
(c) - at 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after date of mastectomy (or 
date of final definitive surgery, if applicable). 
 
(d) - if the post radiotherapy visit or equivalent visit for non-irradiated patients falls 
within 6 weeks of the 12 month follow-up visit, then only 1 combined visit is required . 
 
12.1.2 A ‘Follow up’ form will be completed at each visit. A ‘ morbidity’ form will also 
be completed at these times. The acute morbidity form will be completed at the end of 
the course of radiotherapy only and the late morbidity form will be completed at 12, 
24, 36, 48, 60, 72, 84, 96, 108, 120 months after surgery.  For non-irradiated patients 
acute and late morbidity forms are completed at equivalent time points (see 12.1 b (i) 
and (ii). This is to avoid reporting bias. 
 
12.1.3 An extra follow up visit will be required for patients participating in the cardiac 
substudy who receive chemotherapy (see 12.1.1a).  
 
12.2 Recurrences 
 
Any recurrences (local and/or distant relapse) and/or development of a contralateral 
breast primary) are to be documented on the Follow up form and details of treatment 
recorded on the Recurrence Form. Blood and tissue samples should be obtained 
prior to any subsequent treatment commencing.  Causes of death will be sought 
from hospital or community medical records.  
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12.3 Mammograms 
 
A mammogram of the opposite breast, if appropriate, is recommended at least in 
alternate years for 10 years from the date of mastectomy.  
 
12.4 Serious Adverse Events (SAE’s) 
 
ICH GCP defines an SAE as any untoward medical occurrence shown in Box 1:  
 
BOX 1 
 Results in death 
 Is life-threatening* 
 Requires in-patient hospitalisation** or prolongation of existing hospitalisation 
 Results in persistent or significant disability/incapacity  
 Is a congenital anomaly/birth defect (in offspring of patient regardless of time to 
diagnosis). 
 Is an important medical event (an event that jeopardizes the patient or may require 
intervention to prevent one of the other outcomes listed above). 
 
* The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the 
patient was at risk of death at the time of the event; it does not refer to an event that 
hypothetically might have caused death if it were more severe. 
 
** Hospitalisation is defined as an inpatient admission, regardless of length of stay, 
even if the hospitalisation is a precautionary measure, for continued observation.  
Hospitalisation for a pre-existing condition, including elective procedures, which has 
not worsened, does not constitute a serious adverse event. 
 
Other important medical events that may not result in death, are not life threatening, or 
do not require hospitalisation may be considered as serious adverse events when, 
based upon appropriate medical judgement, the event may jeopardise the patient and 
may require medical or surgical intervention to prevent one of the outcomes listed in 
Box 1. 
 
The SUPREMO trial uses standard radiotherapy schedules and unexpected serious 
adverse events are unlikely to occur. However all SAEs will be reported to the Data 
Monitoring and Ethical Committee. Expected adverse events from radiotherapy 
include skin reactions leading to chest wall tenderness and itching. Skin reactions are 
usually mild but are occasionally severe. Chest wall pain, usually mild and intermittent 
can occur. Rarely, osteoradionecrosis of the ribs can occur. Radiation pneumonitis 
can occur in 1% of patients if treated with tangential fields to the chest wall only. 
Cardiac damage may occur as a late effect.  
 
SAEs should be reported if they occur during radiotherapy or within 30 days of the last 
radiotherapy session (fraction), whether or not they are related to the randomised 
treatment. They should also be reported if they occur at an equivalent time point in 
patients who are randomised to receive no radiotherapy.  
 
In addition, any toxicity assessed as a Grade 4 or 5 Acute or Late Morbidity Score 
(see section 9) must be reported on a SAE/SUSAR report form.  This applies for the 
entire follow-up period for the trial. 
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Patients who are consented and randomised before chemotherapy (eg. those 
recruited to the cardiac sub-study to obtain baseline bloods and cardiac assessments) 
may experience adverse events related to their chemotherapy. Any chemotherapy 
related SAEs that may, in the judgement of the responsible clinician, impact upon the 
delivery of the randomised treatment in SUPREMO should also be reported using the 
appropriate SAE/ SUSAR form. Table 1 lists the expected adverse events from 
chemotherapy which should and should not be reported as SAEs within the 
SUPREMO trial.   
 
Table 1 
Chemotherapy related SAEs that 
require reporting 
Chemotherapy related SAEs that do not 
require reporting on  SAE/ SUSAR form 
(unless they impact on delivery of the 
randomised treatment) 
1. Wound infections 
2. Necrosis of the mastectomy 
skin flaps 
3. Any cardiac event 
4. Development of any other 
serious medical condition 
between date of consent 
and planned start of 
radiotherapy (or equivalent 
period for those patients 
randomised to not receive 
radiotherapy) 
Hospitalisation due to: 
1. Neutropenia 
2. Febrile neutropenia 
3. Diarrhoea 
4. Infections, including those to 
Hickman line, catheter. 
5. Pyrexia 
6. Sore throat 
7. Nausea or vomiting 
8. Cellulitis 
 
 
13. ADMINISTRATION OF THE TRIAL 
 
A senior trial coordinator will be appointed who will report to an executive committee 
responsible for the administration of the trial and to a committee of grant-holders for 
the trial. A trial coordinator will be appointed to assist the senior trial coordinator. The 
quality of life study will be supported by a trial coordinator.  
 
 
14.  DATA MONITORING 
 
An independent Data Monitoring and Ethical Committee will be established and will 
meet every 6 months (or as often as they consider appropriate). None of the members 
of the committee will be involved in the trial. The committee will receive regular reports 
from the trial administration centre. It will submit its comments and recommendations 
to the Steering Committee and the Executive Committee.   
 
Monitoring (source data verification) will be carried out by the Cancer Clinical Trials 
Team in Edinburgh on 10% of the patient data, and we have allowed for site visits in 
the UK. In addition we would expect to check 100% of patient consent forms in the 
UK. Higher levels of monitoring will be performed, if requested, by the Data Monitoring 
Committee, or if particular safety issues are identified by the investigators or the Trial 
Management group or Steering Committee. 
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15. ETHICAL APPROVAL 
 
Ethical approval by a Multi-Centre Research Ethics Committee will be needed before 
the trial can be started. Participants will also need approval of their Local Research 
Ethics Committee (as appropriate until 1st April 2009). Approval by the National 
Cancer Research Network in the UK will be sought. The trial will be carried out 
according to guidelines of good clinical practice (ICH-GCP) as defined by paragraph 
28 and Schedule 1 Part 2 of the Medicines for Human Use (Clinical Trials) 
Regulations, 2004, and the Clinical Trials Directive (2001/20/ECD) elsewhere in the 
European Union and follow the principles of research governance. Outside the 
European Union the trial will conform to international regulations appropriate to the 
local legal requirements. 
 
 
16. PUBLICATIONS POLICY 
 
A writing committee will be established by the grantholders which will be responsible 
for preparing publications of the trial for submission to peer reviewed journals. Similar 
writing committees will be established for TRANS SUPREMO, quality of life, cardiac, 
health economic and other substudies. The writing committee for the main trial will 
include a representative of the European Organisation for Research and Treatment of 
Cancer (EORTC) and other collaborating breast trial groups who have made 
significant contributions to the trial. Names of participating groups that have 
contributed to the trial will be clearly stated in publications reporting the results of the 
trial. Names of investigators who have contributed patients to the trial and their 
centres will be named as an appendix in articles submitted for publication. Articles 
reporting the results of the main trial and substudies will be circulated, where 
appropriate, by the writing committees to representatives of collaborating breast trials 
groups for comment prior to submission. An overview on the publications arising from 
the trial will be maintained by the Trial Steering Committee, who will be the arbiters in 
the event of any disagreement relating to publications. 
 
 
17. RADIOTHERAPY QUALITY ASSURANCE PROGRAMME 
 
The purpose of the radiotherapy quality assurance programme (RT QA)  
 
The complex nature of modern radiotherapy carries inherent problems both in 
ensuring reproducibility and accuracy within a radiotherapy unit and, more particularly, 
when carried out on a multi-centre basis. Specific issues in the treatment of the chest 
wall, with or without lymph node pathways arise from the geometry of the treatment 
volume which varies in contour in all three planes with important radiation sensitive 
structures underlying the chest wall including the lung and myocardium.  
 
Careful localisation, computerised planning, accurate verification of beam position and 
meticulous attention to alignment and matching during treatment are essential.  
 
A quality assurance programme is “a mandatory prerequisite when aiming at high 
dose, high precision radiotherapy” (Horiot et al., 1993) and is an integral component of 
any radiotherapy trial as defined by the EORTC guidelines for trial protocols in 
radiotherapy (Bolla et al., 1995).  
 
In this multi-centre randomised trial the quality assurance programme (QA) will enable 
confirmation that technical guidelines within the protocol have been understood and 
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implemented correctly by participants and that the dose prescription is delivered 
according to protocol with appropriate documentation.  
 
This will ensure that clinical observations in terms of tumour control and normal tissue 
damage reflect differences in the randomised schedules rather that departures from 
trial protocol. Techniques used will be documented.  This data will be available should 
differences in observed end points emerge.  
 
In this way the definition of quality assurance as “all those planned and systematic 
actions necessary to provide adequate confidence that a product will satisfy given 
requirements of quality” (Standing Subcommittee on Cancer of the Standing Medical 
Advisory Committee: Quality Assurance in Radiotherapy, 1991) can be satisfied and 
the scientific worth of the parent trial be validated.  
 
Background to the radiotherapy quality assurance programme  
 
The QA programme will build on that developed for the START trial, which has 
provided a basis for consensus among radiotherapy centres in the UK.   
 
All radiotherapy treatment relies on accurate reproducibility of the beams set up from 
day to day. This ultimately requires the use of light beams and laser alignments on 
skin marks on the patient. Inevitable variation occurs from day to day in a fractionated 
course of treatment which, even in the most rigorous setting, will result in field 
movements of several millimetres when daily verification films are taken (Westbrook et 
al., 1991).   
 
Clinical sequelae may therefore arise because of imperfect technique. Inhomogeneity 
across the chest wall target volume may result in excess normal tissue damage to 
skin, subcutaneous tissues and ribs, and myocardial damage may result from the 
treatment of left sided tumours using techniques, which deliver significant doses to the 
heart. This may well result in an excess mortality from treatment (Cuzick et al., 1987) 
which can be reduced with careful attention to treatment technique (Fuller et al., 
1991). The use of high doses to the nodal areas through a single anterior field will 
result in areas of the volume receiving greater than the prescribed tumour dose in 
larger fractions per day, or, in contrast, underdosage to the deeper parts of the volume 
if the tumour dose is prescribed to the anterior part of the volume only.  
 
The hazards of shoulder stiffness, rib necrosis and skin fibrosis have been highlighted, 
but of equal concern is the question of tumour recurrence if inadequate treatment is 
given. These factors emphasise the importance of meticulous treatment technique in 
the proposed trial and the need for external quality assurance to avoid major clinical 
problems and to ensure equivalence of techniques.   
 
Plan of the RT QA programme  
 
The quality assurance programme will, having established precise details of radiation 
technique in each centre, focus upon measures by the QA team to the centres to 
verify adherence to treatment protocol and technique.  
This follows the guidelines set out by the EORTC (Bolla et al., 1995) and will be co-
ordinated by an experienced QA team based at Mount Vernon Hospital (Aird et al., 
1995; Venables et al., 2001a; Venables et al., 2001b). It is based on an anticipated 
accrual to around 40 UK centres over a four year period. The programme will proceed 
as follows:   
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1. An initial questionnaire establishing precise details of technique to be used within 
the centre, together with specimen patient outlines or CT data, when available, to be 
used for ideal plans to be produced.  
 
* Target volume and treatment technique used together with methods of beam 
matching where appropriate.  
* Planning of radiation distributions across the treatment volume for homogeneity 
and prescription points.  
* Routine QC performed by the centre will be assessed and compared with current 
Institute of Physics and Engineering in Medicine (IPEM) guidelines.  
 
2. A visit by the quality assurance team may be required prior to a centre entering the 
study to validate dosimetry in those centres which have not had dosimetry in a breast 
or chest wall phantom independently verified for the equipment currently being used. 
The QA programme for START revealed differences of nearly 10% in the delivered 
dose at the centre of a chest wall phantom (range 0.946-1.036) (8) and the range of 
delivered dose in patients will be larger than this due to variations in individual patient 
chest wall density and set up.  
 
Measurements in phantoms allow the range of doses delivered during radiotherapy to 
be assessed.   
 
3. The plans for the first 5 patients in the radiotherapy arm, from each radiotherapy 
treatment centre, together with verification images will be collected by the QA team.  
 
4. Subsequently, 1 in 10 plans will be collected by the QA team to ensure continued 
protocol adherence.  
 
5. In vivo dosimetry will be undertaken, preferably within the 1st week of treatment, in a 
subset of patients within the trial who will have thermo luminescent dosimetry (TLD) 
sent from the QA team. These patients will be identified at randomisation. It is 
anticipated that approximately 1 in 10 patients will have TLD sent from the QA 
team. Only UK patients will be selected for the in vivo dosimetry. 
 
6. For all patients entered into the cardiac sub-study, copies of radiation port films, 
electronic portal images or CT plans should be sent for centralised documentation of 
the amount of heart within the irradiated fields. An electronic medium is preferred. If a 
participating centre does use film, each patient’s film should be scanned preferably 
into DICOM format. The same is true for the treatment plan. The latter should be sent 
electronically (preferably batched on a CD). 
 
Quality control of individual patients by department  
 
The verification method must be independent of the planning system.   
  
Analysis of QA programme  
 
The data from the quality assurance programme will be analysed separately from the 
main trial. Major discrepancies from trial protocol will be notified to participating 
centres.  
 
These will include:  
 
1. Discrepancies in documentation, dose prescription and dose recording.  
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2. Dose inhomogeneity of more than 12% across chest wall treatment volume (-5% to 
+7%).  
 
3. Hot spots (>100%) at field matchlines.  
 
4. Inclusion of >3cm of lung in treatment volume.  
 
5. Systematic errors of technique in any stage of treatment from planning through to 
implementation.  
 
More detailed analysis of the quality assurance data will enable:  
 
1. An independent review of variations in chest wall radiotherapy practice in 
participating centres.  
 
2. Quantification of dose uniformity during the treatment period.  
 
3. Correlation of physical parameters of radiation with trial end points:  
 
(a) The association between dose variation across the treatment volume and tumour 
control.  
 
(b) Variations in dose homogeneity and association with rib pain, fracture and 
necrosis.   
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18. BIOLOGICAL SUBSTUDY (TRANS-SUPREMO; UK, Ireland and EORTC only) 
 
Biological Substudy 
 
Background  
 
The SUPREMO trial gives us a unique opportunity to expand our knowledge of the 
molecular mechanisms underlying the relapse of breast cancer and resistance to 
radiation therapy.  
 
Radiotherapy is currently delivered to almost all women with early breast cancer 
undergoing conservation treatment, and to those with mastectomy at high risk of local 
relapse. Without irradiation, 20-40% of women will relapse locally over the succeeding 
10-15 years (Cutuli, 2000).  
 
Standard prognostic factors such as tumour size and grade, node status, age, ER 
status, absence of positive margins, extent of ductal carcinoma-in-situ and vascular 
invasion, do not define the 60-80% of patients in whom radiotherapy might be safely 
omitted (Fourquet et al., 2002). Factors mooted as potentially related to local relapse 
include reduced expression of bcl-2 (Silvestrini et al., 1997), over-expression of the 
IGF-1 receptor (Turner et al., 1997), expression of VEGF (Linderholm et al., 1999), 
cathepsin D (Ardavanis, et al., 1998), p53 (Zellars et al., 2000; Haffty, 2002), 
plasminogen activator inhibitor 1 (Cufer et al., 2002) and c-erb-B2 (Haffty, 2002; 
Koukourakis et al., 2003). Other proteins affecting local invasive potential, such as 
integrins and proteases, and proliferation, such as downstream activities in the Akt 
and MAP kinase pathways may also be important. One recent study has suggested 
that an activated wound signature may predict a poor outcome (Nuyten et al., 2004). 
 
Increased risk of local relapse without but not with radiotherapy has been reported in 
association with positive immunohistochemical staining for p53, increased levels of 
GST and reduced expression of bcl-2 (Silvestrini et al., 1997). This suggests these 
factors may identify a group who benefit from radiotherapy. The role of BRCA1, 
BRCA2 and ATM is unclear in sporadic breast cancer, while cyclin D over-expression 
might contribute to radioresistance (Xia & Powell, 2002). There are no studies relating 
radiation response to other DNA repair proteins or factors involved in apoptosis, 
although several have been suggested to have a role in the development of breast 
cancer. Other factors involved in both these areas (for example Ku, PARP1, XRCC 1 
and 3, Rad51, members of the bcl-2 family and caspases) are likely to have a role in 
radioresistance. 
 
A recent study has used mRNA microarray expression profiling to identify young 
patients with node-negative early breast cancer at low and high risk of systemic 
relapse (van’t Veer et al., 2002; van de Vijver et al., 2002). In this technique, mRNA 
levels were quantified using gene chip technology, and prognostic groups defined by 
patterns of expression of the subset of 70 genes showing a significant variation (2-fold 
or greater) between tumours. We hypothesise that a unique signature may be present 
for both local relapse and radiosensitivity. The aim of the present study is to identify 
these signatures and validate methods by which such patients can be identified in the 
clinic using the SUPREMO trial as a test system. The TRANS-SUPREMO study will 
allow the evaluation of potential pathways predictive of local relapse and 
radiosensitivity/resistance in the context of SUPREMO by constructing tissue 
microarrays from all patients enrolled in this trial. This approach should allow us to 
identify key molecular pathways for the future identification of patients most likely to 
benefit from radiotherapy. A similar approach is being used in early breast cancer, 
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where the use of standard prognostic factors to determine who should have adjuvant 
chemotherapy is being compared with decision making based on molecular signatures 
in the MINDACT trial. 
 
In TRANS-SUPREMO we will construct tissue microarrays from paraffin blocks from 
mastectomy specimens from all patients randomised in the study.  Some, but not 
most, centres involved in SUPREMO are routinely collecting frozen material from 
tumours. However the delay of 1-2 weeks between mastectomy and obtaining 
informed consent will preclude collection and storage of fresh or frozen material in the 
majority of centres. We will also collect whole blood, serum and plasma at 
randomisation, recurrence (local and/or distant relapse) and/or development of a 
contralateral breast primary to look for pharmacogenetic and protein markers of 
relapse/outcome. Further tissue will be collected, where possible, at recurrence (local 
and/or distant relapse) and /or development of a contralateral breast primary. For 
patients who undergo neoadjuvant systemic therapy, tissue from the core taken at 
diagnosis will also be collected, where possible. 
 
Even in a study as large as the proposed SUPREMO study, the relatively small 
number of informative specimens (i.e. those from patients with relapsed disease) 
means that only a small number of individual factors can be tested in proteomic 
studies. Accordingly, we plan a strategy where we will look at the pattern of 
expression of a profile of plausible biologically-linked factors from defined pathways 
suggested as potential predictors by the profiling data, and further factors identified 
from the literature available at the time the proteomics analysis is carried out, as likely 
to influence local relapse or radioresistance. No systematic review has yet been 
carried out in either area to identify potentially important predictive factors. However, 
as discussed above we would anticipate that proteins involved in signal transduction, 
cell adhesion and invasiveness, and apoptotic pathways, would be prognostic for 
relapse, and that radioresistance would also be affected by DNA repair and cell cycle 
control pathways. Given that approximately 300 5micron sections can be cut on every 
TMA block, we anticipate that up to 100 factors could be tested. Carbone and 
coworkers, using matrix-assisted laser desorption-ionisation time of flight (MALDI-
TOF) mass spectroscopy were able to define two prognostic groups of patients with 
resected non-small cell lung cancer exhibiting a four-fold difference in median survival 
using 15 mass spectroscopy peaks (Yanagisawa et al., 2003), suggesting that such a 
hypothesis-driven strategy has a good chance of discovering such profiles of relapse 
and radioresistance in patients with early breast cancer. 
 
Having identified molecular signatures of risk of relapse and radioresistance, we will 
investigate this further in the much larger group of women receiving conservation 
therapy, where identifying those who do not benefit from radiotherapy would have 
major health service resource implications. 
 
Aims 
 
To identify molecular factors associated with increased risk of local relapse. 
 
To identify molecular factors contributing to increased radioresistance. 
 
Methods 
 
(a) Molecular analysis by tissue microarrays 
 
Tissue micro arrays (TMA) represent a significant step forward in our ability to perform 
translational research focusing on specific molecular pathways and developing multi-
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factorial models of prognosis, rather than simplistic screening for single candidate 
genes.  
 
For each patient a representative tumour-containing fixed tissue block will be 
requested from the appropriate pathology laboratory. Given the amount of tissue 
required for these studies it is not foreseen that removal of tissue will compromise the 
future diagnostic evaluation of patient samples. In cases where the block sent is the 
only sample available from the patient, consultation with the consultant pathologist of 
record will be undertaken to ensure that sufficient material remains to allow future 
diagnostic procedures to be performed. In the rare event that there is concern that 
removal of cores may compromise future diagnostic testing on the patients’ tumour 
the patient will be excluded from the pathological study.  The tissue will be sent by 
post to the central reference (banking) laboratory. On receipt each tissue block will 
receive a unique study identification code. Tissue from individual tumours will be 
stored in tissue arrays and also as standard tissue sections before the blocks are 
returned to the referring pathologist. 
 
Briefly, a section of tissue will be stained using haematoxylin & eosin (H&E) to identify 
areas of tumour. Three tumour areas will be selected and 6 x 0.6 mm2 cores of tumour 
tissue will be removed in total from each block. Experience in the laboratory of the 
investigator who will hold this tissue bank (JB) has shown that MLSO are able to 
select these tumour areas with a high degree of accuracy without recourse to a 
pathologist for each section. These cores of tumour tissue will be transferred to 
multiple (6) recipient blocks (100-300 cores per block) to form tissue arrays. From 
each tissue array up to 300 5 m sections will be taken for analysis of biomarkers.  
 
(b) Biological Analysis of tissues 
 
The aim of the biological studies associated with the SUPREMO trial is twofold: to 
define a molecular signature of risk of relapse and radioresistance in patients with 
operable breast cancer, and to begin to characterise the underlying molecular events 
which relate to tumour relapse and patient response or failure to respond to the 
therapies applied in the trial. The “signature” is likely to include proteins and genes 
active in the key pathways involved in relapse and radioresistance, but these 
themselves may not be the factors directly responsible for the outcomes, but rather 
upstream or downstream activities modified as a consequence of the specific events 
leading to relapse or radioresistance. The signature will be useful both for identifying 
prognostic models for further studies and indicating avenues for further investigation 
aimed at modifying the risk of relapse or radioresistance. Currently, as discussed 
above, we would hypothesise that the risk of relapse is related to growth factors, 
signal transduction, cell cycle control and cell adhesion and invasiveness, while 
radiation response will partially overlap this, but also involve DNA (especially double-
strand break) repair pathways and resistance to apoptosis. However, the specific 
factors analysed will be driven by the results of the mRNA expression array analysis. 
 
Tissue arrays and sections will be analysed using immunohistochemistry (IHC) and 
fluorescent in situ hybridisation (FISH), to determine protein expression and RNA 
expression/gene amplification/deletion respectively, using standard methodologies 
and commercially available reagents. The Recht meta-analysis (Recht et al., 1999) 
showed that ER staining was associated with increased risk of loco-regional 
recurrence and therefore there would be an opportunity to test this hypothesis 
prospectively within the context of the current trial.  
 
We will identify a panel of antibodies to test in triplicate on the TMA sections from the 
pathways described. Image analysis tools may be used to score the sections. For 
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economies of scale, consistency of staining and reproducibility of scoring these 
investigations will be performed at the end of the trial when all the samples have been 
collected, but before the individual outcome data is available, thus blinding the scoring 
from biases related to knowledge of the clinical course of each patient.  
 
Informed consent to these investigations will be obtained at the beginning of the study 
when patients are randomised to radiotherapy or no radiotherapy. Since trial patients 
will not be identified until they have had their mastectomy and axillary clearance, 
obtaining consent at an earlier stage is not feasible.  
 
Although our major interest is in local recurrence, this data set will be available for 
investigation of other phenomena such as risk of distant relapse, second primary 
malignancy etc. by other workers. 
 
(c) Statistical power of tissue microarrays 
 
Currently there is no model on which to base power calculations for hierarchical 
analyses of protein expression using tissue microarrays, nor are there previous series 
where large panels of antibodies have been used to establish prognostic signatures in 
this fashion. However, extrapolating from expression profiling studies (Dettling and 
Buhlmann, 2002) and mass spectroscopy studies (Yanagasiwa et al., 2003), where 
sample sizes required to produce highly significant results have typically been of the 
order of 60-80 patients, suggests that the number of events we anticipate (115 and 40 
respectively in the no radiotherapy and radiotherapy cohorts) will provide sufficient 
power for this analysis. 
 
A low stringency test of the univariate prognostic significance of each factor 
investigated by antibody staining will be carried out via CART classification tree 
modelling. All factors selected by this method will be subjected to analysis with a 
logistic discrimination model to identify those factors which together give the highest 
level of significance in discriminating between high and low risk of relapse. 
 
(d) Other biological material 
 
Plasma/serum and whole blood (for tumour and patient DNA) will be obtained from 
patients at baseline, and at disease recurrence (local and/or distant relapse) and/or 
development of a contralateral breast primary and stored for future studies of 
predictive biochemical markers.  
 
(e) Quality assurance 
 
A pathology steering committee including international representation has been 
established for the purposes of quality assurance.  
 
(f) Trial management 
 
The TRANS-SUPREMO sub-study will be supervised by a Trial Management Group 
comprising Prof. Allan Price, University of Edinburgh (Radiation Oncologist); Prof. 
John Bartlett, University of Edinburgh (Biochemist); Dr. Niall Anderson, University of 
Edinburgh (Statistician); Prof. Ian Kunkler, University of Edinburgh (Chief Investigator 
Main Study); Dr. Irene Devine (Principal Trial Coordinator), ISD Cancer Clinical Trials 
Team. International representation will be provided by Dr. Nicola Russell, Amsterdam 
(Radiation Oncologist). 
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19. QUALITY OF LIFE SUBSTUDY (UK only) 
 
Background 
 
Multimodal breast cancer therapy improves survival but also contributes to physical, 
sexual and psychological sequelae. These have been extensively documented for the 
first year of treatment and follow up. There are also late effects of treatment, such as 
the normal tissue effects of radiotherapy, the effect on body image of mastectomy and 
on sexual functioning from chemotherapy. Therefore it is essential to tease out the 
contribution of specific therapies on key aspects of quality of life.   
 
The SUPREMO Quality of Life (QoL) study is designed to provide designated 
secondary endpoints to the trial. We will assess the subjective impact of mastectomy 
and chemotherapy, with or without additional radiotherapy to the chest wall over a ten-
year period. Using a standardised approach it will be possible to compare the impact 
of the different treatment arms and to inform the balance between local tumour control 
rates and adverse treatment effects in terms of QoL.  
 
The contribution of mastectomy and chemotherapy to QoL outcomes has been well 
documented (Ganz et al., 1992, 1998; Hopwood et al., 2002) but the additional effect 
of radiotherapy in mastectomy patients is unknown. Several studies help to inform on 
likely effects. On the one hand, Wallace et al., (1993) found few effects of 
radiotherapy on QoL in a small study of conservatively treated patients. There was a 
significant increase in nausea, tiredness, sleep disturbance and skin irritation on 
completion of radiotherapy but with a minimal impact on daily lives. Anxiety and 
depression were not increased at 6 months but one in three women did not feel 
radiotherapy was worthwhile.  
 
In a much more robust study, Berglund and colleagues (1991) assessed patients 2-10 
years after treatment in a randomised comparison of adjuvant chemotherapy or 
postoperative radiotherapy. Differences between the treatments were generally small. 
Radiotherapy patients had significantly greater problems with decreased stamina, 
symptoms related to their scar and anxiety; chemotherapy patients had significantly 
more problems with smell aversion. Findings were against the hypothesis that 
chemotherapy would be associated with late consequences in the physical, mental 
and social domains compared to radiotherapy.  
 
Stanton et al., (2001) emphasised the need to assess functional aspects of QoL in 
relation to specific treatments for breast cancer. In a study of conservatively treated 
patients receiving radiotherapy, the authors found that treatment related functional 
status, and in particular breast pain, had an important predictive effect on QoL, 
overriding treatment related cosmesis.  
 
Breast pain was also a predictor of depression, significantly so for women 5 years or 
more post diagnosis, and for physical health status. Arm oedema had a similar effect 
on QoL (Krishnan et al., 2001). Therefore the effect of local treatment on functional 
status should be a primary QoL outcome in the SUPREMO trial.  
 
Others (Ganz et al., 1998) have found that mental health was comparable with 
general population samples when assessed several years post-treatment.  
 
Recently the short-term effects of adjuvant chemotherapy have been assessed in 
2062 women entering the START trials. Chemotherapy had a significant effect on 
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global health, body image, sexual functioning and depression, when type of surgery, 
age and time since diagnosis were controlled for (Hopwood et al., 2002).   
 
It seems likely that the additional effects of radiotherapy in the SUPREMO trial will be 
small but may be significant for fatigue, physical functioning and chest wall pain and 
appearance. The expected outcome with respect to mental health is unclear, but data 
from the above studies suggest that, in general, rates of depression and anxiety rates 
are not significantly increased. Therefore, large samples would be needed to search 
for a small effect.  
 
Rationale for QoL measurement 
 
The main priority guiding the QoL approach is to select measures that are 
standardised and scientifically robust so that the data obtained are valid and reliable. 
There is an important opportunity to use measures that have been selected for other 
national breast cancer trials that would allow comparison of results. This is 
increasingly important for the process of informed decision making for future patients, 
and to facilitate familiarity with QoL data for clinicians and nurses helping patients with 
these decisions.   
 
The key effects of treatment and relapse on QoL are hypothesised to be on general 
symptoms such as fatigue, chest wall symptoms, appearance of the chest wall and 
psychological distress. Physical functioning, role and social functioning and specific 
adverse effects of treatment will also be recorded.  
 
The QoL domains of importance will therefore include the following:  
 
* a core quality of life measure to detect general effects of treatments on QoL 
* a breast cancer module to reflect specific symptoms and effects relating to the 
effects of treatment 
* a body image scale to assess the impact of treatment on appearance and 
attractiveness following surgery, chemotherapy and radiotherapy 
* a measure of anxiety and depression that indicates clinical levels of distress 
 
Therefore a preference for measures used in the ABC and START Trials emerged. 
There is sound knowledge of their performance and of analysis methods and 
interpretation of outcome data. Detailed manuals support the EORTC scales. Scoring 
procedures and reference data are available for the BIS and threshold scores for the 
HADS are widely available. Patients in the START trials with excellent compliance 
rates have supported this combination of scales. They do not appear to be 
burdensome to patients, providing care is taken to avoid those who are seriously ill.  
 
Measures 
 
1. Quality of life: the EORTC core quality of life instrument EORTC QLQ-C30 
(Aaronson et al., 1993). This is a 30 item cancer questionnaire comprising five 
functional scales (physical, role, cognitive, emotional and social), global quality of life, 
three symptom scales (fatigue, pain, nausea and vomiting) and a number of single 
items.  
 
2. Breast cancer specific module EORTC BR-23. This is a 23 item questionnaire 
designed to be used together with EORTC QLQ-C30. It comprises scales related to 
chemotherapy specific side effects, shoulder-arm problems, body image, sexuality 
and future perspective (Sprangers et al., 2001). 
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3. Body image: The Body Image Scale - BIS (Hopwood et al., 2001)  
This is a 10-item scale designed specifically for use with cancer patients to assess 
aspects of attractiveness, sexual attractiveness and feelings or satisfaction with 
appearance. (4 items are included in the BR23 and will not be duplicated). 
 
The BIS has very good psychometric properties and has been used in the ABC and 
START trials, as well as European breast cancer trials. A threshold score for a morbid 
level of body image concerns has not been derived but there is extensive reference 
data for subgroups of patients receiving mastectomy or conservative surgery, with or 
without chemotherapy or tamoxifen (Hopwood et al., 2001, Hopwood et al., 2002).  
 
4. Psychological Distress: The Hospital Anxiety and Depression Scale – HADS 
(Zigmond & Snaith 1983)  
The HADS is a 14-item scale (7 items for depression and 7 items for anxiety) 
designed to measure affective disorder in cancer patients. Threshold scores have 
been derived that enables the prevalence of clinical levels of anxiety or depression to 
be estimated. A comparison of instruments showed the HADS to be superior in 
measuring anxiety and depression when compared with a psychiatric interview 
(Ibbotson et al., 1994) and it is the most widely used self-report measure of 
psychological distress used with cancer patients.   
 
5. Cost effectiveness will be assessed by calculating the incremental cost per life year 
gained and the incremental cost per additional quality-adjusted life-year (QALY).  The 
EQ5D (EuroQol,  http://www.euroqol.org/)  will be used in order to quality-adjust 
survival (Brooks, 1996).  This measure is widely used in economic evaluation and is 
readily collected using a self-completed questionnaire.  It comprises five simple 
questions (mobility, self care, ability to undertake usual activities, pain/discomfort, and 
anxiety/depression) each with only three possible responses.  The EQ5D will be given 
to patients in the quality of life study along with the other quality of life questionnaires.  
QALYs will be estimated using an established set of EQ5D values (Dolan, 1997). 
 
6. An open-ended question, inviting comments from patients will be added at the end 
of the questionnaire booklet. 
  
Endpoints 
 
Primary QoL endpoints will be:  
 
1. Fatigue (QLQ-C30) 
 
2. Physical functioning subscale (EORTC QLQ-C30) 
 
3. Chest wall, shoulder and arm symptoms (EORTC BR23) 
 
4. Body image (BIS) 
 
5. Anxiety and depression (HADS) 
 
Descriptive data will be obtained for the following domains from the EORTC:  
 
 Role functioning 
 
 Social functioning 
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 Sexual functioning 
 
 Pain, nausea and vomiting 
 
It is hypothesised that the experimental arm will result in an increase in 
symptoms/decrease in function in the primary outcome domains (either singly or in 
combination) compared with the control arm. This will need to be considered against 
the benefit, if seen, in local disease control.  
 
Breast Reconstruction 
 
Breast reconstruction is not a specific QoL outcome parameter but we need to be able 
to provide descriptive data for these patients.  Therefore date and type of 
reconstruction (immediate or delayed), autologous tissue graft (TRAM, DIEP or LD 
Flap) or implant reconstruction will be annotated in the clinical forms.  The most 
important QoL aspect of reconstruction is body image: this will be adequately captured 
by the body image scale and data are available for comparison from other published 
work using the same scale (AL-Ghazal et al., 2000).  Minimal additional QoL 
parameters for this group will be HADS anxiety and depression and the EORTC 
breast cancer module (BR23).  
 
Plan of study 
 
There will be a detailed multicentre study of the patients’ quality of life after 
chemotherapy and after additional radiotherapy in the experimental arm. A subset of 
centres will take part in the QoL study and, in these centres QoL assessments will 
form an integral part of the trial for all consenting patients. Centres will choose 
whether or not to opt in to the QoL protocol but the geographic (and socio-economic) 
distribution of participating centres will be monitored to ensure that they are 
representative of the trial as a whole.  
 
Selected hospitals will be asked to participate if an imbalance occurs. This method 
has been used successfully in the START Trial and no intervention by the Trials office 
was required.  
 
The assessments will take the form of serial patient self-report questionnaires, using 
validated measures that have been used successfully in the ABC and START Trials. 
Baseline QoL compliance in the START Trial, involving over 2000 patients, was 
98.5% and has remained high at 6 months follow up.  
 
Eligibility  
 
All patients from selected centres who:  
 
* are entered into the SUPREMO Trial 
* consent to take part in the QoL study 
* are willing and able to complete the questionnaires 
 
Sample size and statistical considerations  
 
Although guidelines have been suggested for the size of score changes that represent 
clinically significant differences in QoL scores for EORTC QLQ-C30 (Osoba et al., 
1998; King, 1996), these vary for the subscales and further research is ongoing. For 
this trial, sample size was considered as an estimation problem rather than a problem 
of testing of significance.  
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With 200 evaluable patients per group the proportion of patients exhibiting a particular 
side effect or specified degree of morbidity on a QoL domain will be estimated with a 
standard error of 3.5% or less. The corresponding difference between the groups will 
be estimated with a standard error of 5% or less.  
 
The standard error of the difference in the means for any continuous variable will be 
0.1 standard deviations. In order that QoL may be monitored to this level of precision 
for five years after randomisation, the target for entry will be double the nominal figure 
(800 patients in total), which allows for attrition due to death or withdrawal of 
cooperation at a rate of 13% per year.  
 
All reasonable efforts will be made to ensure full and correct completion of the self-
report questionnaires. The QoL booklet will contain standardised instructions for 
completion. When individual items are missing, the following procedures, which have 
been used in other studies, will be adopted:  
 
* where the item missing is a single QoL item it will be recorded as missing 
* where the missing item forms part of a brief scale or subscale, a pro-rata 
procedure will be used depending on the total number of items in the subscale: 
 
There are known age effects for psychological distress, body image, breast 
symptoms, sexual and physical functioning and these will be controlled for in the 
analysis.  
 
Timing of assessments   
 
Baseline:  
 
After obtaining informed consent, the first assessment for all patients will be 
completed in the clinic prior to randomisation with explanation of the questionnaires by 
a member of staff.   
  
Follow-up:  
 
All follow-up questionnaires will be mailed from the Trials office, by the QoL study co-
ordinator, to minimise staff burden and allow patients to complete the forms in their 
own time, away from the treatment setting. Subsequent follow up for QoL assessment 
will be at 1, 2, 5 and 10 years from randomisation as in the protocol. 
 
Close links will be kept with the Breast team and patients’ general practitioners to 
check that the patient is alive and fit to participate, prior to future mailings. This is 
important given the emphasis on long-term follow-up.  
 
Patients experiencing a relapse 
 
Patients who have experienced a relapse will be asked to continue to complete 
questionnaires, although it is appreciated that some will not do so. At each due 
assessment point patients will be asked to complete a quality of life assessment 
unless they do not wish to continue in the QoL protocol. 
 
Statistical aspects 
 
The principal statistical method used will be a repeated measures of analysis of 
covariance as this makes allowance for observations that are missing and through 
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providing overall tests of treatment by time interaction and the main treatment effect, 
avoids some of the problems arising from multiple testing.  
  
Trial management  
 
Staff: Quality of Life Study Co-ordinators: This part of the trial will run under the 
guidance of Professor Galina Velikova. The staff running the QoL study will be based 
at the Centre for Population Health Sciences, the University of Edinburgh. Close links 
will be maintained with the trials team at ISD, where the main trial database is held to 
ensure correct, up-to-date patient information is available to the QoL study for follow-
up purposes.  
 
In the hospitals: It is intended that each participating hospital will identify a person 
responsible for the conduct of the QoL trial. This person will explain the study to the 
patient and ensure that the patient knows how to complete the QoL questionnaire 
booklet, will check that it is completed correctly and that it is forwarded to the trials 
office.  
 
Informed consent and ethical issues  
 
Ethical approval for the QoL substudy will be obtained at the same time as submitting 
the main trial protocol. The local investigator is responsible for obtaining each patient’s 
signed informed consent prior to the administration of the baseline questionnaire.  
 
Patients with clinically significant scores on the HAD scale (combined score above 19) 
should be further assessed clinically. This will be explained in the Patient Information 
Sheet. Patients will be asked to consent to information about the HADS score being 
passed on to their general practitioner. 
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20. CARDIAC SUBSTUDY (UK only) 
  
Background 
 
Recent studies of radiation toxicity in the treatment of breast cancer show that the 
effects on normal tissues can constitute a significant clinical problem and particularly 
increased cardiac mortality may offset any potential survival benefit (Cuzick et al., 
1994; Host et al., 1986; Rutqvist & Johansson 1990; Rutqvist et al., 1992; Trott 1991; 
Gagliardi et al., 1996; Haybittle et al., 1989). There are no data on non-fatal late 
cardiac damage, but it seems likely that non-fatal ischaemic heart disease and heart 
failure may also be induced. An excess of cardiac deaths starts to manifest itself at 
about 7 years post radiotherapy and increases year on year thereafter (Rutqvist et al., 
1992). Thus, reported values are dependent on length of follow up.   
  
The maximum heart distance is the distance from the posterior field border of the 
tangential fields to the most anterior border of the heart on the simulator film and 
correlates well with the volume of myocardium included in the target volume (Canney, 
unpublished data).  
 
Hurkmans et al., (2000) used the relative seriality model to calculate the Normal 
Tissue Complication Probability (NTCP) for heart damage for increasing values of the 
maximal heart distance. If this parameter is less than 1.5cm the NTCP for cardiac 
toxicity was calculated to be < 1%. The dose used for this calculation was 50 Gy in 25 
fractions. It is important to note that the value of 1.5cm may not apply for different 
doses, fraction sizes or patients receiving cardiotoxic systemic therapy.   
  
There has been no recent long term prospective assessment of potential cardiac 
morbidity in patients having cardiotoxic treatments as adjuvant therapy for breast 
cancer. In particular combinations of cardiotoxic agents may introduce additional risks 
of late morbidity or mortality.   
 
B type natriuretic peptide 
 
B type Natriuretic Peptide (BNP) is synthesized in the myocardium and increased 
levels are found in serum in patients with left ventricular dysfunction. BNP has a high 
negative predictive value for the diagnosis of left ventricular systolic dysfunction 
(McDonagh et al., 1998).  
 
The power to predict normal cardiac function by a low plasma value is further 
enhanced when combined with the standard 12 lead electrocardiogram (Vrtovec et al., 
2003). These clinical investigations merit assessment in the setting of breast cancer 
therapy.  
 
Primary aim  
 
To assess the utility of B type natriuretic peptide in identifying and predicting cardiac 
toxicity in patients undergoing adjuvant radiotherapy and/or chemotherapy.  
 
A subsidiary aim is to store blood for evaluation of potential future markers of cardiac 
function and, in addition, to look for pharmacogenetic and protein markers of 
relapse/outcome of breast cancer. 
 
 
 
Final protocol version 29– 30th August 2010  44
Schedule of investigations  
 
Echocardiography, ECG and blood for B type Natriuretic Peptide plus cardiac history, 
clinical examination (height, weight, BP, pulse, clinical signs of heart failure) to be 
obtained: 
 
1. Before radiotherapy or chemotherapy starts 
 
2. At 1, 5 and 10 years post surgery and  
 
3. At recurrence (local and/or distant relapse) and/or development of a contralateral 
breast primary. Cardiac assessments and blood for BNP should be taken prior to 
any subsequent treatment starting. 
 
In addition, patients will have blood taken for BNP plus cardiac history, clinical 
examination (weight, BP, pulse, clinical signs of heart failure) at the following 
timepoints: 
 
 Within 3 weeks of completing chemotherapy and before any radiotherapy 
starts (this visit applies only to patients who receive chemotherapy) 
 
 On completion of radiotherapy, or at 3 months post chemotherapy in patients 
receiving chemotherapy but who do not undergo radiotherapy, or at 3 months 
post surgery in patients who do not undergo chemotherapy or radiotherapy. 
 
Plan of investigation 
 
Patients should be approached for consent to participate in the cardiac substudy 
either at the patient’s first appointment to discuss chemotherapy or, if chemotherapy is 
not planned, when radiotherapy is discussed. Baseline cardiac investigations should 
be ordered and baseline bloods for BNP taken once consent to the cardiac sub-study 
is obtained. Consent to the main trial, TRANS-SUPREMO and the Quality of Life 
substudy should ideally be obtained at the same time. However it is recognised that 
the patient and/or clinician may wish to defer discussion about the main trial, TRANS-
SUPREMO and the Quality of Life substudy until later during a planned course of 
chemotherapy, particularly where the patient is also being approached about 
participation in a chemotherapy trial. If discussion is deferred, consent may be taken 
for the cardiac substudy alone with the proviso that the patient agrees to be 
approached about the main trial, TRANS-SUPREMO and the Quality of Life substudy 
at a later point during chemotherapy. If, post chemotherapy, the patient declines 
randomisation to the main SUPREMO trial they will remain enrolled in the cardiac 
substudy and complete the schedule of investigations as outlined above. 
 
Consenting patients will have a baseline history (including family history of coronary 
heart disease and personal history of cardiac disease and cardiac symptomatology), 
clinical examination, serum cholesterol, electrocardiogram and assessment of left 
ventricular function by echocardiography. For patients in centres where isotope 
ventriculography is the standard investigation for patients undergoing anthracycline 
containing chemotherapy, an echocardiogram will also be carried out at baseline. 
Echocardiography and not isotope ventriculography will be the follow up investigation 
at all subsequent time points outlined in the schedule of investigations. Data collection 
for the various time points of the cardiac substudy including blood pressure, cardiac 
symptoms of chest pain, breathlessness, ankle swelling and palpitations will be 
collected by a research nurse in each participating UK centre. A suitably qualified 
clinician must complete the ‘Clinical Signs of Heart Failure’ section. 
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All ECGs and a digital recording of the echocardiogram images will be sent to the 
trials office for analysis by a core laboratory. Blood from patients will be collected in 
chilled EDTA tubes and plasma separated by local biochemistry labs before storing at 
-80ºC. A whole blood sample will be sent immediately in heparinised tubes to the 
central laboratory in Edinburgh for analysis of BNP within 72 hours. Centres will be 
notified of the result within 7 days with a copy also sent to the trials office. Results will 
be documented in the CRF and forwarded to the trials office.  If BNP becomes 
elevated above the normal range (0-100pg/ml) during the study period, the patient will 
be recalled for clinical and cardiac assessment by the local investigator and referred, if 
necessary, to a cardiologist. The local investigator will request ECG and 
echocardiography in the participating centre to assess cardiac function. It is 
recommended that patients with new and increasing cardiac symptomatology or a 
raised BNP level are referred to a cardiologist for assessment. Copies of clinical 
correspondence, copies of ECGs and echocardiograms performed locally in relation to 
any such events will be sent to the trials office, including digital images of 
echocardiograms for analysis in the core echo-lab. Advice on the management of 
individual patients will be available from the Chief Investigator (Dr. Peter Canney) and 
the trial cardiologists (Dr. Martin Denvir, Dr. Theresa McDonagh and Dr. David 
Northridge).  
 
It is recognized that radio-isotope ventriculography would be the most reproducible 
method to assess changes in left ventricular systolic function but lack of availability in 
all centres and expense preclude this. 
 
In patients randomized to chest wall irradiation, the maximum heart distance at 
simulation will be measured on beam’s eye view. 
 
Statistical considerations  
 
The cohort of patients used to assess the negative predictive value of BNP in this 
setting will therefore be a combination of patients randomised into the main 
SUPREMO trial and also those who agree to the cardiac substudy pre-chemotherapy 
but later decline the main randomisation. Assuming a 5% rate of cardiac dysfunction 
within the first year and an annual rate of 3% in years 2-10 then the number of 
patients needed to provide adequate precision in estimating NPV (negative predictive 
value) will be 300 (this assumes estimation of NPV of approximately 90% with a 
confidence interval of total width 8 percentage points, ie a 95% CI of (86,94)%). 
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21. HEALTH ECONOMIC SUBSTUDY (UK only) 
 
Aim 
 
The economic study will assess the cost effectiveness of adjuvant irradiation. 
 
While the initial treatment costs for those receiving chest wall irradiation will be higher, 
if the irradiation is successful the better outcomes for patients might be expected to be 
associated with lower future resource use.  Irradiation might use sufficiently few 
additional resources that when combined with the savings in future treatment costs 
that it is cost-reducing.  However, it is more likely that the net effect of irradiation will 
be to increase costs overall.  Thus it is anticipated that the focus of the economic 
evaluation will be on the incremental cost per quality-adjusted life-year (QALY) from 
irradiation. 
 
Eligibility 
  
All patients from selected UK centres who: 
 
 are entered into the SUPREMO Trial 
 consent to take part in the Health Economics study 
 are willing and able to complete the patient diary 
 
Sample size 
 
Since it is difficult to estimate the underlying distribution of costs to calculate an 
appropriate sample size, it is proposed to cost the treatment received by all 
consenting UK trial participants and the future costs of those in either arm of the trial 
with suspected or actual recurrence or morbidity.  The estimation of QALYs will be 
based on data gathered from the sub-sample taking part in the Quality of Life study. 
 
A subset of UK centres will take part in the Health Economics study and are expected 
to be those sites who are also participating in the Quality of Life study. 
 
The assessments will take the form of a single patient self-reporting diary to be given 
to consenting patients by a member of staff at the centre at the time of randomisation 
to the SUPREMO trial. There will be separate diaries given to patients dependent on 
whether the patient is randomised to receive radiotherapy to chest wall or randomised 
to receive no radiotherapy to chest wall and whether the patient received post-
operative chemotherapy. These diaries are colour coded for clarification at sites to 
ensure that the correct diary is given to the patient based on their randomisation and 
whether the patient received post-operative chemotherapy. 
 
For those patients randomised to receive radiotherapy to the chest wall and received 
post-operative chemotherapy, the Health Economics patient diary will collect details of 
any visits to a health professional that the patient made during the period between the 
end of their post-operative chemotherapy and the commencement of their course of 
radiotherapy, information on the patient’s radiotherapy appointments and details of 
any visits to a health professional that the patient has made during their course of 
radiotherapy and during the period up to 8 weeks after the end of their radiotherapy. 
 
For those patients randomised to receive radiotherapy to the chest wall and received 
surgery and hormonal therapy alone OR neoadjuvant systemic therapy and surgery 
+/- postoperative hormonal therapy, the patient diary will collect details of any visits to 
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a health professional that the patient made during the period between the date of their 
last definitive surgery (mastectomy or axillary clearance) and the commencement of 
their course of radiotherapy, information on the patient’s radiotherapy appointments 
and details of any visits to a health professional that the patient has made during their 
course of radiotherapy and during the period up to 8 weeks after the end of their 
radiotherapy. 
 
For those patients randomised to receive no radiotherapy to the chest wall, but 
received post-operative chemotherapy, the patient diary will collect information about 
any visits the patient has made to a health professional during the first five months 
following the patient completing their post-operative chemotherapy.  
 
For those patients randomised to receive no radiotherapy to the chest wall and 
received surgery and hormonal therapy alone OR neoadjuvant systemic therapy and 
surgery +/- postoperative hormonal therapy, the patient diary will collect information 
about any visits the patient has made to a health professional during the first five 
months following the date of the patient’s last definitive surgery (mastectomy or 
axillary clearance). The five month period for those patients nor randomised to receive 
radiotherapy to the chest wall is estimated to be the equivalent time period to those 
patients randomised to receive radiotherapy to allow comparative analysis to be 
performed. 
 
Effectiveness 
 
In the event that health outcomes are generally better with irradiation, the key 
economic question is what is the cost of achieving these improved outcomes (and 
how does this compare with other potential uses of these resources).  Cost-
effectiveness will be assessed by calculating the incremental cost per life year gained 
and the incremental cost per additional quality-adjusted life-year (QALY).  The EQ5D 
(EuroQol,  http://www.euroqol.org/)  will be used in order to quality-adjust survival 
(Brooks, 1996).  This measure is widely used in economic evaluation and is readily 
collected using a self-completed questionnaire.  It comprises five simple questions 
(mobility, self care, ability to undertake usual activities, pain/discomfort, and 
anxiety/depression) each with only three possible responses.  The EQ5D will be given 
to patients in the quality of life study along with the other quality of life questionnaires, 
that is, at baseline and follow-up at one, two, five and ten years post-randomisation.  
QALYs will be estimated using an established set of EQ5D values (Dolan, 1997). 
 
Resource use 
 
An NHS perspective is adopted for the estimation of costs.  The economic evaluation 
requires the following patient-level information: details of chest wall irradiation for 
patients in the irradiation arm; and subsequent breast cancer related use of health 
care resources by patients in both arms 
 
Unit cost data is required for irradiation and subsequent resource use.  Differences in 
future resource use will arise primarily if there are differences in recurrence rates. With 
respect to subsequent resource use it is differences in resource use which matter, 
rather than the total cost.  Thus it will only be necessary to collect unit cost data for 
those elements of health care that differ between the two arms.  Detailed costing will 
be undertaken initially in two or three centres in order to develop a protocol to be 
applied in all centres.  Towards the end of the study detailed patient-level information 
on the use of health care resources will be combined with the centre-specific unit 
costs. 
 
Final protocol version 29– 30th August 2010  48
 
 
Analysis 
 
A particular feature of this trial is the large number of centres.  Multilevel modelling will 
be used to take account of the clustering of cost data by centre (Manca et al., in 
press).    
 
Patient-specific information on quality of life and survival will then be used to estimate 
the difference between arms in terms of QALYs and this will be related to the cost 
data in order to estimate the incremental cost per additional QALY.   
 
For the purposes of cost-effectiveness analysis the appropriate time horizon is the 
lifetime of the patients.  Thus the data collected during the five year follow-up of 
patients will be used to extrapolate the QALY difference between the arms.   
 
Finally the sensitivity of the results to key parameters will be assessed (Briggs et al., 
2002), and cost-effectiveness acceptability curves will be plotted to demonstrate the 
likelihood that a particular intervention is cost-effective for a range of monetary 
valuations of additional QALYs (Fenwick et al., 2004).   
 
Informed consent and ethical issues 
 
Ethical approval for the Health Economics substudy will be obtained at the same time 
as submitting the main trial protocol. The local investigator is responsible for obtaining 
each patient’s signed informed consent prior to receiving the Health Economics 
substudy patient diary. 
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Appendix I  
Patient information sheet (main trial and TRANS-SUPREMO) 
 
 
Invitation to participate in the SUPREMO trial 
 
Patient Information Sheet  
 
We would like to invite you to take part in the SUPREMO breast cancer trial (Selective 
Use of Postoperative Radiotherapy aftEr MastectOmy). The SUPREMO trial aims to 
establish the benefits of postoperative radiotherapy to the chest wall in patients such 
as yourself who are at intermediate risk of recurrence.  To help you decide if you 
would like to take part, please read this information sheet. It gives you details of what 
will be involved if you decide to take part in the trial, and also who to contact if you 
would like to discuss any aspect of the trial.  A glossary of medical terms and words 
used in clinical trials is also included at the back of this leaflet. 
 
Introduction to Clinical Trials 
 
Great progress in the treatment of cancer has been possible through medical 
research.  One of the most crucial aspects of this research is the participation of 
people like yourself. 
 
A clinical trial is a study involving people and is designed to answer questions such as 
- 
 
 Is there a better way of administering an existing treatment? 
 
 Is the new approach better than the current procedure? 
 
 Are there any side effects/ long term effects? 
 
Carrying out clinical trials is the only sure way to evaluate as accurately as possible 
the real benefits and risks of a new treatment.  
 
More than 14% cancer patients participate in cancer trials (Cancer Research UK, 
2006) 
 
Strict controls govern how clinical trials are conducted.  Any research within the NHS 
that involves people, their tissue or data must have prior approval of the appropriate 
ethics committee.  The primary responsibility of the ethics committee is the welfare 
and safety of individual research participants. 
 
Sometimes the medication used in a clinical trial is not “new”, it is simply being used in 
a different way.  In other cases, as with radiotherapy, the treatment has already been 
shown to be effective and safe for patients.  Here researchers are looking at the 
outcomes of the trial to see what treatment works best for patients.  This will allow 
doctors to improve cancer treatments for future patients. 
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Background to SUPREMO Trial 
 
You have recently been diagnosed with breast cancer that has been completely 
removed by surgery. Anti-cancer drugs in the form of chemotherapy or hormonal 
therapy (or a combination of both) will also be given as part of your treatment. Another 
therapy that is currently offered to some patients with your type of cancer is 
radiotherapy to treat the site of your recent operation to remove your breast 
(mastectomy). Radiotherapy treats breast cancer using high energy x-rays to destroy 
the cancer cells and the aim of radiotherapy is to reduce the risk of the tumour coming 
back. In addition, when given in conjunction with anti-cancer drug treatment, it may 
also improve long-term survival. Postoperative radiotherapy is routinely given to 
patients at higher risk of recurrence than you (for example when 4 or more lymph 
nodes under the armpit are involved or the tumour is large). In patients (such as 
yourself) where there are less than 4 lymph nodes involved by cancer or there are no 
lymph nodes involved but there are other features of the cancer which increase the 
risk of the cancer recurring, it is not clear whether postoperative radiotherapy is 
needed.   
  
Currently, there is wide variation in the use of radiotherapy across the UK and 
internationally, for patients in your risk group. The decision whether to give 
radiotherapy or not is generally based on local preference rather than established 
guidelines.   
 
We would like to ask you to take part in our study to help us decide whether 
radiotherapy is helpful for women with your particular type of cancer. Your specialist 
has indicated that she or he thinks that you are suitable to take part in the SUPREMO 
study.   Half of the patients in the trial will receive radiotherapy and half will not receive 
radiotherapy to the chest wall. In every other aspect the treatments will be the same. 
The trial will involve 1600 women. 
 
What will I have to do if I take part?  
 
If you agree to take part you will be asked to give your written consent to participate. 
To determine whether or not you will receive radiotherapy, your specialist will 
telephone the central office in Edinburgh that runs the SUPREMO trial.  
 
The study office will check some details about you, your disease and the treatment 
you have been prescribed and will use a computer to allocate your treatment. You will 
have the same chance of receiving radiotherapy as not receiving it. Your specialist will 
be told whether you have been allocated a course of radiotherapy. You will also be 
seen in the hospital clinic for a routine examination following the completion of your 
radiotherapy or at an equivalent time if you are not allocated radiotherapy. You will 
subsequently be reviewed annually by a doctor, for at least 10 years, who will assess 
your medical condition. You will be asked particular questions in relation to the 
treatment that you have received.  A breast X-ray (mammogram) of your other breast 
is recommended at least every two years for 10 years following your surgery. During 
the trial you may be asked to keep a record of all health services that you receive.   
 
If you decide not to take part in the study you will receive the usual high standard 
treatment that is currently employed for patients with early breast cancer. You may be 
offered radiotherapy, if this is standard practice at your cancer centre, and you will be 
followed up at the surgical outpatient clinics in the usual way.  
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What does radiotherapy involve?  
 
 Radiotherapy treats cancer using high energy x- rays in order to destroy the 
cancer cells, whilst doing as little harm as is possible to normal cells. 
 
 Radiotherapy to the chest wall (the site of your mastectomy) is normally 
carried out over a period of 3 – 5 weeks, usually as an out patient. 
 
 The detail of your radiotherapy planning and treatment will be discussed with 
you by a clinical/radiation oncologist. 
 
 To plan your radiotherapy you will be asked to lie on a couch, then a series of 
measurements will be taken from your chest wall area by a team of 
radiographers.  A CT scan may form part of the planning process.  Planning 
usually takes around 20 – 40 minutes to complete.  
 
 When you are treated you will be asked to lie on the couch so that the team of 
radiographers will be able to set you up in the same position as you were in at 
your planning session. 
 
 A small dose of radiotherapy will be delivered to your chest wall from the 
treatment machine.  Your specialist may in addition recommend radiotherapy 
on the same side to a part of the glandular area above your collarbone (known 
as the medial supraclavicular fossa) or to the glandular area beneath the 
breast bone (known as the internal mammary chain).  
 
 The radiotherapy is normally given to the chest wall in a small dose each day.  
Treatments are given for about 10 – 15 minutes per day on week days.  No 
treatment is given over the week ends. 
 
 Radiation to the chest wall does not mean that you will not be considered 
suitable for a possible breast reconstruction.  The surgeon will take into 
consideration the fact that tissue in this area has been irradiated when 
advising which reconstruction technique should be used.   
 
 Furthermore, if breast reconstruction has already been performed at the time 
of the mastectomy operation (immediate reconstruction) then this does not 
mean that you will not be considered suitable for subsequent irradiation to the 
chest wall. 
 
 Radiotherapy, after breast reconstruction (where an implant has been used) 
may, in the long term, cause the implant to harden and change shape as the 
result of the formation of scar tissue following the radiotherapy.  This can be 
treated by removing the scar tissue and changing the implant at a later date. 
 
What are the possible risks of taking part?  
 
Like all treatments there may be side effects with radiotherapy. Radiotherapy may 
cause skin reactions leading to chest wall tenderness, redness and itching. These 
develop in the latter part of the course of radiotherapy and usually settle within one 
month of the treatment finishing. Chest wall pain, which is usually mild and 
intermittent, can occur. Rarely (less than 1% of patients), radiotherapy may cause a 
temporary inflammation of the lung causing shortness of breath which can last for a 
number of weeks in the first year of treatment, and occasionally long term. Rib 
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fractures may occur in the longer term (less than 1% of patients). Studies have shown 
that 10-30 years after radiation treatment there can be an increased chance of heart 
problems. For this reason the position of the heart in relation to the radiation fields is 
nowadays very carefully determined at the time of the treatment planning so that no, 
or as little as possible of heart tissue lies in the radiation fields. It should be 
emphasised that these serious complications are rare. The trial will look at the 
possible risks of radiotherapy over the ten year follow up period.  
 
If you undergo breast reconstruction it is possible that radiotherapy to the chest wall 
may in the long-term cause some shrinkage of the breast. 
 
The possible risk of not being given radiotherapy is that there may be a slightly higher 
chance of breast cancer returning compared to women who have received 
radiotherapy. However in women with 1-3 affected lymph nodes or non-involved 
lymph nodes but other risk factors for local recurrence and the type of surgery that you 
have had, the chances of the disease recurring at the site of your operation are small. 
If the disease did recur at the site of your mastectomy, a course of radiotherapy to 
your chest wall would be considered.  
 
Are there any benefits to taking part?  
 
Radiotherapy reduces the risk of recurrence of the cancer in the area where you have 
had surgery and might improve your life expectancy.  Whether or not you decide to 
take part in the study you will receive the highest standards of care.  You will have 
increased contact with specialist nurses.  The information that we get from the study 
will help us gain knowledge about the best way of treating breast cancer. It will help us 
to measure the advantages of radiotherapy in women with the type of breast cancer 
that you have.  
 
Pathology Examination  
 
After your operation, the breast tissue and any lymph nodes removed were examined 
in the laboratory in order to determine the type of tumour and any spread. The results 
of this examination, and the consequences for your further treatment, have already 
been discussed with you. Part of the tumour that has been removed is kept in the 
pathology archive in a small block. If it is ever needed in the future, these blocks can 
be used again to do new tests on the tumour tissue.  An independent trials 
pathologist, based at a central laboratory in the UK or the Netherlands, will examine a 
small sample of the breast tissue taken during your operation. This will allow the 
central pathologist to compare their review of the tissue with the one done at the time 
of your operation by the pathologist at your local hospital. This examination of the 
pathology reporting will involve sending one of the blocks containing your breast 
tissue to the central laboratory. After the review of the tissue by the central 
pathologist, the tissue block will be returned to your hospital.  In addition, if you 
received chemotherapy or hormone therapy before your surgery, a small piece of 
tissue taken at the time of the original diagnosis will also be requested and examined 
as described above. 
 
TRANS-SUPREMO  
If you agree to be entered into the SUPREMO trial we would like to do some further 
research on your breast cancer tissue.  With your permission we would like to send a 
part of your breast cancer to a central laboratory where we can analyse the tissue for 
some special molecular features.  We would also like to retain a tiny piece of your 
breast cancer tissue and use this in the future for research to help understand more 
Final protocol version 29– 30th August 2010  62
about breast cancer and radiotherapy treatments. After removing this sample we will 
return the rest of the cancer tissue to your hospital.  Tissue would be stored in a way 
such that it would not be identifiable and no one would be informed about specific 
findings relating to you. For those patients who experience a recurrence of their 
cancer or develop a cancer in their other breast, we would also like to store samples 
of this tissue, if available, as outlined above. 
We do not at present know all the molecular markers or genes we will be looking at 
but the tissue we collect could be analysed for the presence of many different proteins 
and genes inside the breast cancer cells. We will be looking at particular proteins or 
genes that we think might help improve our ability to treat breast cancer and in 
particular to help predict if some cancers are best treated with radiotherapy, whilst 
others are not. Because the samples are not identifiable results of this research will 
have no influence on your treatment but doctors taking part in the study will be 
informed of the general findings of this research. If you do not want your tissue used in 
this way please tell us.  You can still take part in the main trial. 
We would also like to do further research on your blood, including your genetic 
information (DNA). Recently we have become aware that some people have a 
particular profile of genes or proteins in their blood which mean they respond better to 
different forms of cancer therapy or which can identify if their cancer is more likely to 
recur. We need to do further research to identify those genes or proteins which might 
be important in this study.  With your permission we would like to send a sample of 
your blood to a central laboratory where we can analyse it for genes (using your DNA) 
or proteins.  We would collect no more than the equivalent of 2 tablespoons of blood 
when you first enter the study and, for those who experience a recurrence of their 
cancer, the same amount at the time of this recurrence. Your blood and DNA would 
be stored in a way such that it would not be identifiable and no one would be informed 
about specific findings relating to you.  
 
Because the samples are not identifiable, results of this research will have no 
influence on your treatment, nor will anyone be able to access them, but doctors 
taking part in the study will be informed of the general findings of this research. If you 
do not want your blood or DNA used in this way please tell us.  You can still take part 
in the main trial. 
 
It is possible that other scientists or doctors may want to use this material to improve 
diagnosis and treatment of cancer, but their request will have to be considered and 
approved by an ethics committee before they are allowed to do so.  
 
Tumour and other material collected during this study will not be sold to third parties or 
used for commercial gain.  Intellectual property rights (knowledge gained from the 
trial) that may arise as a result of findings from this research could be exploited 
commercially.  The rights to any intellectual property will reside with the investigators. 
 
 
Do I have to take part?  
 
No, taking part is voluntary. If you would prefer not to take part you do not have to give 
a reason. Your doctor would not be upset and your treatment would not be affected. If 
you take part but later change your mind you can withdraw from the study at any time 
without giving a reason and without hindrance or detriment to your future treatment. 
We will give you a copy of your consent form to keep. 
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Confidentiality 
 
All the study data will be confidential to the research team.  You will not be identified in 
any published study results.  All study data will be handled under the auspices of the 
MRC- Trial Management Group and treated confidentially in compliance with the Data 
Protection Act (1998). 
 
What do I do now? 
 
You will be contacted by a member of the research staff in a day or so.  Please let 
him/her know if you are interested in taking part. 
 
We would want to inform your General Practitioner that you are taking part in the trial.  
 
Thank you very much for considering taking part in our research.  Please discuss this 
information with your family, friends or GP if you wish. 
 
Prof. Ian Kunkler Chief Investigator, SUPREMO trial  
 
Local contact name(s) and phone number(s): 
 
If you would like to speak to a doctor who is independent of the trial, please contact:   
_______________________________ 
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Appendix II Informed consent form (main trial and 
TRANS-SUPREMO) 
 
SUPREMO breast cancer trial     
Selective Use of Postoperative Radiotherapy aftEr MastectOmy 
 
Informed Consent Form 
 
Patient identification number for this trial:………………………………….. 
 
Name of patient:      ……………………………………………………………… 
 
Name of clinician     ……………………………………………………………... 
 
Hospital:                     ……………………………………………………………………. 
    
 Please initial boxes 
1. I have read and understood the patient information sheet provided and 
have had sufficient time to decide whether to take part in both the 
clinical trial and research study (TRANS-SUPREMO). I have had the 
opportunity to ask questions and consider the answers given. 
 
2. I understand that participation in the trial is voluntary and that I may 
withdraw from the trial at any time of my own accord and without giving 
any reason and without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked 
at by research staff from the Information Services Division (ISD) 
Cancer Clinical Trials Team, and other collaborating UK Clinical trials 
units for the purpose of data monitoring, where it is relevant to my 
taking part in research.  I give permission for these individuals to have 
access to my records. 
 
4. I understand that data will be passed to the ISD Cancer Clinical Trials 
Team and that this information will include my name, date of birth, 
hospital number and NHS number (or Community Health Index 
number) from which it is possible to identify me as an individual. 
 
5. I agree that my General Practitioner will be informed of my 
participation in this study and will be advised of any clinically significant 
information that comes to light. 
 
6. I understand that a small sample of my breast tissue taken during my 
surgery and, if I received chemotherapy or hormone therapy prior to 
surgery, as part of my original diagnosis will be sent to a central 
laboratory for review. 
 
I confirm that I have explained the nature of this trial and the research study (TRANS-
SUPREMO) to the above named patient and that she has understood the explanation 
given to her. 
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Clinician’s signature:……………………………………………  Date:…………………. 
 
 
I hereby freely give my consent to take part in the SUPREMO trial 
 
Patient’s signature: ……………………………………………    Date:…………………. 
 
 
I hereby freely give my consent to take part in the TRANS-SUPREMO study 
and I donate:  
 
tumour tissue  
    
serum/plasma   (Please initial boxes) 
     
and DNA   
    
for these studies. (We will only be able to collect material if you initial these boxes.) 
 
Patient’s signature: ……………………………………………… Date:………………….. 
 
(A separate signature for TRANS-SUPREMO is required for legal reasons). 
 
Signature on this form does not affect your legal rights, you may take part in the main 
trial and decline to take part in the TRANS-SUPREMO research study. 
 
 
 
 
4 copies of consent form required: 1 original for patient, 1 original for researcher (to be 
kept in site file), 1 copy for trials office, 1 copy to be kept with hospital notes. 
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Glossary Of Terms 
 
Anthracycline:  A type of chemotherapy drug used to lessen the risk of recurrence. 
 
Breast tissue: A complicated arrangement of tissues closely tied to nerves, blood 
vessels and fatty tissues. 
 
Breast reconstruction: A procedure to reshape a woman’s breast after mastectomy. 
 
Cancer: A group of diseases in which malignant cells grow out of control and spread 
to other parts of the body. 
 
Chemotherapy: Is the use of anti-cancer drugs to destroy cancer cells. 
 
Clinical oncologist/ radiation oncologist:  A person who specialises in treating 
cancer with radiation. 
 
Clinical trial:  A scientific test of the effectiveness and safety of a particular treatment 
using consenting human participants. 
 
CT: (Computed tomography) scan.  An imaging technology which uses a computer to 
assemble multiple x-ray images into a cross-section image of the head or the body. 
 
Diagnosis:  Process of identifying a disease from symptoms and tests. 
 
DNA: Deoxyribonucleic acid is a nucleic acid that contains genetic instructions used in 
the development and functioning of all known living organisms. 
 
Hormonal Therapies: Act by altering the production or activity of particular hormones 
in the body. 
 
Mammogram: A low-dose x-ray of the breast to check for any abnormal tissue. 
 
Mastectomy:  Surgical removal of all or part of the breast. 
 
Medical oncologist:  A person who specialises in treating cancer with drugs. 
 
Radiographer:  A healthcare professional who takes x-rays and scans (diagnostic 
radiographer) or gives radiotherapy (therapeutic radiographer) 
 
Radiotherapy: Treatment of disease by x-rays. 
 
Randomisation: The treatment each patient receives is determined “by chance” 
(using a computer) 
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Appendix III 
 
Patient information sheet (Quality of Life and Health 
Economics substudies) 
 
Invitation to participate in the SUPREMO trial Quality of Life 
and Health Economics substudies 
 
Patient Information Sheet  
  
We would like to invite you to take part in the SUPREMO (Selective Use of 
Postoperative Radiotherapy aftEr MastectOmy) Quality of Life and Health Economics 
substudies. To help you decide if you would like to take part, please read this 
information sheet. It gives you details of what will be involved if you decide to take part 
in the trial, and also who to contact if you would like to discuss any aspect of the trial. 
 
As part of the SUPREMO trial we are asking women to fill in questionnaires so that we 
can learn about the effects of treatment in more detail. Your specialist has indicated 
that s/he thinks that you are suitable to take part in the SUPREMO Quality of Life and 
Health Economics substudies. 
 
What will I have to do if I take part? 
 
Quality of Life substudy  
 
If you agree, you will be asked to complete a questionnaire before starting your 
treatment and again one year, two years, five years and ten years later. The 
questionnaires will be explained to you on the first occasion by a member of staff who 
will answer any questions you have about how to fill it in.  
 
The questionnaires have been carefully developed with the help of doctors, nurses 
and women like yourself. They contain questions about a range of physical symptoms 
and activities, your emotional wellbeing and other aspects of your everyday life. We 
also want to know how you feel about your appearance after treatment to the chest 
wall and any side effects you experience. There are no 'right' or 'wrong' answers – we 
simply want to find out about the experience of treatment for women in this trial. Each 
questionnaire will take about 30 minutes to complete.  
 
In addition, as part of the assessment of the cost effectiveness of radiotherapy in the 
trial we would like you to complete, at the same time as the quality of life 
assessments, a short questionnaire known as EQ5D. This has 5 questions on 
mobility, self care, ability to undertake usual activity, pain/discomfort and mood. The 
questionnaire takes only a few minutes to complete. This additional information will 
allow us to take account of the quality of life of patients in the overall economic 
evaluation of radiotherapy after a mastectomy. 
 
Health Economics substudy 
 
If you agree, you will be asked to complete a patient diary colour coded to match your 
treatment and whether you received post-operative chemotherapy. If you are 
randomised to receive radiotherapy and received post-operative chemotherapy, you 
will receive a red booklet where you will be asked to record information about your 
radiotherapy appointments and details of any visits to a health professional during the 
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period following your post-operative chemotherapy and the start of your radiotherapy, 
during your course of radiotherapy and during the period up to 8 weeks after the 
completion of your radiotherapy. If you are randomised to receive radiotherapy and 
received surgery and hormonal therapy alone OR neoadjuvant systemic therapy and 
surgery +/- postoperative hormonal therapy, you will receive an orange booklet where 
you will be asked to record information about your radiotherapy appointments and 
details of any visits to a health professional during the period following the date of your 
last surgery and the start of your radiotherapy, during your course of radiotherapy and 
during the period up to 8 weeks after the completion of your radiotherapy. 
 
If you are randomised to not receive radiotherapy, but did receive post-operative 
chemotherapy, you will receive a blue booklet where you will be asked to record any 
visits to a health professional during the first five months following the completion of 
your post-operative chemotherapy. If you are randomised to not receive radiotherapy 
and received surgery and hormonal therapy alone OR neoadjuvant systemic therapy 
and surgery +/- postoperative hormonal therapy, you will receive a green booklet 
where you will be asked to record any visits to a health professional during the first 
five months following the date of your last surgery (either mastectomy or axillary 
clearance).  
 
The Health Economics substudy will allow us to capture certain aspects of the costs 
associated with your treatment, both to organisations like the NHS and to you 
personally. 
 
Are there any benefits to taking part? 
 
The opportunity for interaction with a trials/research nurse can be considered a 
benefit.  
 
Do I have to take part?  
 
No, taking part is voluntary. If you would prefer not to take part you do not have to give 
a reason. Your doctor would not be upset and your treatment would not be affected in 
any way. If you take part, but later change your mind, you can withdraw from the study 
at any time without giving any reason and without hindrance or detriment to your 
future treatment. We will give you a copy of your consent form to keep.  
 
Confidentiality 
 
All the study data will be confidential to the research team.  You will not be identified in 
any published study results.  All study data will be handled under the auspices of the 
MRC- Trial Management Group and treated confidentially in compliance with the Data 
Protection Act (1998). 
 
 
What do I do now? 
 
You will be contacted by a member of the research staff in a day or so.  Please let 
him/her know if you are interested in taking part. 
 
We would want to inform your General Practitioner that you are taking part in these 
studies. If the scores on The Hospital Anxiety and Depression (HAD) scale within the 
Quality of Life study suggest that you are distressed then we will inform your GP. 
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Thank you very much for considering taking part in our research.  Please discuss this 
information with your family, friends or GP if you wish. 
 
 
Prof. Ian Kunkler 
 
Chief investigator, SUPREMO trial  
 
Local contact name(s) and phone number(s): 
 
If you would like to speak to a doctor who is independent of the trial, please contact:    
_______________________________ 
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Appendix IV Informed consent form (Quality of Life 
and Health Economics substudies) 
 
SUPREMO breast cancer trial   
Selective Use of Postoperative Radiotherapy aftEr MastectOmy 
 
Quality of Life and Health Economics studies 
Informed Consent Form 
 
Patient identification number for this trial:………………………………….. 
 
Name of patient:      ……………………………………………………………… 
 
Name of clinician     ……………………………………………………………... 
 
Hospital:                  ………………………………………………………………. 
 
 Please initial boxes 
1. I have read and understood the Quality of Life and Health Economics 
patient information sheet provided and have had sufficient time to 
decide whether to take part in these studies. I have had the opportunity 
to ask questions and consider the answers given. 
 
2. I understand that participation in these studies is voluntary and that I 
may withdraw at any time of my own accord and without giving any 
reason and without my medical care or legal rights being affected. 
 
3. I agree that my General Practitioner will be informed of my 
participation in these studies and will be advised of any clinically 
significant information that comes to light. 
 
4. I agree to researchers from the Centre of Population Health Sciences, 
the University of Edinburgh telephoning my GP to confirm I am fit and 
well to receive Quality of Life questionnaire booklets to be sent out by 
post.  I understand that my full name and address will be collected for 
this purpose only. 
 
 
I confirm that I have explained the nature of this study to the above named patient and 
that she has understood the explanation given to her. 
 
Clinician’s signature:…………………………………………………Date:……………… 
 
 
I hereby freely give my consent to take part in the SUPREMO quality of life study. 
 
Patient’s signature: …………………………………………………  Date:……………… 
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I hereby freely give my consent to take part in the SUPREMO health economics study. 
 
Patient’s signature: …………………………………………………  Date:……………… 
 
 
 
(Signature on this form does not affect your legal rights. You may take part in the main 
trial and decline to take part in the Quality of Life substudy. You may also take part in 
the Quality of Life substudy and not the Health Economics substudy and vice versa) 
 
 
 
 
 
4 copies of consent form required: 1 original for patient, 1 original for researcher (to be 
kept in site file), 1 copy for trials office, 1 copy to be kept with hospital notes. 
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Appendix V 
 
Patient information sheet (Cardiac substudy) 
 
Invitation to participate in the SUPREMO trial Cardiac sub-
study 
 
Patient Information Sheet 
 
We would like to invite you to take part in the SUPREMO breast cancer trial (Selective 
Use of Postoperative Radiotherapy aftEr MastectOmy) cardiac sub-study. To help you 
decide if you would like to take part, please read this information sheet. It gives you 
details of what will be involved if you decide to take part in the cardiac substudy, and 
also who to contact if you would like to discuss any aspect of the substudy. 
 
The main SUPREMO trial aims to find out if chest wall radiotherapy is beneficial after 
mastectomy, chemotherapy and/or hormone treatments. The cardiac substudy aims to 
assess a new way to detect possible damage to the heart that can result from these 
treatments using a blood test called BNP (B-type natriuretic peptide). This is the first 
study to investigate the effect of chemotherapy and radiotherapy, alone or in 
combination, on the heart. If you do agree to take part in this sub-study we need your 
agreement to take part after surgery and before starting chemotherapy (if applicable). 
We would also like to approach you about taking part in the main SUPREMO trial and 
the TRANS-SUPREMO and Quality of Life substudies. We may do this now or, if you 
do not want to think about taking part in the main trial or other substudies now, later 
on towards the end of your course of chemotherapy. 
 
Introduction 
 
Radiotherapy reduces the risk of recurrence of the cancer in the area where you have 
had surgery and might improve your life expectancy. Like many treatments 
radiotherapy and chemotherapy have side effects, both short term and long term.  
One of the potential long-term side effects of radiotherapy for breast cancer and of 
certain forms of chemotherapy (known as anthracylines) is damage to the heart. It 
should be emphasised that this complication is rare. The total doses of anthracyclines 
are limited to reduce the risk of cardiac damage. Where possible the dose to the heart 
from radiotherapy is also limited. However, we have relatively little information on the 
frequency of cardiac damage in patients receiving either radiotherapy or anthracyline 
chemotherapy alone, or together. The SUPREMO cardiac substudy will help us to 
collect this information.  
 
Conventionally, damage to the heart is detected by measuring the electrical activity of 
the heart. This is known as an electrocardiogram (or ECG). An ECG is a non-invasive 
painless test. It involves placing small adhesive pads temporarily to your chest and 
recording the electrical activity of your heart. It takes only a few minutes. 
 
The pumping action of the heart can also be assessed by passing sound waves 
through the heart. This is known as echocardiography. This test takes around 30-45 
mins. More recently B type natriuretic peptide (BNP), a chemical substance produced 
by the heart when it is damaged, has been used to assess the health of the heart. 
BNP can be measured on a simple blood test. In this research study we will be 
assessing the value of BNP and other blood measurements in detecting any damage 
to the heart at the earliest possible stage. 
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What will I have to do if I take part? 
 
If you agree to take part in this study, you will be asked about any cardiac symptoms 
(such as chest pain), family history of heart disease, risk factors for heart disease 
(such as smoking, high blood pressure, high cholesterol) and your height, weight, 
pulse rate and blood pressure will be recorded. You will be asked to have a blood test 
for BNP (and other blood measurements of cardiac damage). You will also have an 
ECG and an echocardiogram on entry to the study. These tests will be repeated at 
one, five and 10 years after surgery and for those patients who experience a 
recurrence of their breast cancer or develop a cancer in their other breast, these tests 
will be repeated at the time of the recurrence/ new diagnosis. 
  
If you have chemotherapy, an additional 2 clinic visits will be required to take blood 
for BNP (and other blood measurements of cardiac damage). These will be: 
 
1. within 3 weeks of completing chemotherapy and before radiotherapy (if given) 
starts. 
 
2. on completion of radiotherapy or 3 months after chemotherapy if no 
radiotherapy is given. 
 
If you do not have chemotherapy, 1 additional clinic visit will be required to take 
blood for BNP (and other blood measurements of cardiac damage). This will be: on 
completion of radiotherapy or 3 months after surgery if no radiotherapy is given. At 
each of these visits we would collect no more than the equivalent of 2 teaspoons of 
blood.   
 
If the level of BNP rises significantly, we will notify your oncologist, and recommend to 
him/her that you have an echocardiogram and ECG to give us further information 
about the function of your heart. A copy of your ECG and echocardiogram will be sent 
to the study team for assessment. If your ECG or echocardiogram or blood test are 
abnormal you will be referred to a heart specialist for further assessment and possible 
treatment.   
 
Are there any risks to participating in the study? 
 
We do not anticipate any side effects relating to the blood test for BNP or to 
measuring your heart function. 
 
Are there any benefits to taking part? 
 
The information that we obtain from the study will help us gain knowledge about the 
impact of cancer treatment on your heart.  You will have regular monitoring of how 
your heart is working.  You will have increased contact with specialist nurses. 
 
Do I have to take part? 
 
No, taking part is voluntary. We would encourage women who agree to this sub-study 
to go on to take part in the main SUPREMO trial, but this is also voluntary. If you 
would prefer not to take part you do not have to give a reason. Your doctor would not 
be upset and your treatment would not be affected in any way. If you take part but 
later change your mind you can withdraw from the study at any time without giving a 
reason and without hindrance or detriment to your future treatment. We will give you a 
copy of your consent form to keep. 
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Confidentiality 
 
All the study data will be confidential to the research team.  You will not be identified in 
any published study results.  All study data will be handled under the auspices of the 
MRC- Trial Management Group and treated confidentially in compliance with the Data 
Protection Act (1998). 
 
What do I do now? 
 
You will be contacted by a member of the research staff in a day or so.  Please let 
him/her know if you are interested in taking part. 
 
We would want to inform your General Practitioner that you are taking part in this 
study.  
Thank you very much for considering taking part in our research.  Please discuss this 
information with your family, friends or GP if you wish. 
 
Prof. Ian Kunkler Chief Investigator, SUPREMO trial 
 
Local contact name(s) and phone number(s):  
 
If you would like to speak to a doctor who is independent of the study, please  contact:     
_______________________________________________ 
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Appendix VI Informed consent form (Cardiac substudy) 
  
SUPREMO breast cancer trial   
Selective Use of Postoperative Radiotherapy aftEr MastectOmy 
 
Cardiac Substudy 
 
Informed Consent Form 
 
Patient identification number for this trial:………………………………….. 
 
Name of patient:      ……………………………………………………………… 
 
Name of clinician     ……………………………………………………………... 
 
Hospital:                  ………………………………………………………………. 
 
 Please initial boxes 
1. I have read and understood the Cardiac Study patient information 
sheet provided and have had sufficient time to decide whether to take 
part in this study. I have had the opportunity to ask questions and 
consider the answers given. 
 
2. I understand that participation in the study is voluntary and that I may 
withdraw at any time of my own accord and without giving any reason 
and without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked 
at by research staff from the Information Services Division (ISD) 
Cancer Clinical Trials Team, and other collaborating UK Clinical trials 
units for the purpose of data monitoring, where it is relevant to my 
taking part in research.  I give permission for these individuals to have 
access to my records. 
 
4. I agree that my General Practitioner will be informed of my 
participation in this study and will be advised of any clinically significant 
information that comes to light. 
 
5. I agree to donate serum/plasma for this study which will be stored for 
future research to learn about, prevent or treat cancer. 
 
For those who wish to enter the Cardiac study only at present: 
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6. I agree to be approached towards the end of my chemotherapy about 
entering the main SUPREMO radiotherapy trial and TRANS SUPREMO 
and Quality of Life substudies. 
 
7. I agree to baseline data and details of my cancer treatments being 
collected for the purposes of the trial even if I decide not to enter the 
main SUPREMO trial and other substudies at the end of my 
chemotherapy. 
 
 
I confirm that I have explained the nature of this study to the above named patient and 
that she has understood the explanation given to her. 
 
Clinician’s signature:…………………………………………………… Date:……………. 
 
I hereby freely give my consent to take part in the SUPREMO cardiac study. 
 
 
Patient’s signature: ……………………………………………………  Date:…………….. 
 
 
(Signature on this form does not affect your legal rights, you may take part in the main 
trial and decline to take part in this part of the trial) 
 
 
 
 
 
 
 
 
4 copies of consent form required: 1 original for patient, 1 original for researcher (to be 
kept in site file), 1 copy for trials office, 1 copy to be kept with hospital notes. 
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 Appendix VII  Letter to general practitioner covering 
main trial and sub-studies 
 
Dear Colleague, 
 
SUPREMO trial (Selective Use of Postoperative Radiotherapy aftEr MastectOmy)  
 
I am writing to let you know that your patient:  
 
Mrs/Ms………………………………………………………………………  
of ……………………………………………………………………………… 
  
has agreed to take part in an international Phase III randomised trial (SUPREMO) to 
assess the role of postoperative chest wall irradiation after mastectomy and axillary 
surgery for breast cancer. Eligibility is restricted to women with intermediate risk 
breast cancer (ie with 1-3 histologically involved nodes or histologically negative 
nodes with high grade histology and/or lymphovascular invasion). (Neo)adjuvant 
systemic therapy with chemotherapy and/or endocrine therapy is given as appropriate. 
The value of adjuvant chest wall irradiation in this group of patients is uncertain and at 
present this is not standard therapy.  In women with > 4 involved nodes there is good 
evidence that loco-regional irradiation after mastectomy given with systemic therapy 
improves overall survival. However the role of loco-regional irradiation in women at 
lower risk of loco-regional recurrence is unclear.  The recent guidance from the UK 
National Institute for Clinical Excellence (NICE; 2009) encourages recruitment of 
patients with intermediate risk breast cancer after mastectomy into the SUPREMO 
trial. 
   
The trial aims to assess whether the addition of radiotherapy will improve overall 
survival in women at intermediate risk of recurrence. In addition we will be assessing 
the impact of chest wall irradiation on quality of life, cardiac morbidity and use of 
health service resources.  Medical history and examination will be conducted on entry 
to the study, after radiotherapy (if given) or at an equivalent time point if no 
radiotherapy is given and annually for 10 years. A mammogram of the opposite 
breast, if appropriate, is recommended at least in alternate years for 10 years from the 
date of mastectomy. 
 
 
Sub-studies  
(please note that participation in sub studies is optional and requires separate 
informed consent). 
 
a) Cardiac substudy 
The primary aim of the cardiac sub study is to assess the utility of B type natriuretic 
peptide (BNP) in identifying and predicting cardiac toxicity in patients undergoing 
adjuvant radiotherapy and/or chemotherapy.  Cardiac risk factors, including 
measurement of serum cholesterol, will be documented by a doctor/research nurse at 
baseline. Blood levels of BNP will be measured in conjunction with 
electrocardiography (ECG) and echocardiography.  If cardiac symptoms or signs 
warrant or BNP rises significantly above threshold levels patients will be referred for 
additional cardiac assessment to a cardiologist. The last BNP measurement along 
with a further clinical cardiac assessment and ECG will be carried out at 10 years after 
surgery. 
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b) TRANS-SUPREMO translational research substudy 
In TRANS-SUPREMO tissue microarrays will be constructed from pathological blocks 
for subsequent identification of a molecular signature of radiosensitivity and relapse.  
We will also collect whole blood, serum and plasma at randomisation, recurrence 
(local and/or distant relapse) and/or development of a contralateral breast primary to 
look for pharmacogenetic and protein markers of relapse/outcome.   
 
c) Quality of life substudy 
The patient will complete Quality of Life assessment questionnaire booklets before 
randomisation and at 1, 2, 5 and 10 years post-mastectomy.  The baseline 
assessment will be completed in the clinic, and subsequent questionnaire booklets will 
be posted to the patient’s home.  A member of the Centre for Population Health 
Sciences, the University of Edinburgh will contact your practice in advance of sending 
out the questionnaires to confirm that the patient is alive and well enough to receive 
the booklet. 
 
d) Health Economics substudy 
The patient will complete a patient diary received on entry into the study by a hospital 
staff member. The diary will capture aspects of the costs associated with the patient’s 
treatment both to organisations such as the NHS and to the patient themselves. 
 
The study has been approved by the Multi-centre Ethics Committee and your local 
ethical committee. It is anticipated that 1600 patients will be randomised over a six 
year recruitment period. A Data Monitoring Committee will meet at least six monthly to 
review study progress and safety. The final trial report will be submitted to a peer 
reviewed journal and this will be made available to you if requested. 
 
If you have any questions about the trial, you may wish to contact Chief Investigator, 
Prof Ian Kunkler, or the local Principal Investigator: 
 
Dr ………………………………………………………………………………. 
 
Address:………………………………………………………………………………… 
 
………………………………………………………………………………………….. 
 
Tel: ………………………………Email: 
 
 
Yours sincerely, 
Prof Ian Kunkler on behalf of the SUPREMO trial study team 
 
 
Prof Ian Kunkler, Consultant in Clinical Oncology, University Department of Clinical 
Oncology, Western General Hospital, University of Edinburgh, Crewe Road, 
Edinburgh, EH4 2XU. Telephone +44 (0)131 537 2214; Fax:+44 (0)131 275 7512 
Appendix VIII 
 
RTOG/EORTC acute radiation morbidity scoring system 
 
 
Organ 0 1 2 3 4 
Skin No change 
over baseline 
Follicular, faint or 
dull erythema/ 
epilation/ dry 
desquamation/decr
eased sweating 
Bright erythema, patchy 
moist 
desquamation/moderate 
oedema 
Confluent moist 
desquamation other than 
skin folds, pitting oedema 
Ulceration, 
haemorrhage, necrosis 
Lung No change Mild symptoms of 
dry cough or 
dyspnoea on 
exertion 
Persistent cough 
requiring narcotic, anti-
tussive agents/dyspnoea 
with minimal effort but 
not at rest 
Severe cough 
unresponsive to narcotic 
antitussive agent or 
dyspnoea at rest/clinical or 
radiological evidence of 
acute pneumonitis/ 
intermittent oxygen or 
steroids may be required 
Severe respiratory 
insufficiency/ continous 
oxygen or assisted 
ventilation 
Heart No change 
over baseline 
Asymptomatic but 
objective evidence 
of ECG changes or 
pericardial 
abnormalities 
without evidence of 
other heart disease 
Symptomatic with ECG 
changes and radiological 
findings of congestive 
heart failure or 
pericardial disease/no 
specific treatment 
required 
Congestive heart failure, 
angina pectoris, 
pericardial disease 
responding to therapy 
Congestive heart 
failure, angina pectoris, 
pericardial disease, 
arrhythmias not 
responsive to 
nonsurgical measures 
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RTOG/EORTC late radiation morbidity scoring system 
 
 
 
Organ 0 1 2 3 4 5 
Skin None Slight atrophy; 
pigmentation 
change; some hair 
loss 
Patchy atrophy; total hair 
loss 
Marked atrophy; gross 
telangiectasia 
Ulceration Death directly related 
to Radiation Late 
Morbidity 
Lung None Asymptomatic or 
mild symptoms 
Moderate symptomatic 
fibrosis or pneumonitis 
(severe cough); Low 
grade fever; patchy 
radiographic changes 
Severe symptomatic 
fibrosis or pneumonitis; 
Dense radiographic 
changes 
Severe respiratory 
insufficiency/ 
Continuous 
O2/Assisted Ventilation 
Death directly related 
to Radiation Late 
Morbidity 
Heart None Asymptomatic or 
mild symptoms; 
transient T wave 
inversion & ST 
change; sinus 
tachycardia> 110 
(at rest) 
Moderate angina on 
effort; Mild pericarditis; 
normal heart size; 
persistent abnormal T 
wave and ST changes; 
low ORS 
Severe angina; pericardial 
effusion; constrictive 
pericarditis; moderate 
heart failure; cardiac 
enlargement; ECG 
abnormalities 
Tamponade/Severe 
heart failure/Severe 
constrictive pericarditis 
Death directly related 
to Radiation Late 
Morbidity 
Bone None Asymptomatic. No 
growth; reduced 
bone density 
Moderate pain or 
tenderness; growth 
retardation; irregular 
sclerosis 
Severe pain or 
tenderness; complete 
arrest of bone growth; 
dense bone sclerosis 
Necrosis/Spontaneous 
fracture 
Death directly related 
to Radiation Late 
Morbidity 
Appendix IX  TNM Clinical Classification 
 
T - Primary tumour  
 
TX:  Primary tumour cannot be assessed  
 
T0:  No evidence of primary tumour  
 
Tis:  Carcinoma in situ,  
Tis (DCIS): Ductal carcinoma in situ 
Tis (LCIS): Lobular carcinoma in situ 
Tis (Paget): Paget's disease of the nipple with no tumour.  
   
Note: Paget disease associated with a tumour is classified according to the size of 
the tumour. 
 
T1:  Tumour 2.0 cm or less in greatest dimension 
 T1mic: Microinvasion 0.1 cm or less in greatest dimension  
 
Note: Microinvasion is the extension of cancer cells beyond the basement 
membrane into the adjacent tissues with no focus more than 0.1cm in greatest 
dimension. When there are multiple foci of microinvasion, the size of only the 
largest focus is used to classify the microinvasion. (Do not use the sum of all 
individual foci.) The presence of multiple foci of microinvasion should be noted, as 
it is with multiple larger invasive carcinomas. 
 
T1a: More than 0.1 cm but not more than 0.5 cm in greatest dimension  
T1b: More than 0.5 cm but not more than 1.0 cm in greatest dimension  
T1c: More than 1.0 cm but not more than 2.0 cm in greatest dimension  
 
T2:  Tumour more than 2.0 cm but not more than 5.0 cm in greatest 
dimension 
 
T3:  Tumour more than 5.0 cm in greatest dimension 
 
T4:  Tumour of any size with direct extension to chest wall or skin, only as 
described in T4a to T4d 
 
Note: Chest wall includes ribs, intercostal muscles, and serratus anterior muscle but 
not pectoral muscle. 
 
 T4a: Extension to chest wall 
 T4b: Oedema (including peau d’orange) or ulceration of the skin of the 
breast, or satellite skin nodules confined to the same breast   
 T4c: Both 4a and 4b above 
 T4d: Inflammatory carcinoma  
 
Note: Inflammatory carcinoma of the breast is characterised by diffuse, brawny 
induration of the skin with an erysipeloid edge, usually with no underlying mass. If the 
skin biopsy is negative and there is no localised measurable primary cancer, the T 
category is pTX when pathologically staging a clinically inflammatory carcinoma 
(T4d). Dimpling of the skin, nipple retraction, or other skin changes, except those in 
T4b and T4d, may occur in T1, T2, or T3 without affecting the classification. 
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N - Regional lymph nodes  
 
NX:  Regional lymph nodes cannot be assessed (e.g., previously removed) 
  
N0:  No regional lymph node metastasis 
  
N1:  Metastasis in movable ipsilateral axillary lymph node(s) 
  
N2: Metastasis in fixed ipsilateral axillary lymph node(s), or in clinically 
apparent* ipsilateral internal mammary lymph node(s) in the absence 
of clinically evident axillary lymph node metastasis 
 
N2a: Metastasis in axillary lymph node(s) fixed to one another or to 
other structures 
N2b: Metastasis only in clinically apparent* internal mammary lymph 
nodes and in the absence of clinically evident axillary lymph node 
metastasis 
 
N3:  Metastasis in ipsilateral infraclavicular lymph node(s) with or without 
axillary lymph node involvement, or in clinically apparent* ipsilateral 
internal mammary lymph node(s) and in the presence of clinically 
evident axillary lymph node metastasis; or, metastasis in ipsilateral 
supraclavicular lymph node(s) with or without axillary or internal 
mammary lymph node involvement 
 
 N3a: Metastasis in infraclavicular lymph node(s) 
 N3b: Metastasis in internal mammary and axillary lymph node(s) 
 N3c: Metastasis in supraclavicular lymph node(s) 
 
* [Note: Clinically apparent = detected by clinical examination or by imaging studies 
(excluding lymphoscintigraphy).] 
 
M - Distant metastasis  
 
 MX: Distant metastasis cannot be assessed  
 M0: No distant metastasis  
 M1: Distant metastasis  
 
pTNM Pathological classification 
 
pT – Primary Tumour 
 
The pathological classification requires the examination of the primary carcinoma 
with no gross tumour at the margins of resection. A case can be classified pT if there 
is only microscopic tumour in a margin.  
The pT categories correspond to the T categories.  
 
Note: When classifying pT the tumour size is a measurement of the invasive 
component. If there is a large in situ component (eg 4cm) and a small invasive 
component (eg 0.5cm), the tumour is coded pT1a. 
 
PN – Regional Lymph nodes 
The pathological classification requires the resection and examination of at least the 
low axillary lymph nodes (level I). Such a resection will ordinarily include 6 or more 
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lymph nodes. If the lymph nodes are negative, but the number ordinarily examined is 
not met, classify as pN0. 
 
Examination of one or more sentinel lymph nodes may be used for pathological 
classification. If classification is based solely on sentinel node biopsy without 
subsequent axillary lymph node dissection it should be designated (sn) for sentinel 
node, eg pN1(sn).  
 
pNX:  Regional lymph nodes cannot be assessed (not removed for study or 
previously removed)  
 
pN0:  No regional lymph node metastasis*  
 
 
[Note: *cases with only isolated tumour cells (ITCs) in regional lymph nodes are 
classified as pN0. ITC are single tumour cells or small clusters of cells not more than 
0.2 mm in greatest dimension, that are usually detected by immunohistochemistry or 
molecular methods but which may be verified on H&E stains. ITCs do not typically 
show evidence of metastatic activity, e.g., proliferation or stromal reaction.] 
 
 
pN1mi: Micrometastasis (larger than 0.2 mm but none larger than 2.0 mm in 
greatest dimension) 
 
pN1:  Metastasis in 1 to 3 ipsilateral axillary lymph node(s), and/or in 
ipsilateral internal mammary nodes with microscopic metastasis 
detected by sentinel lymph node dissection but not clinically 
apparent**  
 
pN1a: Metastasis in 1 to 3 axillary lymph node(s), including at least 
one larger than 2mm in greatest dimension.  
pN1b: internal mammary lymph nodes with microscopic metastasis 
detected by sentinel lymph node dissection but not clinically 
apparent**  
pN1c: Metastasis in 1 to 3 axillary lymph nodes and internal mammary 
lymph nodes with microscopic metastasis detected by sentinel lymph 
node dissection but not clinically apparent.  
 
pN2:  Metastasis in 4 to 9 ipsilateral axillary lymph nodes, or in clinically 
apparent* ipsilateral internal mammary lymph node(s) in the absence 
of axillary lymph node metastasis  
 
** [Note: Not clinically apparent = not detected by clinical examination or by imaging 
studies (excluding lymphoscintigraphy)  
* [Note: Clinically apparent = detected by clinical examination or by imaging studies 
(excluding lymphoscintigraphy) or grossly visible pathologically]  
 
pN2a: Metastasis in 4 to 9 axillary lymph nodes including at least  one 
that is larger than 2.0 mm) 
pN2b: Metastasis in clinically apparent internal mammary lymph 
node(s) in the absence of axillary lymph node metastasis 
 
pN3:  Metastasis in 10 or more ipsilateral axillary lymph nodes; or in 
ipsilateral infraclavicular lymph nodes; or in clinically apparent 
ipsilateral internal mammary lymph node(s) in the presence of one or 
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more positive axillary lymph nodes; or, in more than 3 axillary lymph 
nodes with clinically negative microscopic metastasis in internal 
mammary lymph nodes; or, in ipsilateral supraclavicular lymph nodes 
 
pN3a: Metastasis in 10 or more axillary lymph nodes (at least  one 
larger than 2.0 mm) or, metastasis in infraclavicular lymph nodes 
pN3b: Metastasis in clinically apparent internal mammary lymph nodes 
in the presence of positive axillary lymph node(s); or, metastasis in 
more than 3 axillary lymph nodes and in internal mammary lymph 
nodes with microscopic metastasis detected by sentinel lymph node 
dissection but not clinically apparent 
pN3c: Metastasis in supraclavicular lymph node(s) 
 
 
pM – Distant Metastasis 
 
The pM categories correspond to the M categories. 
 
Source:  UICC TNM Classification of Malignant Tumours Sixth Edition 2002 Edited 
by L.H.Sobin and Ch. Wittekind 
 
Additional Descriptors 
 
In addition to c and p to designate clinical or pathological stage further information 
can be used by the use of optional descriptors for example: 
 
y 
 
If patients receive neoadjuvant therapy prior to surgery or radiotherapy the TNM may 
not be same as if no neoadjuvant treatment was given. To overcome this problem the 
additional descriptor y can be used as a prefix to indicate the extent of disease at the 
time of assessment even if multimodality therapy has already commenced (i.e., 
yT1N0M0 means that the patient was staged following neoadjuvant treatment, and 
the anatomic extent of disease at that time was confined to the primary site, and of a 
size commensurate with the T1 category for that tumour type). 
 
Source: UICC (2009). How to use the TNM Classification, accessed July 21 2009 from 
http://www.uicc.org/index.php?option=com_content&task=view&id=14296&Itemid=428 
 
c 
 
Clinical classification, designated cTNM or TNM. Clinical classification is based on 
evidence acquired before primary treatment. Clinical assessment uses information 
available prior to first definitive treatment including, but not limited to, physical 
examination, imaging, endoscopy, biopsy, and surgical exploration. Clinical stage is 
assigned prior to any cancer-directed treatment and is not changed on the basis of 
subsequent information. Clinical staging ends if a decision is made not to treat the 
patient. The clinical stage is essential to selecting and evaluating primary therapy. 
 
Source: AJCC Comparison Guide: Fifth versus Sixth Edition, accessed August 19 2010 
from http://www.cancerstaging.org/products/ajccguide.pdf. 
Final protocol version 29– 30th August 2010  85
Appendix X  Collaborating Organisations 
 
Contacts: 
 
 
Anglo-Celtic Co-operative Oncology Group: 
Prof. Robert C F Leonard 
 
Borstkanker Onderzoeksgroep Nederland: 
Dr. Nicola Russell 
 
Central East European Oncology Group:  
Prof. Jacek Jassem 
 
Chinese Network of 9 Hospitals (under leadership of National Cancer Centre, 
Academy of Medical Sciences, Beijing) 
Prof. Yexiong Li and Associate Prof. Shulian Wang 
 
European Organisation for Research and Treatment of Cancer:  
Dr. Geertjan van Tienhoven 
 
GECO Peru: 
Dr. Henry Gomez Moreno 
 
Hellenic Breast Surgical Society: 
Prof. Christos Markopoulos 
 
International Breast Cancer Study Group: 
Prof. Aron Goldhirsch 
 
Irish Clinical Oncology Research Group: 
Dr. Brian Moulton 
 
Japanese Breast Cancer Research Group: 
Dr. Masakazu Toi 
   
National Cancer Institute of Canada –Cancer Trials Group: 
Prof. Tim Whelan 
 
National Cancer Research Institute Breast Cancer Studies Group: 
Prof. Alastair Thompson 
 
Swedish Breast Group: 
Prof. Per-Olof Malmstrom 
 
Swiss Group for Clinical Cancer Research: 
Dr Olivia Pagani 
 
Trans-Tasman Radiation Oncology Group: 
Associate Prof. Boon Chua 
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Appendix XI Compatibility with Other Studies 
 
Given the number of breast cancer trials running in the UK it is important to avoid the 
problem of “over-burdening” patients with trial choices. The SUPREMO trial should 
be compatible with most current non-interventional breast cancer studies and will not 
be applicable to the same patient population as any treatment trials for non-invasive 
or metastatic disease.  
 
Quality of Life Substudy 
However patients entered into the SUPREMO Quality of Life sub-study should not be 
enrolled into another trial’s QoL sub-study. 
Similarly, if they have already been enrolled into an ongoing QoL study of another 
trial they should not be entered into SUPREMO QoL substudy.   
 
Please refer to the SUPREMO website (www.supremo-trial.com) for a current list of 
trials that are compatible with SUPREMO.  
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Appendix XII  Abbreviations 
 
 
AC Adriamycin and Cyclophosphamide 
BNP B Type Natriuretic Peptide 
CAF Cyclophosphamide, Adriamycin and 5-fluorouracil 
CD Compact Disk 
CEF Cyclophosphamide, Epirubicin and 5-fluorouracil 
CI Confidence Interval 
CMF Cyclophosphamide, Methotrexate and 5-fluorouracil 
CT Computed Tomography 
CT-Sim Computed Tomography- simulator 
CTV Clinical Target Volume 
DCIS Ductal Carcinoma In Situ 
DICOM Digital Imaging and Communications in Medicine 
Dmax Maximum Dose 
EBCTCG Early Breast Cancer Trialists’ Collaborative Group 
EC Epirubicin and Cyclophosphamide 
ECG Electrocardiogram 
ECHO Echocardiogram 
ECOG Eastern Cooperative Oncology Group 
EORTC European Organisation for Research and Treatment 
of Cancer 
EpiCMF Epirubicin and Cyclophosphamide, Methotrexate and 
5-fluorouracil 
LCIS Lobular Carcinoma In Situ 
ER Oestrogen Receptor 
FAC 5-fluorouracil, Adriamycin and Cyclophosphamide 
FEC 5-fluorouracil, Epirubicin and Cyclophosphamide 
GP General Practitioner 
Gy Gray 
H&E Haematoxylin & Eosin 
GCP Good Clinical Practice 
ICRU 50 International Commission on Radiation Units 
IGF-1 Insulin-Like Growth factor-1 
IMC Internal Mammary Chain 
IPEM Institute of Physics and Engineering in Medicine 
ISD Information Services Division 
LRF Loco-regional Failure 
LRR Loco-regional Recurrence 
LVD Left Ventricular Dysfunction 
MSCF Medial Supraclavicular Fossa 
MV Mega Voltage 
NIH National Institutes of Health 
NSABP National Surgical Adjuvant Breast and Bowel Project 
NHS National Health Service 
PMRT Postmastectomy Radiotherapy 
PTV Planning Target Volume 
QA Quality Assurance 
QC Quality Control 
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QALY Quality-Adjusted Life-Year 
QoL Quality of Life 
RR Relative Risk 
RT Radiotherapy 
RTOG Radiation Therapy Oncology Group 
SAE Serious Adverse Event 
SEER Surveillance Epidemiology and End Results 
SIGN Scottish Intercollegiate Guidelines Network 
START Standardisation of Breast Radiotherapy Trial 
TAD Target Absorbed Dose 
TLD Thermo Luminescent Dosimetry 
TNM  Tumour, Node, Metastasis (Clinical Classification) 
UICC International Union Against Cancer 
VEGF Vascular Endothelial Growth Factor 
TRAM Transverse Rectus Abdominis Muscle 
DNA Deoxyribonucleic Acid 
mRNA Messenger Ribonucleic Acid 
RNA Ribonucleic Acid 
MAPK Mitogen-Activated Protein Kinase 
GST Glutathione S-Transferase 
ATM Ataxia Telangiectasia Mutated 
PARP Poly (ADP-ribose) Polymerase 
ADP Adenosine Diphosphate 
TMA Tissue Microarray 
MALDI-TOF Matrix-assisted Laser Desorption-Ionisation Time Of 
Flight 
MLSO Medical Laboratory Scientific Officer 
IHC Immunohistochemistry 
FISH Fluorescent In Situ Hybridisation 
CART Classification And Regression Trees 
BIS Body Image Scale 
HADS Hospital Anxiety and Depression Scale 
LD flap Latissimus Dorsi flap 
EQ EuroQol 
NTCP Normal Tissue Compliance Probability 
EDTA Ethylenediamine Tetraacetic 
sn Sentinel node 
ITC Isolated Tumour Cell 
HER2 HER2/neu protein 
ICH-GCP International Conference on Harmonisation of Good 
Clinical Practice 
 
  
Necessary Additional Data- statistical plan
Click here to download Necessary Additional Data: QoL Statistical  Analysis Plan v2.3 20Jan2017 signed.docx
  
CONSORT checklist
Click here to download Necessary Additional Data: Velikova CONSORT 2010 Checklist.doc
  
List of co-investigators
Click here to download Necessary Additional Data: UK co-investigators SUPREMO QOL.xlsx
